Conditions: Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 597
Healthy volunteers: no

Brief summary:
Primary Objective:

To demonstrate non-inferiority of SAR341402 versus NovoLog/NovoRapid in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 or type 2 diabetes mellitus (T1DM or T2DM) also using Lantus®.

Secondary Objectives:

* To assess the immunogenicity of SAR341402 and NovoLog/NovoRapid in terms of positive/negative status and anti-insulin antibody (AIA) titers during the course of the study.
* To assess the relationship of AIAs with efficacy and safety.
* To assess the efficacy of SAR341402 and NovoLog/NovoRapid in terms of proportion of participants reaching HbA1c lesser than (\<) 7.0% and change in HbA1c, fasting plasma glucose (FPG), and self-measured plasma glucose (SMPG) profiles from baseline to Week 26 and Week 52 (only Week 52 for HbA1c).
* To assess safety of SAR341402 and NovoLog/NovoRapid.

Detailed description:
The study consisted of a 2-week screening period, a 26-week treatment period, a 26-week comparative safety extension period, and a 1-day follow-up period. The maximum study duration was 54 weeks per participant and a 1 day safety follow-up.

Arms:
arm 1: SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52. arm 2: NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.

Interventions: intervention 1: Insulin aspart intervention 2: NovoLog/NovoRapid intervention 3: Insulin glargine (HOE901)
Intervention descriptions: intervention 1: SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia. intervention 2: NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia. intervention 3: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.

Protocol document:
Prot_000.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: QSD-002579 VERSION N°14.0 (04-FEB-2016) 
Page 1 
AMENDED CLINICAL TRIAL PROTOCOL NO. 02 
COMPOUND: SAR341402  
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to 
NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin 
Glargine, with a 6-month Safety Extension Period 
STUDY NUMBER: EFC15081 
STUDY NAME: GEMELLI 1 
CLINICAL STUDY DIRECTOR: 
VERSION DATE / STATUS: 13-Dec-2017 / Approved 
Protocol Amendment 03 
Version number: 1 (electronic 1.0) 
Date : 13-Dec-2017 
Amended Clinical Trial Protocol 01 
Version number: 1 (electronic 1.0) 
Date : 31-Oct-2017 
Protocol Amendment 02 
Version number: 1 (electronic 1.0) 
Date : 31-Oct-2017 
Amended Clinical Trial Protocol 01 - 
Japanese 
Version number: 1 (electronic 1.0) 
Date : 27-Jul-2017 
Protocol Amendment 01 - Japanese 
Version number: 1 (electronic 1.0) 
Date : 27-Jul-2017 
Clinical Trial Protocol 
Version number: 1 (electronic 1.0) 
Date : 28-Apr-2017 
EudraCT  
2017-000091-28 
IND Number(s) 
133678 
Version Number: 
1  
WHO universal trial number: 
U1111-1191-5775 
Date: 
13-Dec-2017
Total number of pages: 
115 
(electronic 3.0)
NCT03211858


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 2 
NAMES AND ADDRESSES OF 
COORDINATING 
INVESTIGATOR 
 
Name: 
Address: 
 
 
Tel: 
Fax: 
E-mail: 
 
 
MONITORING TEAM’S 
REPRESENTATIVE 
 
Name: 
Address: 
 
 
 
Tel: 
Fax: 
E-mail: 
 
 
SPONSOR 
 
Company: 
Address: 
 
 
 
 
 
 
OTHER EMERGENCY 
TELEPHONE NUMBERS 
 
 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 3 
CLINICAL TRIAL SUMMARY 
COMPOUND: SAR341402 
STUDY No.: EFC15081  
TITLE 
Six-month, Randomized, Open-label, Parallel-group Comparison of 
SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes 
Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension 
Period 
INVESTIGATOR/TRIAL LOCATION 
Multinational 
PHASE OF DEVELOPMENT 
Phase 3 
STUDY OBJECTIVE(S) 
 
Primary objective: 
• 
To demonstrate non-inferiority of SAR341402 versus 
NovoLog/NovoRapid in glycated hemoglobin A1c (HbA1c) 
change from baseline to Week 26 in patients with type 1 or 
type 2 diabetes mellitus (T1DM or T2DM) also using 
Lantus®. 
Secondary objectives: 
• 
To assess the immunogenicity of SAR341402 and 
NovoLog/NovoRapid in terms of positive/negative status and 
anti-insulin antibody (AIA) titers during the course of the 
study. 
• 
To assess the relationship of anti-insulin antibodies with 
efficacy and safety. 
• 
To assess the efficacy of SAR341402 and 
NovoLog/NovoRapid in terms of proportion of patients 
reaching HbA1c <7.0% and change in HbA1c, fasting 
plasma glucose (FPG) and self-measured plasma glucose 
(SMPG) profiles from baseline to Week 26 and Week 52 
(only Week 52 for HbA1c). 
• 
To assess safety of SAR341402 and NovoLog/NovoRapid. 
STUDY DESIGN 
Randomized, open-label, active-controlled, 2-arm parallel-group, 
multicenter trial. 
The study treatment, SAR341402 and NovoLog/NovoRapid, will be 
assigned in a 1:1 ratio. 
Randomization will be stratified by geographical region (Europe, US, 
Japan), by type of diabetes (T1DM, T2DM [T2DM only for US]), by 
HbA1c obtained at the screening visit (<8.0%, ≥8.0%), and by prior 
use of NovoLog/NovoRapid (Yes, No). 
The study will include a 2-week screening period, a 6-month (26-week) 
efficacy and safety period and a 6-month (26-week) safety extension 
period. 
STUDY POPULATION  
Main selection criteria 
Inclusion criteria: 
• 
Patients with T1DM or with T2DM (T2DM US only) 
diagnosed for at least 12 months, who have been treated 
with a multiple daily injection regimen with 
- 
NovoLog/NovoRapid  
OR  
insulin lispro (100 U/mL) in the last 6 months prior to 
screening visit 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 4 
AND 
- 
insulin glargine (100 U/mL) in the last 6 months prior to 
screening visit  
OR  
insulin detemir (Levemir®) in the last 12 months prior to 
screening visit. 
• 
Signed written informed consent obtained. 
Exclusion criteria: 
• 
At screening visit, age under legal age of adulthood. 
• 
HbA1c <7.0% or >10% at screening. 
• 
Patients with incomplete baseline 7-point SMPG profile, 
defined as patients who do not have 7-point profiles with at 
least 5 points on at least 2 days in the week before 
randomization Visit 3. 
• 
Less than 1 year on continuous insulin treatment. 
• 
Use of insulin pump in the last 3 months before screening 
visit. 
• 
Patients with T1DM: Use of glucose lowering agents other 
than insulin including use of non-insulin injectable peptides in 
the last 3 months prior to screening. 
• 
Patients with T2DM:  
- 
Use of glucagon-like peptide-1 (GLP-1) receptor 
agonists in the last 3 months before screening visit. 
- 
Use of oral antidiabetic drugs (OADs) not on stable 
dose in the last 3 months before screening visit 
(sulfonylureas will be discontinued at baseline). 
• 
At screening visit, body mass index (BMI) ≥35 kg/m2 in 
patients with T1DM and ≥40 kg/m2 in patients with T2DM. 
• 
Use of insulin other than  
- 
insulin glargine 100 U/mL and NovoLog/NovoRapid or 
insulin lispro 100 U/mL as part of a multiple injection 
regimen in the last 6 months before screening visit, OR 
- 
insulin detemir 100 U/mL in the 12 months before 
screening visit and NovoLog/NovoRapid or insulin lispro 
100 U/mL in the last 6 months before screening visit as 
part of a multiple injection regimen. 
• 
Status post pancreatectomy. 
• 
Status post pancreas and/or islet cell transplantation. 
• 
Hospitalization for recurrent diabetic ketoacidosis (DKA) in 
the last 3 months before screening visit. 
• 
History of severe hypoglycemia requiring Emergency Room 
admission or hospitalization in the last 3 months before 
screening visit. 
• 
Unstable proliferative diabetic retinopathy or any other 
rapidly progressive diabetic retinopathy or macular edema 
likely to require treatment (eg, laser, surgical treatment or 
injectable drugs) during the study period. 
• 
Pregnant or breastfeeding women. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 5 
• 
Women of childbearing potential not protected by highly 
effective method(s) of birth control. 
Total expected number of patients 
Approximately 580 randomized patients 
(SAR341402: n = 290; NovoLog/NovoRapid: n = 290). 
It is planned to randomize approximately 480 patients with T1DM and 
100 patients with T2DM (US only). The number of patients with T1DM 
expected to be randomized in the US versus outside of the US may 
change owing to the recruitment potential at those regions, however, 
enrollment will target randomization of approximately 250 patients in 
countries using EU-approved NovoRapid (including Europe and Japan) 
and approximately 230 T1DM patients in the US using US-approved 
NovoLog. 
STUDY TREATMENT(s) 
 
Investigational medicinal product(s) 
 
Formulation: 
Tested drug: SAR341402 product 
SAR341402 will be supplied as 100 U/mL solution in 3 mL pre-filled 
disposable SoloSTAR® pens.  
Control drug: NovoLog/NovoRapid 
NovoLog/NovoRapid will be supplied as 100 U/mL solution in 3 mL 
pre-filled disposable FlexPen® pens.  
US-approved NovoLog (hereafter referred to as NovoLog) and 
EU-approved NovoRapid (hereafter referred to as NovoRapid) 
comparator will be used at sites depending on the countries, and will 
be clearly identified. 
Route(s) of administration: 
Tested drug: SAR341402 will be self-administered by SC 
injections. 
Control drug: NovoLog/NovoRapid will be self-administered by 
SC injections. 
Dose regimen: 
SAR341402 and NovoLog/NovoRapid: 
SAR341402 or NovoLog/NovoRapid will be injected SC immediately 
(within 5 to 10 minutes) prior to the start of a meal. When necessary, 
NovoRapid/NovoLog can be given soon after a meal if allowed by the 
national product label. 
Changes in the meal related rapid-acting insulin dose will be based on 
SMPG measurements and the carbohydrate content of the meal (when 
available).  
Insulin doses will be self-adjusted/titrated by the patients to achieve a 
2-hour postprandial plasma glucose of <10.0 mmol/L (<180 mg/dL) 
while avoiding hypoglycemia. If pre-prandial glucose tests are used, 
the target range of 4.4 to 7.2 mmol/L (80 to 130 mg/dL) is 
recommended (1). For the purpose of this protocol, 2 hours 
postprandial is defined as 2 hours after the start of the meal. 
Noninvestigational medicinal product(s) 
 
Formulation: 
Insulin glargine solution for SC injection 100 U/mL (Lantus) will be 
used as basal insulin. Lantus will be supplied in 3 mL pre-filled 
disposable SoloSTAR pens. 
Mixing of Lantus with other insulin is not allowed. 
Route(s) of administration: 
Lantus will be self-administered by SC injections. 
 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 6 
Dose regimen: 
 
Lantus will be injected once daily. The time of injection will be fixed at 
the start of the study and will be maintained during the study. Dose will 
be self-titrated with site oversight to reach a fasting, prebreakfast 
SMPG of 4.4 to 7.2 mmol/L (80 to 130 mg/dL). 
Changes in the Lantus dose are based on fasting (prebreakfast) 
SMPG measurements. 
ENDPOINT(S) 
 
Primary endpoint: 
• 
Change in HbA1c (%) from baseline to Week 26. 
Secondary endpoints: 
Immunogenicity 
• 
Anti-SAR341402/NovoLog/NovoRapid antibody 
positive/negative status, titers and cross-reactivity to human 
insulin at each sampling visit up to Week 26, and during the 
extension period up to Week 52. 
• 
Treatment-induced, treatment-boosted and 
treatment-emergent anti-insulin antibodies (AIAs) (2) during 
the main 6-month and the 12-month on-treatment periods. 
Efficacy 
• 
Change in HbA1c (%) from baseline to Week 52. 
At Week 26 and Week 52: 
• 
The percentage of patients with HbA1c <7 %. 
• 
Change from baseline in FPG. 
• 
Change from baseline in the mean 24-hour plasma glucose 
concentration, based on the 7-point SMPG profiles. 
• 
Change from baseline in postprandial plasma glucose 
excursions (difference between 2-hour postprandial and  
pre-prandial plasma glucose values at breakfast, lunch and 
dinner), based on the 7-point SMPG profiles. 
• 
Change from baseline in 7-point SMPG profiles per  
time-point. 
 
Safety 
During the main 6-month and the 12-month on-treatment periods: 
• 
Injection site reactions, hypersensitivity reactions. 
• 
Hypoglycemia (according to ADA Workgroup on 
Hypoglycemia) (3, 4, 5). 
• 
Adverse events (AEs), serious adverse events (SAEs). 
• 
Vital signs. 
• 
Laboratory data. 
• 
Body weight. 
ASSESSMENT SCHEDULE 
Efficacy: see study schedule. 
Safety: see study schedule. 
STATISTICAL CONSIDERATIONS 
 
 
 
 
 
Randomization: 
Patients will be randomized to SAR341402 or NovoLog/NovoRapid in 
a 1:1 ratio. Randomization will be stratified by geographical region 
(Europe, US, Japan), by type of diabetes (T1DM, T2DM [T2DM only 
for US]), by HbA1c obtained at the screening visit (<8.0%, ≥8.0%), and 
by prior use of NovoLog/NovoRapid (Yes, No). 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size determination: 
The sample size calculations are performed based on the primary 
endpoint, change in HbA1c from baseline to Week 26 (in %). 
A sample size of 580 patients (290 patients per treatment group; 
approximately 480 T1DM patients [230 patients in the US using 
NovoLog and 250 patients in countries using NovoRapid] and 
100 T2DM patients [all in the US using NovoLog]) will ensure that the 
upper bound of the 2-sided 95% confidence interval (CI) for the 
adjusted mean difference between SAR341402 and 
NovoLog/NovoRapid would not exceed a non-inferiority margin of 
0.3% HbA1c with at least 95% power. This sample size will also 
ensure that the lower bound of this 2-sided 95% CI would not be below 
-0.3% HbA1c with at least 95% power, thus will provide at least 90% 
power to show both non-inferiority of SAR341402 over 
NovoLog/NovoRapid (primary analysis) and inverse non-inferiority of 
NovoLog/NovoRapid over SAR341402 (secondary analysis). These 
calculations assume a common standard deviation (SD) of 1.0% and a 
true difference in HbA1c between the treatment groups of zero. 
An exploratory analysis of the percentage of patients with 
treatment-emergent AIAs (AIA incidence) will be performed to compare 
the immunogenicity of SAR341402 versus NovoLog/NovoRapid. The 
sample size of 580 patients would ensure that the 2-sided 90% CI for 
the adjusted risk difference between SAR341402 and 
NovoLog/NovoRapid would be included within the [-10%; 10%] interval 
with at least 68% power. This calculation assumes a true risk 
difference between the treatment groups of zero and a maximum AIA 
incidence of 30% (in previous Sanofi clinical studies performed with 
rapid-acting insulin analogs, AIA incidence in the range of 15-20% 
were observed at 6 months). The power calculations are presented in 
the table below. 
Power calculation based on the percentage of patients with 
treatment-emergent AIAs 
Percentage of patients with 
treatment-emergent AIAs 
10% 
20% 
30% 
Power for N=580 (290/arm) 
97% 
82% 
68% 
Analysis population: 
The primary efficacy population will be the intent-to-treat (ITT) 
population, which includes all randomized patients, irrespective of 
compliance with the study protocol and procedures. 
Patients will be analyzed for efficacy analyses in the treatment group to 
which they are randomized. 
The safety analyses will be conducted on the safety population, 
defined as all randomized patients who receive at least one dose of 
investigational medicinal product (IMP) (regardless of the amount of 
treatment administered). The immunogenicity analyses will be 
conducted on the AIA population, defined as all patients from the 
safety population with at least one AIA sample available for analysis 
during the on-treatment period.  
For safety and immunogenicity, patients will be analyzed according to 
the treatment actually received. 
Analyses will be presented overall (NovoLog/NovoRapid and the 
corresponding SAR341402 groups) and then for the subgroups defined 
by region-approved NovoLog/NovoRapid comparing SAR341402 with 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NovoLog in patients enrolled in the US (approximately 330 patients, 
230/330 with T1DM and 100/330 with T2DM) and comparing 
SAR341402 and NovoRapid in regions using NovoRapid 
(approximately 250 patients with T1DM). Further subgroup analyses 
will be defined in the SAP. 
Primary analysis: 
The statistical test for the primary efficacy endpoint (change in HbA1c 
from baseline to Week 26) will be one-sided, with alpha level of 0.025 
and using a non-inferiority margin of 0.3% HbA1c. 
The baseline value is defined as the last available value up to the date 
of randomization. 
The primary endpoint will be analyzed on the ITT population using all 
post-baseline data available during the main 6-month randomized 
period (ITT estimand). 
A multiple imputation approach in two parts will be used with missing 
data imputed separately for patients who did not adhere to IMP and 
patients who adhered to IMP: 
• 
Missing data in patients who prematurely discontinued IMP 
during the main 6-month randomized period will be imputed 
using a model estimated solely from data observed in other 
patients who discontinued IMP during the main 6-month 
randomized period but have the measurement for the 
primary endpoint at Week 26. 
• 
Missing data in patients who completed the main 6-month 
treatment period will be imputed separately, using a model 
estimated solely from data observed in other patients who 
completed the main 6-month treatment period and have the 
measurement for the primary endpoint at Week 26. 
Data obtained after the above imputations will be analyzed using an 
analysis of covariance (ANCOVA) of the change in HbA1c from 
baseline to Week 26, including the fixed categorical effects of 
treatment group (SAR341402, NovoLog/NovoRapid), randomization 
strata, as well as the continuous fixed covariate of baseline value. 
The adjusted least squares mean (LS mean) of the change in HbA1c 
from baseline to Week 26 for each treatment group (SAR341402, 
NovoLog/NovoRapid) will be estimated, as well as the between-group 
LS mean difference of SAR341402 versus NovoLog/NovoRapid, with 
the corresponding standard errors and 2-sided 95% CIs. 
Non-inferiority will be demonstrated if the upper bound of the 2-sided 
95% CI of the difference between SAR341402 and 
NovoLog/NovoRapid on the ITT population is <0.3%. If non-inferiority 
of SAR341402 over NovoLog/NovoRapid is demonstrated, using a 
hierarchical step-down testing procedure, the following additional 
analysis will be performed (not as primary objective): the inverse  
non-inferiority (of NovoLog/NovoRapid over SAR341402) will be tested 
looking at the lower bound of the 2-sided 95% CI of the difference 
between SAR341402 and NovoLog/NovoRapid in the ITT population. 
Non-inferiority of NovoLog/NovoRapid over SAR341402 will be 
demonstrated if the lower bound is >-0.3%. If SAR341402 is shown to 
be non-inferior to NovoLog/NovoRapid and NovoLog/NovoRapid  
non-inferior to SAR341402, similar efficacy (equivalence) of 
SAR341402 and NovoLog/NovoRapid will be assumed. 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 9 
Analysis of secondary endpoints: 
Secondary efficacy endpoints will be analyzed in the ITT population, 
using all post-baseline data available (ITT estimand). 
A similar multiple imputation approach in two parts, as for the primary 
efficacy endpoint, will be used for continuous secondary efficacy 
endpoints (change in HbA1c from baseline to Week 52, and change in 
FPG, mean 24 hour plasma glucose concentration, and postprandial 
plasma glucose excursions from baseline to Week 26 and Week 52), 
followed by a similar ANCOVA model. 
The categorical secondary efficacy endpoint (HbA1c responders) will 
be analyzed using a logistic regression model with fixed-effect term for 
treatment group (SAR341402, NovoLog/NovoRapid) and the 
randomization strata. Patients without assessment at Week 26 
(or Week 52 for the analysis at Week 52) will be considered as failure. 
Analyses on the secondary efficacy endpoints will be performed for 
descriptive purpose only (no formal statistical testing). 
Safety analyses during the main 6-month and the 12-month  
on-treatment periods will be descriptive, based on the safety 
population. Treatment-emergent AEs (TEAEs) are defined as AEs that 
developed or worsened or became serious during the period from the 
first administration of study treatment up to 1 day after the last 
administration. 
Immunogenicity analyses during the main 6-month and the 12-month 
on-treatment periods will be descriptive (no formal statistical testing), 
based on the AIA population. The analysis will focus on the change in 
AIA response observed following the IMP administration: 
• 
Patients with treatment-induced AIAs will be defined as 
patients with AIAs that developed de novo (seroconversion) 
following the IMP administration. 
• 
Patients with treatment-boosted AIAs will be defined as 
patients with pre-existing AIAs that were boosted to a 
significant higher titer following the IMP administration (at 
least 4-fold increase in titer values). 
• 
Patients with treatment-emergent AIAs (AIA incidence) will 
be defined as patients with treatment-induced or  
treatment-boosted AIAs. 
For exploratory purposes, the difference between SAR341402 and 
NovoLog/NovoRapid in the percentage of patients with 
treatment-emergent AIAs (AIA incidence) will be provided with 
associated 2-sided 90% CI. Results will be obtained by fitting a 
binomial regression model with an identity-link function. The model will 
include fixed categorical effects for treatment, the randomization strata 
of geographical region and type of diabetes (Europe T1DM, US T1DM, 
US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%), and prior use 
of NovoLog/NovoRapid (Yes, No). The risks within each treatment 
group and risk difference will be provided with their 90% CIs using the 
adjusted LS mean estimates of the treatment effect. 
Subgroup analyses and/or scatterplots will be conducted as 
appropriate to assess the relationship between AIA endpoints and 
efficacy/safety assessments. 
 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 10 
DURATION OF STUDY PERIOD (per patient) The study will consist of:  
• 
A 2-week screening period. 
• 
A 26-week treatment period. 
• 
A 26-week comparative safety extension period. 
• 
A 1-day follow-up period. 
In total, the study duration will be 54 weeks per patient (+ 1 day safety 
follow-up). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 11 
1 
FLOW CHARTS 
1.1 
GRAPHICAL STUDY DESIGN 
 
 
Note: For patients with T2DM, background as allowed in Section 7.2.1 and Section 8.8 at a stable dose can be continued during the study.  
(electronic 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 12 
1.2 
STUDY FLOW CHART 
 
Period 
Screening 
Treatment period (26 weeks) 
Comparative Safety 
Extension period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 
Wk-1 
a 
Wk 0 
(Baseline) 
Wk2 
a 
Wk4 
Wk8 
a 
Wk12 
Wk20 
Wk26b 
(Endpoint) 
Wk34 
a 
Wk40 
Wk52b 
(End of 
treatment) 
+1 dayc 
a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 (±3) 
238 
(±5) 
280 
(±5) 
364 (±5)   
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion criteria 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
Demography, medical history, diabetes history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination  
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Vital signsd 
X 
 
X 
 
X 
  
X 
X 
X 
 
X 
X 
 
Body weight, heighte 
X 
 
X 
 
 
 
 
 
X 
 
 
X 
 
12-lead ECG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Dispensation of study glucometer and e-diary 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Training (glucometer, SMPG profiles, 
hypoglycemia reporting e-diary) 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
Training or refresher instructions on glucose 
meter use and routine review of diet and 
lifestyle counseling along with instructions on 
dosage self-adjustment  including carbohydrate 
intakef  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispensation of study medicationg 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
• IMP (SAR341402 or NovoLog/NovoRapid) 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
• NIMP (Lantus) 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
Counting / collecting used, unused and in use 
pens 
 
 
 
 
X 
 
X 
X 
X 
 
X 
X 
 
Compliance check 
(Review of diary, returned IMP) 
 
 
 
 
X 
 
X 
X 
X 
 
X 
X 
 
IRT call 
X 
 
X 
 
X 
 
X 
X 
X 
 
X 
X 
X 
(electronic 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 13 
Period 
Screening 
Treatment period (26 weeks) 
Comparative Safety 
Extension period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 
Wk-1 
a 
Wk 0 
(Baseline) 
Wk2 
a 
Wk4 
Wk8 
a 
Wk12 
Wk20 
Wk26b 
(Endpoint) 
Wk34 
a 
Wk40 
Wk52b 
(End of 
treatment) 
+1 dayc 
a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 (±3) 
238 
(±5) 
280 
(±5) 
364 (±5)   
 
Visit date confirmation in e-diary web portal 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Randomizationh 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Patient to come fasting to study site 
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Insulin dose collected i 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
7-point SMPG j 
 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
SMPG to support insulin dose titrationk 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Central laboratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
HbA1c  
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Fasting plasma glucose 
 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
C-peptide (fasting) 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Anti-insulin antibody l 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
Safety laboratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematologym, Clinical chemistryn 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Lipids (fasting)o 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Hepatitis serology 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test (WOCBP only)p 
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Serum FSH and estradiol (menopausal women 
only) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
AE / SAE 
To be assessed and reported (if any) throughout the study (report SAE to the sponsor within 24 hours) 
X 
Injection site reactions 
To be assessed and reported (if any)  throughout the study 
X 
Hypersensitivity reactions 
To be assessed and reported (if any)  throughout the study 
X 
Hypoglycemia recording 
To be assessed and reported (if any)  throughout the study 
SMPG to be performed and documented in e-diary / e-CRF in case of symptoms suggesting hypoglycemia 
X 
(electronic 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 14 
ALP: alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, eGFR: estimated glomerular filtration rate, FSH: follicle stimulating hormone, IMP: investigational medicinal product, IRT: 
interactive response technology, NIMP: noninvestigational medicinal product, SMPG: self-measured plasma glucose, Wk: week 
a Mandatory telephone visit or optional clinical visit.  
b Or early termination visit. When early termination, refer to the e-CRF completion guidelines. 
c Or 2 to 3 days in the event this visit falls on a weekend or holiday. 
d Heart rate, blood pressure (BP). At screening visit only: determination of reference arm for BP. 
e Height only at Visit 1. 
f 
Site will provide training at screening visit and baseline visit on the correct handling including regular calibration of the glucose meter provided by the Sponsor; regular refresher instructions will be provided at each 
on-site visit throughout the study. 
g Patients are trained on the use of IMP and NIMP pens and needles by the study staff and provided with instruction leaflets during the randomization visit. 
h Randomization should be performed only after all baseline evaluations have been done. 
i 
Mealtime and basal insulin doses are to be documented in the 7 days prior to Baseline (Visit 3) and during the first 7 days after start of IMP, and on 2 days in the weeks prior to Visit 5 (Week 4), Visit 7 (Week 12), 
Visit 9 (Week 26), Visit 11 (Week 40) and Visit 12 (Week 52). 
j 
7-point SMPGs (fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch, pre- and 2 hours after dinner, and at bedtime) are requested on at least 2 days in the week before Visit 3 (Baseline), 
Visit 7 (Week 12), Visit 9 (Week 26 [Endpoint]), and Visit 12 (Week 52; End of treatment), measured in a single, 24-hour period; they must be recorded into the e-diary before the visit. 
k SMPG for titration oversight and supporting insulin dosing and carbohydrate intake documentation are recommended daily during the first weeks of study treatment until reaching target ranges for SMPG, and 
thereafter on at least 3 days each week or more frequently as requested by the Investigator (as specified in titration manual):  
Î To assist titration of the basal insulin (Lantus):  fasting (prebreakfast) SMPG. 
Î To assist titration of SAR341402 or NovoLog/NovoRapid: either postprandial or next-meal preprandial (in the case of dinner, bedtime) SMPG will be used, depending on the preference of the 
Investigator and patient and consistent with standard of care. 
These SMPGs, supporting optimization of the basal and mealtime insulin dose are recommended to be recorded in the e-diary at least weekly; they will be uploaded in the web portal for review by the site or the 
Sponsor (titration oversight working group). See titration oversight manual. The results will be discussed between Investigator and patient during on-site and scheduled or unscheduled telephone visits at the 
discretion of the Investigator. 7-point SMPG can also be used for titration oversight. 
For SMPG ≤3.9 mmol/L (≤70 mg/dL) the hypoglycemia form has to be completed. 
l 
Eight-hour delay must be respected between the last mealtime insulin dose and antibody sampling. 
m Hematology: erythrocytes, hemoglobin, hematocrit, leukocytes, differential blood count (neutrophils, lymphocytes, monocytes, eosinophils, basophils) and platelets. 
n Clinical chemistry: sodium, potassium, creatinine, eGFR (MDRD), ALT, AST, ALP and total bilirubin (in case of values above the normal range, differentiation in conjugated and non-conjugated bilirubin). 
o Serum lipids: total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides (in fasting conditions). 
p For women of childbearing potential (WOCBP): Serum pregnancy test for screening; urine pregnancy test for subsequent monitoring. 
(electronic 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 15 
2 
TABLE OF CONTENTS 
 
1 
FLOW CHARTS.............................................................................................................................11 
1.1 
GRAPHICAL STUDY DESIGN ......................................................................................................11 
1.2 
STUDY FLOW CHART ..................................................................................................................12 
2 
TABLE OF CONTENTS ................................................................................................................15 
2.1 
LIST OF TABLES...........................................................................................................................21 
2.2 
LIST OF FIGURES.........................................................................................................................21 
3 
LIST OF ABBREVIATIONS ..........................................................................................................22 
4 
INTRODUCTION AND RATIONALE.............................................................................................24 
5 
STUDY OBJECTIVES ...................................................................................................................27 
5.1 
PRIMARY.......................................................................................................................................27 
5.2 
SECONDARY ................................................................................................................................27 
6 
STUDY DESIGN ............................................................................................................................28 
6.1 
DESCRIPTION OF THE STUDY...................................................................................................28 
6.2 
DURATION OF STUDY PARTICIPATION ....................................................................................30 
6.2.1 
Duration of study participation for each patient .............................................................................30 
6.2.2 
Determination of end of clinical trial (all patients) ..........................................................................30 
6.3 
INTERIM ANALYSIS......................................................................................................................30 
6.4 
STUDY COMMITTEES..................................................................................................................30 
7 
SELECTION OF PATIENTS..........................................................................................................31 
7.1 
INCLUSION CRITERIA..................................................................................................................31 
7.2 
EXCLUSION CRITERIA ................................................................................................................31 
7.2.1 
Exclusion criteria related to study methodology ............................................................................31 
7.2.2 
Exclusion criteria related to the active comparator and/or mandatory background therapies.......33 
7.2.3 
Additional exclusion criteria during or at the end of screening before randomization ...................34 
8 
STUDY TREATMENTS .................................................................................................................35 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 16 
8.1 
INVESTIGATIONAL MEDICINAL PRODUCT(S) ..........................................................................35 
8.1.1 
Name of the investigational medicinal product ..............................................................................35 
8.1.2 
Pharmaceutical forms of the investigational medicinal product and injection devices ..................35 
8.1.2.1 
SAR341402....................................................................................................................................36 
8.1.2.2 
NovoLog/NovoRapid......................................................................................................................36 
8.1.3 
Route and method of investigational medicinal product administration.........................................37 
8.1.3.1 
SAR341402....................................................................................................................................37 
8.1.3.2 
NovoLog/NovoRapid......................................................................................................................37 
8.1.4 
Timing of investigational medicinal product administration............................................................37 
8.1.5 
Dose of investigational medicinal product......................................................................................38 
8.1.5.1 
Starting dose..................................................................................................................................38 
8.1.5.2 
Dose adjustment ............................................................................................................................38 
8.1.6 
Evaluation of patients not meeting glycemic goals........................................................................39 
8.1.7 
Reasons for treatment discontinuation ..........................................................................................40 
8.2 
NONINVESTIGATIONAL MEDICINAL PRODUCT(S) ..................................................................40 
8.2.1 
Starting dose of noninvestigational medicinal product (Lantus) ....................................................40 
8.2.2 
Dose adjustment of noninvestigational medicinal product (Lantus) ..............................................41 
8.3 
BLINDING PROCEDURES............................................................................................................41 
8.3.1 
Methods of blinding........................................................................................................................41 
8.4 
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP ..............................................42 
8.5 
PACKAGING AND LABELING ......................................................................................................43 
8.6 
STORAGE CONDITIONS AND SHELF LIFE................................................................................43 
8.7 
RESPONSIBILITIES ......................................................................................................................43 
8.7.1 
Treatment accountability and compliance......................................................................................44 
8.7.2 
Return and/or destruction of treatments ........................................................................................45 
8.8 
CONCOMITANT MEDICATION.....................................................................................................45 
8.8.1 
Prohibited concomitant therapy .....................................................................................................45 
9 
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT ..............................................47 
9.1 
PRIMARY ENDPOINT ...................................................................................................................47 
9.2 
SECONDARY ENDPOINTS ..........................................................................................................47 
9.2.1 
Immunogenicity endpoints .............................................................................................................47 
9.2.1.1 
Observation period of immunogenicity variables ...........................................................................47 
9.2.1.2 
Immunogenicity assessments........................................................................................................47 
9.2.1.3 
Immunogenicity variables definition...............................................................................................48 
9.2.2 
Secondary efficacy endpoints........................................................................................................49 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 17 
9.2.2.1 
Observation period of efficacy variables........................................................................................49 
9.2.2.2 
Efficacy assessment methods .......................................................................................................49 
9.2.3 
Safety endpoints ............................................................................................................................51 
9.2.3.1 
Observation period for safety variables .........................................................................................52 
9.2.3.2 
Safety assessment methods..........................................................................................................52 
9.3 
OTHER ENDPOINTS.....................................................................................................................57 
9.3.1 
Pharmacokinetics...........................................................................................................................57 
9.3.2 
Insulin dose....................................................................................................................................57 
9.4 
FUTURE USE OF SAMPLES ........................................................................................................57 
9.5 
APPROPRIATENESS OF MEASUREMENTS ..............................................................................57 
10 
STUDY PROCEDURES ................................................................................................................59 
10.1 
VISIT SCHEDULE..........................................................................................................................59 
10.1.1 
Screening period............................................................................................................................60 
10.1.1.1 On-site Visit 1 (Week -2) screening visit........................................................................................60 
10.1.1.2 Screening telephone visit: Visit 2 (Week-1) +/- 3 days ..................................................................62 
10.1.2 
Open-label randomized treatment period and comparative safety extension period (Week 0 
to Week 52)....................................................................................................................................63 
10.1.2.1 Baseline visit (Visit 3, Week 0/Day 1) ............................................................................................64 
10.1.2.2 On-site visits: Visit 5 (Week 4), Visit 8 (Week 20) +/- 3 days ........................................................66 
10.1.2.3 On-site visits: Visit 7 (Week 12) +/- 3 days and Visit 11 (Week 40) +/- 5 days .............................67 
10.1.2.4 Visit 9 (Week 26, primary efficacy endpoint) +/- 3 days ................................................................69 
10.1.2.5 Telephone visits: Visit 4 (Week 2) +/-3 days, Visit 6 (Week 8) +/-3 days, Visit 10 (Week 34) 
+/- 5 days; unscheduled telephone/fax/email visits .......................................................................70 
10.1.2.6 End of treatment visit: Visit 12 (Week 52) +/- 5 days.....................................................................71 
10.1.3 
Post-treatment follow-up ................................................................................................................72 
10.1.3.1 Post-treatment follow-up telephone visit: Visit 13 (Week 52 + 1 day) ...........................................72 
10.2 
DEFINITION OF SOURCE DATA..................................................................................................72 
10.2.1 
Source data to be found in patient´s file ........................................................................................72 
10.2.2 
Source data verification requirements for screen failures .............................................................73 
10.3 
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION.......................................73 
10.3.1 
Temporary treatment discontinuation with investigational medicinal product(s) ...........................74 
10.3.2 
Permanent treatment discontinuation with investigational medicinal product(s) ...........................74 
10.3.3 
List of criteria for permanent treatment discontinuation.................................................................74 
10.3.4 
Handling of patients after permanent treatment discontinuation ...................................................75 
10.3.5 
Procedure and consequence for patient withdrawal from study....................................................75 
10.4 
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING ..........................76 
10.4.1 
Definitions of adverse events.........................................................................................................76 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 18 
10.4.1.1 Adverse event ................................................................................................................................76 
10.4.1.2 Serious adverse event ...................................................................................................................76 
10.4.1.3 Adverse event of special interest...................................................................................................77 
10.4.2 
Serious adverse events waived from expedited regulatory reporting to regulatory 
authorities.......................................................................................................................................78 
10.4.3 
General guidelines for reporting adverse events ...........................................................................78 
10.4.4 
Instructions for reporting serious adverse events ..........................................................................78 
10.4.5 
Guidelines for reporting adverse events of special interest...........................................................79 
10.4.5.1 Reporting of adverse events of special interest with immediate notification .................................79 
10.4.5.2 Reporting of adverse events of special interest without immediate notification ............................79 
10.4.6 
Guidelines for management of specific laboratory abnormalities ..................................................79 
10.5 
OBLIGATIONS OF THE SPONSOR .............................................................................................80 
10.6 
SAFETY INSTRUCTIONS .............................................................................................................81 
10.6.1 
Hypoglycemia.................................................................................................................................81 
10.6.2 
Injection site reactions ...................................................................................................................81 
10.6.3 
Hypersensitivity reactions ..............................................................................................................82 
10.6.4 
SMPG.............................................................................................................................................82 
10.6.5 
Follow-up of laboratory abnormalities............................................................................................82 
10.6.6 
Other ..............................................................................................................................................82 
10.7 
ADVERSE EVENTS MONITORING..............................................................................................82 
11 
STATISTICAL CONSIDERATIONS..............................................................................................83 
11.1 
DETERMINATION OF SAMPLE SIZE...........................................................................................83 
11.2 
DISPOSITION OF PATIENTS .......................................................................................................83 
11.3 
ANALYSIS POPULATIONS...........................................................................................................85 
11.3.1 
Efficacy populations .......................................................................................................................85 
11.3.1.1 Intent–to-treat population ...............................................................................................................85 
11.3.1.2 Per protocol population ..................................................................................................................85 
11.3.2 
Safety population ...........................................................................................................................85 
11.3.3 
Anti-insulin antibody population .....................................................................................................86 
11.4 
STATISTICAL METHODS .............................................................................................................86 
11.4.1 
Extent of study treatment exposure ...............................................................................................86 
11.4.1.1 Extent of investigational medicinal product exposure....................................................................86 
11.4.1.2 Daily insulin doses .........................................................................................................................87 
11.4.2 
Analyses of efficacy endpoints.......................................................................................................87 
11.4.2.1 Analysis of primary efficacy endpoint(s) ........................................................................................87 
11.4.2.2 Analyses of secondary efficacy endpoints.....................................................................................90 
11.4.2.3 Multiplicity considerations ..............................................................................................................90 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 19 
11.4.3 
Analyses of safety data..................................................................................................................91 
11.4.3.1 Hypoglycemia.................................................................................................................................91 
11.4.3.2 Injection site reactions and hypersensitivity reactions...................................................................91 
11.4.3.3 Adverse events ..............................................................................................................................92 
11.4.3.4 Analyses of laboratory variables....................................................................................................92 
11.4.3.5 Analyses of vital sign variables ......................................................................................................92 
11.4.3.6 Drug-induced liver injury ................................................................................................................92 
11.4.4 
Analysis of immunogenicity data....................................................................................................93 
11.4.5 
Analyses of pharmacokinetic and pharmacodynamic variables ....................................................94 
11.5 
INTERIM ANALYSIS......................................................................................................................94 
12 
ETHICAL AND REGULATORY CONSIDERATIONS...................................................................95 
12.1 
ETHICAL AND REGULATORY STANDARDS ..............................................................................95 
12.2 
INFORMED CONSENT .................................................................................................................95 
12.3 
HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT 
ETHICS COMMITTEE (IRB/IEC)...................................................................................................95 
13 
STUDY MONITORING...................................................................................................................97 
13.1 
RESPONSIBILITIES OF THE INVESTIGATOR(S).......................................................................97 
13.2 
RESPONSIBILITIES OF THE SPONSOR.....................................................................................97 
13.3 
SOURCE DOCUMENT REQUIREMENTS....................................................................................97 
13.4 
USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST......................................................................................................................................98 
13.5 
USE OF COMPUTERIZED SYSTEMS..........................................................................................98 
14 
ADDITIONAL REQUIREMENTS...................................................................................................99 
14.1 
CURRICULUM VITAE....................................................................................................................99 
14.2 
RECORD RETENTION IN STUDY SITES ....................................................................................99 
14.3 
CONFIDENTIALITY .......................................................................................................................99 
14.4 
PROPERTY RIGHTS...................................................................................................................100 
14.5 
DATA PROTECTION...................................................................................................................100 
14.6 
INSURANCE COMPENSATION..................................................................................................101 
14.7 
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES ...............................101 
14.8 
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE..........................................................................................................................................101 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 20 
14.8.1 
By the Sponsor.............................................................................................................................101 
14.8.2 
By the Investigator .......................................................................................................................102 
14.9 
CLINICAL TRIAL RESULTS ........................................................................................................102 
14.10 
PUBLICATIONS AND COMMUNICATIONS ...............................................................................102 
15 
CLINICAL TRIAL PROTOCOL AMENDMENTS ........................................................................103 
16 
BIBLIOGRAPHIC REFERENCES...............................................................................................104 
17 
APPENDICES..............................................................................................................................106 
APPENDIX A GUIDANCE ON CONTRACEPTIVE METHODS AND COLLECTION OF 
PREGNANCY INFORMATION..........................................................................................106 
APPENDIX B 
GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY 
ABNORMALITIES BY SANOFI.........................................................................................110 
APPENDIX C COUNTRY SPECIFIC REQUIREMENTS .........................................................................115 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 21 
2.1 
LIST OF TABLES 
Table 1 - Summary of adverse event reporting instructions..........................................................................80 
Table 2 - Power calculation based on the percentage of patients with treatment-emergent AIAs ...............83 
 
2.2 
LIST OF FIGURES 
Not applicable. 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 22 
3 
LIST OF ABBREVIATIONS 
 
ADA: 
American Diabetes Association 
AE: 
adverse event 
AESI: 
adverse event of special interest 
AIA: 
anti-insulin antibody 
ALP: 
alkaline phosphatase 
ALT: 
alanine transaminase 
ANCOVA: 
analysis of covariance 
ARAC: 
Allergic Reaction Assessment Committee 
AST: 
aspartate transaminase 
BP: 
blood pressure 
CI: 
confidence interval 
CPK: 
creatine phosphokinase 
CSII: 
continuous subcutaneous insulin infusion 
CSR: 
clinical study report 
CV: 
curriculum vitae 
DBP: 
diastolic blood pressure 
DKA: 
diabetic ketoacidosis 
DRF: 
discrepancy resolution form 
e-CRF: 
electronic case report form 
eGFR: 
estimated glomerular filtration rate 
FPG: 
fasting plasma glucose 
FSH: 
follicle stimulating hormone 
GAD: 
glutamic acid decarboxylase 
GCP: 
good clinical practice 
GLP-1: 
glucagon-like peptide-1 
HbA1c: 
glycated hemoglobin A1c 
HBs-Ag: 
Hepatitis B surface antigen 
HC-Ab: 
Hepatitis C antibody 
HDL: 
high-density lipoprotein 
HLGT: 
high level group term 
HLT: 
high level term 
HRT: 
hormonal replacement therapy 
ICH: 
International Council for Harmonisation 
IEC: 
Independent Ethics Committee 
IMP: 
investigational medicinal product 
INR: 
international normalised ratio 
IRB/IEC: 
Institutional Review Board / Independent Ethics Committee 
IRT: 
interactive response technology 
ITT: 
intent-to-treat 
IUD: 
intrauterine device 
IUS: 
intrauterine hormone-releasing system 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 23 
J-S: 
James-Stein 
LDL: 
low-density lipoprotein 
LLT: 
lower level term 
LS: 
least squares 
MCMC: 
Markov Chain Monte Carlo 
MDI: 
multiple daily injection 
MDRD: 
Modification of Diet in Renal Disease 
MedDRA: 
Medical Dictionary for Regulatory Activities 
NGSP: 
National Glycohemoglobin Standardization Program 
NIMP: 
noninvestigational medicinal product 
NovoLog: 
Novo Nordisk’s insulin aspart, US-approved 
NovoRapid: 
Novo Nordisk’s insulin aspart, EU-approved 
NYHA: 
New York Heart Association 
OAD: 
oral antidiabetic drug 
PCSA: 
potentially clinically significant abnormality 
PT: 
preferred term 
PTC: 
Product Technical Complaint 
rDNA: 
recombinant DNA 
SAE: 
serious adverse event 
SBP: 
systolic blood pressure 
SC: 
subcutaneous(ly) 
SD: 
standard deviation 
SMPG: 
self-measured plasma glucose 
SMQ: 
standardized MedDRA query 
SOC: 
system organ class 
SUSAR: 
suspected unexpected serious adverse reaction 
T1DM: 
type 1 diabetes mellitus 
T2DM: 
type 2 diabetes mellitus 
TEAE: 
treatment-emergent adverse event 
TG: 
triglycerides 
ULN: 
upper limit of the normal laboratory range 
WOCBP: 
woman of child-bearing potential 
β-HCG: 
β-human chorionic gonadotropin 
 
  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 24 
4 
INTRODUCTION AND RATIONALE 
Intensive insulin therapy (multiple daily injection [MDI], with 3 or more injections per day of 
insulin or continuous subcutaneous insulin infusion [CSII], ie, insulin pump therapy) was 
demonstrated in the Diabetes Control and Complications Trial (6, 7) to result in improved blood 
glucose control and reduced micro-vascular complications and neuropathy (6). According to the 
American Diabetes Association (ADA), recommended therapy for type 1 diabetes mellitus 
(T1DM) (8) consists of: 1) use of multiple-dose insulin injections (three to four injections per day 
of basal and prandial insulin) or CSII therapy; 2) matching prandial insulin to carbohydrate intake, 
pre-meal blood glucose, and anticipated activity; and 3) most individuals should use rapid-acting 
insulin analogs to reduce hypoglycemia risk (1). In patients with type 2 diabetes mellitus (T2DM) 
who are insufficiently controlled on basal insulin with or without metformin and other non-insulin 
antihyperglycemic drugs, initiation of rapid acting insulin is recommended. With further 
progression of the diabetes due to the progressive β-cell failure, insulin replacement using a 
multiple daily injection regimen (with a standard method for adjusting insulin dose that may 
include matching prandial insulin to carbohydrate intake) is indicated in patients with T2DM to 
manage hyperglycemia (9). 
SAR341402 is insulin aspart, a rapid-acting human insulin analog of recombinant DNA (rDNA) 
origin. Insulin aspart (rDNA origin) is the active ingredient of NovoLog/NovoRapid, which has 
been approved and marketed in many countries worldwide since 1999. Apart from the exchange 
of proline at position 28 of the B chain for aspartic acid, insulin aspart is structurally identical to 
human insulin. This modification renders the insulin molecule less prone to self-associate into 
hexamers and accounts for faster absorption and activity as compared to human insulin given 
subcutaneously (SC). 
Further details on SAR341402 can be found in the Investigator’s Brochure SAR341402, latest 
Edition. 
The objectives of Study EFC15081 will be to demonstrate the non-inferiority of SAR341402 
versus NovoLog/NovoRapid on glycemic control measured as the glycated hemoglobin A1c 
(HbA1c) reduction from baseline to Week 26, to assess the immunogenicity of SAR341402 and 
NovoLog/NovoRapid by measuring anti-insulin antibodies (AIAs) and to determine the safety of 
SAR341402 and NovoLog/NovoRapid.  
Patients with T1DM or with T2DM on insulin treatment for at least one year with a measured 
HbA1c in the range of 7% to 10% on a multiple daily insulin injection treatment regimen with 
insulin glargine (100 U/mL) or insulin detemir (100 U/mL, Levemir) and that includes either 
NovoLog/NovoRapid or insulin lispro 100 U/mL as the rapid-acting insulin are eligible for the 
study (refer to Section 7.1). For exclusion criteria, see Section 7.2. 
A total of approximately 580 patients will be randomized to one of the two treatment groups, 
SAR341402 or NovoLog/NovoRapid (1:1). Randomization will be stratified according to 
geographical region (Europe, US, Japan), type of diabetes (T1DM, T2DM [T2DM only for US]), 
patients screening HbA1c (<8.0%, ≥8.0%), and prior use of NovoLog/NovoRapid (Yes, No). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 25 
The primary efficacy analysis will test non-inferiority of SAR341402 compared to 
NovoLog/NovoRapid in terms of HbA1c change from baseline to Week 26. A non-inferiority 
margin of 0.3 % HbA1c has been defined, which is in line with recommendations by regulatory 
agencies (10, 11). HbA1c reflects glycemic control over the last 2 to 3 months and has been 
accepted as measure of overall, long-term blood glucose control in patients with diabetes. HbA1c 
is an appropriate primary endpoint to support a claim based on glycemic control. 
Secondary efficacy analyses will include percentage of patients reaching HbA1c <7%, fasting 
plasma glucose (FPG; central laboratory) and change in the mean 24-hour glucose concentration 
and post-prandial plasma glucose excursions from baseline to Week 26 based on self-measured 
plasma glucose (SMPG) profiles (7-point glucose profiles). 
The immunogenic potential will be assessed by determination of antibody formation to 
SAR341402 or NovoLog/NovoRapid. Antibody titers and cross-reactivity to human insulin will 
also be determined. Clinically relevant AIA formation in response to exposure to an insulin 
product may change the pharmacokinetics and pharmacodynamics of the insulin by binding the 
insulin or even neutralizing the insulin, resulting in an overall unstable glycemic control and 
increase in HbA1c. This supports further the primary endpoint HbA1c in study EFC15081. 
In order to assess the clinical relevance of the AIAs, analyses will be conducted to investigate the 
relationship of AIAs with efficacy and safety endpoints (12, 13). 
Safety evaluation will be based on hypersensitivity reactions, injection site reactions, 
hypoglycemia (classification according to ADA definition [3]), treatment-emergent adverse 
events (TEAEs), vital signs, and laboratory data. 
Analyses will be presented overall (US-approved NovoLog [hereafter referred to as 
NovoLog]/EU-approved NovoRapid [hereafter referred to as NovoRapid] and the corresponding 
SAR341402 groups) and then for the subgroups comparing SAR341402 with NovoLog in patients 
randomized in the US (approximately 330 patients, 230 with T1DM, 100 with T2DM) and 
comparing SAR341402 and NovoRapid in regions using NovoRapid (approximately 250 patients 
with T1DM). Further subgroup analyses will be defined in the SAP.  
The study will consist of a 2-week screening period, a 26-week active-controlled treatment period, 
a 26-week comparative safety extension period and a 1-day follow-up period. 
At the end of the screening period, eligible patients will be randomized to SAR341402 or 
NovoLog/NovoRapid and depending on their prior basal insulin treatment switch to the 
mandatory basal insulin Lantus (insulin glargine 100 U/mL) or continue to use once daily Lantus 
(insulin glargine 100 U/mL). Patients will adjust the basal and mealtime insulin throughout the 
treatment and safety extension period to reach or maintain glucose control. SAR341402 will be 
administered using the SAR341402 SoloSTAR disposable pen. NovoLog/NovoRapid will be 
injected using the NovoLog/NovoRapid FlexPen. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 26 
Risk Benefit Assessment 
NovoLog has been marketed since 2000 and NovoRapid since 1999, and their safety profiles are 
well documented. No relevant quantitative or qualitative differences in the safety profile are 
expected for SAR341402. The adverse reactions observed with NovoLog and NovoRapid are 
known in the pharmacological class of blood glucose-lowering drugs and common to insulin 
products. A comparable safety profile is expected for SAR341402. 
Efficacy of NovoLog and NovoRapid are well described and SAR341402 is expected to have a 
similar efficacy. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 27 
5 
STUDY OBJECTIVES 
The primary objective will be assessed at the end of the main 6-month period (Week 26), and the 
result will be presented in the 6-month clinical study report (CSR). 
The secondary objectives will be assessed for both the main 6-month (up to Week 26) and  
12-month (up to Week 52, including the safety extension) periods, and the results will be 
presented respectively in the 6-month and 12-month CSR. 
5.1 
PRIMARY  
• To demonstrate non-inferiority of SAR341402 versus NovoLog/NovoRapid in HbA1c 
change from baseline to Week 26 in patients with T1DM or T2DM also using Lantus. 
5.2 
SECONDARY  
• To assess the immunogenicity of SAR341402 and NovoLog/NovoRapid in terms of 
positive/negative status and AIA titers during the course of the study. 
• To assess the relationship of AIAs with efficacy and safety. 
• To assess the efficacy of SAR341402 and NovoLog/NovoRapid in terms of proportion of 
patients reaching HbA1c <7.0% and change in HbA1c, FPG and SMPG profiles from 
baseline to Week 26 and Week 52 (only Week 52 for HbA1c). 
• To assess safety of SAR341402 and NovoLog/NovoRapid. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 28 
6 
STUDY DESIGN 
6.1 
DESCRIPTION OF THE STUDY 
This is a multicenter, multinational, open-label, randomized, active-controlled, 2-arm parallel 
group comparative Phase 3 study which will recruit outpatients with T1DM or with T2DM (in the 
US only) of at least one year (12 months) duration and who have been on MDI regimen using 
insulin glargine (100 U/mL) in the last 6 months prior to screening visit or Levemir 
(insulin detemir) in the last 12 months prior to screening visit and NovoLog/NovoRapid or insulin 
lispro 100 U/mL in the last 6 months prior to screening visit, comparing: 
• Insulin glargine 100 U/mL (Lantus) in combination with SAR341402.  
• Insulin glargine 100 U/mL (Lantus) in combination with NovoLog/NovoRapid. 
The study is open-label as injection devices, leaflets and other training material, and treatment kits 
are distinguishable from each other.  
The protocol-mandated background therapy is the insulin glargine (Lantus), which will be 
continued throughout the study, including the comparative safety extension period.  
Approximately 580 patients will be randomized to the rapid-acting insulins SAR341402 or 
NovoLog/NovoRapid in a 1:1 ratio at the end of the screening period. 
• Approximately 250 patients with T1DM will be randomized in the geographical area using 
NovoRapid (including Europe and Japan). 
• Approximately 330 patients, including 230 with T1DM and 100 with T2DM, will be 
randomized in the geographical region using NovoLog (all in the US). 
The number of patients with T1DM expected to be randomized in the US versus outside of the US 
may change owing to the recruitment potential at those regions.  
Randomization will be stratified by geographical region (Europe, US, Japan), by type of diabetes 
(T1DM, T2DM [T2DM only for US]), by HbA1c obtained at the screening visit (<8.0%, ≥8.0%), 
and by prior use of NovoLog/NovoRapid (Yes, No). 
Patients with T1DM or T2DM (T2DM US only) on a MDI regimen are eligible for the study. 
The clinical data that support the diagnosis of T1DM or T2DM are placed into the source 
documentation prior to randomization. Antibodies such as glutamic acid decarboxylase (GAD) 
antibodies or C-peptide levels may be supportive but are not alone considered diagnostic of 
T1DM, and in this trial are not assessed at screening. Patients with late onset T1DM are not 
excluded from the study. The diagnosis of T2DM will be based on the medical history, including 
high blood glucose levels caused by a lack of insulin and/or insulin resistance, with an onset most 
often in middle-aged and older adults. Common co-morbidities include obesity, hypertension, and 
hyperlipidemia.  Insulin is typically initiated when diet and life-style changes, followed by add-on 
metformin and other oral antihyperglycemic drugs, have failed. The exclusion criteria in this trial 
based on the pre-trial basal and rapid-acting insulin include: use of an insulin pump in the 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 29 
3 months before screening visit, use of basal insulin other than insulin glargine in the 6 months 
before screening visit or insulin detemir in the 12 months before screening visit and use of 
rapid-acting insulin other than Novolog/NovoRapid or insulin lispro in the 6 months before 
screening visit. 
The dose of SAR341402/NovoLog/NovoRapid will be adjusted at each meal and snack (“meal or 
snack” will be hereafter referred to as “meal”) by the patient based on the pre-meal SMPG and an 
assessment of the carbohydrate content of the meal (when available). Changes in activity may also 
be taken into account. 
SAR341402/NovoLog/NovoRapid will be injected SC immediately (within 5 to 10 minutes) 
before meal intake. Occasional postprandial injection soon after meal intake may be done if 
deemed necessary and if allowed by the national product label for NovoLog/NovoRapid.  
Lantus will be injected SC once daily. The dose of Lantus is to be optimized based on the fasting 
(prebreakfast) SMPG, and with the titration goal being an SMPG of 4.4 to 7.2 mmol/L 
(80 to 130 mg/dL), while avoiding hypoglycemia. 
At the screening visit, patients will be familiarized with the use of the insulin pens and will be 
shown how to accurately measure plasma glucose values with the Sponsor glucometer provided in 
this study. Study patients will be given detailed instruction on use of the electronic diary (e-diary) 
according to manufacturer’s instructions and how to transfer data from the glucometer to the  
e-diary. This will include how to assign SMPG and insulin doses that are related to routine 
“usual habit” daily use and how to assign the 7-point SMPG profiles at pre-specified times that 
are needed for endpoint analysis. In addition to SMPG measurement per ”usual habit”, fasting 
prebreakfast SMPGs and 3- or 4-point profiles are recommended for site oversight of insulin 
titration and are not used for endpoint analysis. All data captured in the e-diary including insulin 
dosing data will be available via the vendor web based portal for review by the Site, Monitoring 
team and Clinical Study Director. 
Detailed instruction will be provided on completion of the hypoglycemic episode diary pages in 
the e-diary and the importance of avoiding missing data. This training will be repeated at the 
randomization visit, as needed. 
Patients who are unable or unwilling to use the electronic diary during the screening period will 
be excluded from randomization since there is no alternate paper diary. Patients who have not 
completed the minimum of 5 out of 7 measurements for either of the 2 required 7-point profiles at 
baseline are not randomized.  
All study patients will receive intensive training at the time of randomization in techniques of 
using MDI by a trained professional. This may include carbohydrate counting/estimation and dose 
adjustment for food. When used, supplemental/correction scales for glucose out of goal range and 
carbohydrate counting ratios will be reviewed and assigned according to insulin sensitivity and 
previous use, and recorded in source documents at the randomization visit. Review of dosage 
self-adjustment and re-instruction on MDI will be done at each visit. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 30 
6.2 
DURATION OF STUDY PARTICIPATION 
6.2.1 Duration of study participation for each patient 
For each patient, the maximum study duration will be 54 weeks per patient + 1 day safety  
follow-up. 
6.2.2 Determination of end of clinical trial (all patients) 
The end of the study in all countries concerned by the trial is reached as soon as the last patient 
has completed all the scheduled study procedures. 
6.3 
INTERIM ANALYSIS 
No interim analysis is planned for this study. The study will not be terminated early for positive 
efficacy or safety.  
6.4 
STUDY COMMITTEES 
Allergic Reaction Assessment Committee (ARAC) 
As a biological protein, insulin has the potential to be immunogenic. Therefore an Allergic 
Reaction Assessment Committee (ARAC) independent from the Sponsor and the Investigators 
will be implemented.  The ARAC consists of 4 permanent members who are experts in the field of 
allergy and at least one of the members will be a diabetologist. The members of the ARAC will be 
blinded regarding the study treatment. 
The mission of the ARAC will be: 
• To adjudicate all potential hypersensitivity or hypersensitivity-like events and determine 
the nature of each event. 
• To assess a potential association of the hypersensitivity or hypersensitivity-like event with 
AIAs (see Section 9.2.1). 
• To recommend a follow up of patients with increase of AIA titers as defined in the ARAC 
charter and ongoing hypersensitivity or hypersensitivity like events and/or potential 
indicators of reduced efficacy as defined in the ARAC charter. 
The ARAC reviews the reported cases, determines the nature of the events, and based on the 
information reported by the Investigator confirms whether or not the event is allergic in nature. 
All ARAC reviews are recorded in addition to the Investigator’s assessment. List of allergic 
reaction codes will be included in the ARAC charter and in the statistical analysis plan (SAP). 
Members of the ARAC team will review relevant AIA data and determine if a high titer of AIA 
correlates with decreased efficacy or an increase in immunological or hypersensitivity reactions. 
If follow-up of AIA titers by ARAC is recommended, they will be followed up by the Sponsor 
until return to baseline or until the ARAC decides that no further follow-up is deemed necessary. 
A detailed charter describes the ARAC procedures. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 31 
7 
SELECTION OF PATIENTS 
7.1 
INCLUSION CRITERIA 
I 01. Patients with T1DM or with T2DM (T2DM US only) diagnosed for at least 12 months, 
and have been treated with an MDI regimen with 
- 
NovoLog/NovoRapid  
OR  
insulin lispro (100 U/mL) in the last 6 months prior to screening visit 
AND 
- 
insulin glargine (100 U/mL) in the last 6 months prior to screening visit 
OR  
insulin detemir (Levemir) in the last 12 months prior to screening visit 
I 02. Signed written informed consent obtained. 
7.2 
EXCLUSION CRITERIA 
Patients who have met all the inclusion criteria listed in Section 7.1 will be screened for the 
following exclusion criteria: 
7.2.1 Exclusion criteria related to study methodology 
E 01.  At screening visit, age under legal age of adulthood. 
E 02. HbA1c <7% or >10% at screening. 
E 03. Less than 1 year on continuous insulin treatment. 
E 04. Use of insulin pump in the last 3 months before screening visit. 
E 05. Patients with T1DM: Use of glucose-lowering agents other than insulin including use of 
non-insulin injectable peptides in the last 3 months prior to screening. 
E 06. Patients with T2DM:  
- 
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in the last 3 months before 
screening visit, 
- 
Use of oral antidiabetic drugs (OADs) not on stable dose in the last 3 months before 
screening visit (sulfonylureas will be discontinued at baseline). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 32 
E 07. Use of insulin other than 
- 
insulin glargine 100 U/mL and NovoLog/NovoRapid or insulin lispro 100 U/mL as 
part of a multiple injection regimen in the last 6 months before screening visit, OR 
- 
insulin detemir 100 U/mL in the 12 months before screening visit and 
NovoLog/NovoRapid or insulin lispro 100 U/mL in the last 6 months before screening 
visit as part of a multiple injection regimen. 
E 08. At screening visit, body mass index (BMI) ≥35 kg/m2 in patients with T1DM and 
≥40 kg/m2 in patients with T2DM. 
E 09. Positive serum pregnancy test in women of childbearing potential (WOCBP). 
E 10. Patients who have impaired renal function with estimated glomerular filtration rate (eGFR) 
(using the Modification of Diet in Renal Disease [MDRD] formula) <30 mL/min/1.73/m2. 
E 11. Liver injury related criteria: 
- 
Alanine transaminase (ALT) or aspartate transaminase (AST): >3 upper limit of the 
normal laboratory range (ULN), 
- 
Total bilirubin >1.5 ULN (except in case of Gilbert’s syndrome). 
E 12. Positive test for Hepatitis B surface antigen (HBs-Ag) and/or Hepatitis C antibody 
(HC-Ab). In the case of a positive HC-Ab test, negative Hepatitis C RNA test determines 
absence of active infection and patient is not excluded. 
E 13. Uncontrolled treated/untreated hypertension (systolic blood pressure [SBP] >180 mmHg 
and/or diastolic blood pressure [DBP] >95 mmHg at screening as the recorded screening 
blood pressures [BPs], refer to Section 9.2.3.2.5). 
E 14. Patients with severe or unstable hepatic, gastrointestinal, cardiovascular (including 
congestive heart failure New York Heart Association [NYHA] III/IV, history of 
myocardial infarction, stroke or heart failure requiring hospitalization in the last 3 months 
prior to screening visit), respiratory, neurological, psychiatric, hematological, renal, 
endocrine, dermatological disease, active malignant tumor, other major systemic disease or 
patients with short life expectancy or any other medical condition that might interfere with 
the evaluation of study medication according to Investigator’s medical judgment. 
E 15. Any clinically significant abnormality identified on physical examination, laboratory tests 
or ECG that in the judgment of the Investigator or any subInvestigator would preclude safe 
completion of the study or constrains efficacy assessment. 
E 16. Known history of drug or alcohol abuse within 6 months prior to the time of screening. 
E 17. Participation or planned participation in another clinical study other than disease registries. 
E 18. Use of investigational drugs or prohibited therapy for this study within 3 months or  
5 half-lives, whichever is longer, prior to the screening visit. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 33 
E 19. Conditions/situations such as: 
- 
Status post pancreatectomy, 
- 
Status post pancreas and/or islet cell transplantation, 
- 
History of severe hypoglycemia requiring Emergency Room admission or 
hospitalization in the last 3 months before screening visit, 
- 
Hospitalization for recurrent diabetic ketoacidosis (DKA) in the last 3 months before 
screening visit, 
- 
Patients with conditions/concomitant diseases making them non evaluable for the 
primary efficacy endpoint (eg, hemoglobinopathy or hemolytic anemia, receipt of 
blood products within the last 3 months prior to the screening visit); any anemia with 
anticipated rapid correction, 
- 
Patients with conditions/concomitant diseases precluding their safe participation in this 
study (unstable proliferative diabetic retinopathy or any other rapidly progressive 
diabetic retinopathy or macular edema likely to require treatment [eg, laser, surgical 
treatment or injectable drugs, etc]) during the study period, 
- 
No latest exam by an ophthalmologist (US/Canada: ophthalmologist or optometrist) 
within 12 months for patients with retinopathy or within 24 months for those with no 
evidence of retinopathy (exam during the screening period is acceptable, too), 
- 
Impossibility to meet specific protocol requirements (eg, scheduled visits, patients 
unable to fully understand patient’s study documents and to complete them, etc) 
including conditions that could make the patient potentially non-compliant to the study 
procedures, 
- 
Patient is an employee of Sanofi or of sponsor representatives, the Investigator or any  
SubInvestigator, research assistant, pharmacist, study coordinator, other staff or 
relative thereof directly involved in the conduct of the protocol, 
- 
Use of systemic glucocorticoids (excluding topical application or inhaled forms) 
greater than replacement dose for one week or more within 3 months prior to screening 
visit, 
- 
Likelihood of requiring treatment during the study period with drugs not permitted by 
the study protocol. 
7.2.2 Exclusion criteria related to the active comparator and/or mandatory background 
therapies  
E 20. Any contraindication to use of insulin glargine and/or NovoLog/NovoRapid as defined in 
the national product labels; history of hypersensitivity to insulin glargine and 
NovoLog/NovoRapid, or to any of the excipients. 
E 21. Pregnant or breast-feeding women. 
E 22. Women of childbearing potential  not protected by highly-effective method(s) of birth 
control and/or who are unwilling or unable to be tested for pregnancy (see contraceptive 
guidance in Appendix A). Pregnancy tests may be performed more frequently in some 
countries due to local legislations related to WOCBP randomized in clinical trials. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 34 
7.2.3 Additional exclusion criteria during or at the end of screening before randomization  
E 23. Patients who have incomplete baseline 7-point SMPG profile data, defined as patients who 
do not have 7-point profiles with at least 5 points on at least 2 days in the week before 
randomization Visit 3. 
E 24. Patients who have demonstrated during the screening period an unwillingness or inability 
to use the electronic diary according to Investigator’s discretion. 
E 25. Patient who has withdrawn consent before randomization. 
E 26. Any country-related specific regulation that would prevent the subject from entering the 
study. 
A patient should not be randomized more than once. In cases where original screen failure was 
due to reasons expected to change at rescreening and based upon the Investigator’s clinical 
judgment, the patient can be rescreened one time for this study. 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 35 
8 
STUDY TREATMENTS 
Diet and lifestyle counseling is an essential component of this trial. At randomization, a detailed 
session  by a professional competent in treating T1DM or T2DM (as appropriate) will include 
training  in dosage adjustment, consistent with the recommendations of international or local 
guidelines and practices for T1DM or T2DM patients. This may include patients who perform 
flexible dosing as well as those who choose to use consistent dosing with more consistent food 
intake. Compliance with recommendations for insulin dose changes and general information 
regarding diet and lifestyle recommendations consistent with local practices will be discussed 
with the patient throughout the study (Section 1.2), and more specifically in case of insufficient 
glucose control (Section 8.1.6). 
Investigators and site staff will be required to routinely provide oral instructions, written 
educational material and training consistent with local practices and individualized for each 
patient to ensure that the patients understand the importance of routine monitoring and routine 
dose self-adjustment of their rapid-acting insulin. The goal for all patients must be to attain good 
glycemic control by titrating to the defined glucose targets without increase of hypoglycemia. 
Monitoring of the insulin doses and changes in the titration recommendations are made by the 
Investigators and subInvestigators who are qualified to do so and who are trained in the protocol. 
8.1 
INVESTIGATIONAL MEDICINAL PRODUCT(S) 
8.1.1 Name of the investigational medicinal product  
SAR341402 product (Sanofi’s insulin aspart) (tested drug) and NovoLog/NovoRapid 
(Novo Nordisk’s insulin aspart) (comparator/control drug). 
The NovoLog and NovoRapid comparator will be used at sites depending on the countries and 
will be clearly identified. 
8.1.2 Pharmaceutical forms of the investigational medicinal product and injection 
devices 
SAR341402 will be provided as SAR341402 SoloSTAR pen and NovoLog/NovoRapid as 
NovoLog/NovoRapid FlexPen. 
Handling procedures of the pen and needles, administration technique and storage instructions are 
provided in an instruction leaflet. Patients will be trained by the study staff on the use of the 
injection devices and needles used in this study in addition to being provided with these 
instruction materials.  No training kits are provided for either investigational medicinal product 
(IMP). 
For the duration of the study, the patients will be required to use the study drug pens and needles 
supplied by the Sponsor. Different needle lengths supplied may be used interchangeably. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 36 
Any defect in the insulin pens must be reported as soon as possible by the Investigator to the 
monitoring team that will complete a Product Technical Complaint (PTC) form within required 
timelines. Appropriate information (eg, samples, labels or documents like pictures or photocopies) 
related to product identification and to the potential deficiencies may need to be gathered. 
The Investigator will assess whether or not the quality issue has to be reported together with an 
adverse event (AE) or serious adverse event (SAE). 
Mixing of either SAR341402 or NovoLog/NovoRapid with other insulin is not allowed nor is 
dilution. 
8.1.2.1 SAR341402 
The tested drug SAR341402 will be supplied as a 100 U/mL solution for SC injection in 3 mL 
pre-filled disposable SAR341402 SoloSTAR pens, allowing a maximum dose of SAR341402 per 
injection of 80 units and minimum dose of 1 unit. 
The following commercial pen needles will be provided for use with the SAR341402 SoloSTAR 
pen: 
• BD Ultra-Fine Needles 31 G x 5 mm. 
• BD Ultra-Fine Needles 31 G x 8 mm. 
In countries where the BD Ultra-Fine needle is not available, the smallest bore BD needle 
available will be used. 
Patients who are randomized to SAR341402 are trained on the use of the study drug pen and 
needles by the study staff and provided with an instruction leaflet during the randomization visit 
(Visit 3, Day 1). 
8.1.2.2 NovoLog/NovoRapid 
The comparator drug, NovoLog/NovoRapid, will be supplied as a 100 U/mL insulin solution for 
SC injection in the 3 mL NovoLog/NovoRapid FlexPen disposable prefilled pens, allowing a 
maximum dose of the NovoLog/NovoRapid of 60 units and minimum dose of 1 unit. 
The following commercial pen needles will be provided for use with the NovoLog/NovoRapid 
FlexPen: 
• BD Ultra-Fine Needles 31 G x 5 mm. 
• BD Ultra-Fine Needles 31 G x 8 mm. 
In countries where the BD Ultra-Fine needle is not available, the smallest bore BD needle 
available will be used. 
Patients will be trained on the use of NovoLog/NovoRapid FlexPen and provided with an 
instruction leaflet during the randomization visit (Visit 3, Day 1). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 37 
8.1.3 Route and method of investigational medicinal product administration 
SAR341402 or NovoLog/NovoRapid is self-administered by SC injection, in the abdominal wall, 
thighs, upper arms, or the deltoid or gluteal region. The area of the injections will be consistent 
with the habits of the individual patient. Injection sites will be rotated within that area. Changes in 
the area of injection during the study should be avoided as far as possible. The area of injection 
will be entered into the electronic case report form (e-CRF) at each study visit. The injection areas 
for IMP and noninvestigational medicinal product (NIMP) should be different so that any 
injection site reactions can be attributed specifically either to IMP (SAR341402; 
NovoLog/NovoRapid) or NIMP (Lantus). 
8.1.3.1 SAR341402  
• Patients randomized to SAR341402 will be supplied with the appropriate number of 
disposable SAR341402 SoloSTAR pens specifically labeled for the use in the study where 
required by local regulation along with BD needles. These will be dispensed at all 
subsequent on site visits up to Visit 11 (Week 40) included. The appropriate number of 
kits will be dispensed to cover up to the next dispensation visit (please refer to flowchart 
in Section 1.2). 
• Each SAR341402 SoloSTAR pen contains a cartridge with a total of 300 units of 
SAR341402. Doses can be set in increments of 1 U up to a maximum single injection of 
80 U. If a dose greater than 80 units is required, it will be given as two or more 
consecutive SC injections at the same time with the dose split in equal or close to equal 
doses.  
8.1.3.2 NovoLog/NovoRapid 
Patients randomized to NovoLog/NovoRapid will be supplied with the appropriate number of 
NovoLog/NovoRapid FlexPen disposable prefilled pens specifically labeled for the use in the 
study where required by local regulation along with BD needles. These will be dispensed at all 
subsequent on-site visits up to Visit 11 (Week 40) included. The appropriate number of kits will 
be dispensed to cover up to the next dispensation visit (please refer to flowchart Section 1.2).  
• Each NovoLog/NovoRapid FlexPen contains a total of 300 units of NovoLog/NovoRapid. 
Doses can be set in increments of 1 U up to a maximum single injection of 60 U. If a dose 
greater than 60 units is required, it will be given as two or more consecutive SC injections 
at the same time with the dose split in equal or close to equal doses. 
8.1.4 Timing of investigational medicinal product administration 
SAR341402 or NovoLog/NovoRapid is self-administered by SC injection immediately (within 
5 to 10 minutes) prior to the start of a meal. When necessary, NovoLog/NovoRapid can be given 
soon after a meal, if allowed by the national product label. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 38 
8.1.5 Dose of investigational medicinal product 
8.1.5.1 Starting dose 
At baseline, patients will be randomized to SAR341402 or NovoLog/NovoRapid, with a unit to 
unit conversion from the insulin lispro or NovoLog/NovoRapid dose used prior to the trial or with 
a dose at the discretion of the Investigator, taking into account the glucose control at the time of 
randomization. The usual or average total daily dose of insulin lispro or NovoLog/NovoRapid and 
the average number of daily mealtime injections used in the screening period are recorded once in 
the clinical database at the time of randomization. The patient’s usual supplemental/correction 
scale if one is used is recorded in source.  
8.1.5.2 Dose adjustment 
Changes in the SAR341402 or NovoLog/NovoRapid dose will be based on SMPG measurements 
and the carbohydrate content of the meal (when available). 
Doses will be self-titrated by the patients to achieve a 2-hour postprandial plasma glucose of 
<10.0 mmol/L (<180 mg/dL) while avoiding hypoglycemia. If pre-prandial glucose tests are used, 
the target range of 4.4 to 7.2 mmol/L (80 to 130 mg/dL) is recommended (1). For the purpose of 
this protocol, 2 hours postprandial is defined as 2 hours after the start of the meal. 
Glycemic targets may be adapted for individual patients, if deemed necessary, eg, due to age, 
comorbid conditions, and individual patient considerations. The individual targets will be 
recorded in source documents. Insulin doses may be reduced or modified at any time for 
hypoglycemia.  
Patients who experienced mild to moderate hypoglycemia as a result of a missed meal, unusual 
exercise or alcohol use will be counseled on the correction of those behaviors and will not have 
their insulin dose decreased. 
Regular plasma glucose monitoring is important to achieve these plasma glucose targets. Efforts 
should be made to reach the target range for fasting, prebreakfast plasma glucose and 2-hour 
postprandial or premeal plasma glucose in the first 12 weeks of the study. 
The doses of the mealtime insulin should be reviewed when the basal insulin dose is increased, as 
they may have to be reduced to avoid daytime hypoglycemia. 
On specified days (refer to Section 9.2.2.2.3, Section 9.3.2 and titration manual), patients must 
record all of the SAR341402 or NovoLog/NovoRapid doses, and the Lantus dose in their e-diary. 
SMPG and insulin doses are used to adjust doses of both basal and rapid-acting insulin and 
monitor trends in use of insulin. Insulin doses related to specified days are transferred to the 
clinical database. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 39 
8.1.6 Evaluation of patients not meeting glycemic goals 
In addition to the scheduled SMPG done by patients, central laboratory alerts on FPG and on 
HbA1c are set up to ensure that glycemic parameters remain below predefined threshold values. 
There is no specified rescue treatment. The thresholds values are defined as follows: 
• From Visit 7 (Week 12) onwards and inclusive to Visit 9 (Week 26): FPG >11 mmol/L 
(>200 mg/dL) or HbA1c >8.5%. 
• In case of FPG or HbA1c above the target values and/or SMPG are not improving as 
expected in spite of successive insulin dose titration, the Investigator should ensure that no 
reasonable explanation exists for insufficient glucose control and in particular that: 
- 
Plasma glucose was actually measured in fasting condition (ie, after at least 8 hours 
fasting), 
- 
Rebound hyperglycemia is excluded, 
- 
IMP dose is properly adjusted, 
- 
NIMP dose is properly adjusted, 
- 
Correction doses for pre-prandial glucose values above goal are used by patient, 
- 
There is no inter-current disease which may jeopardize glycemic control (eg, infectious 
disease), 
- 
Compliance to diet and lifestyle is appropriate, in particular, dosage adjustment for 
changes in carbohydrate content of the meal and SMPG. 
• If any of the above can reasonably explain the insufficient glycemic control, the 
Investigator should undertake appropriate action, ie: 
- 
Titrate the mealtime insulin dose of IMP, 
- 
Set up adequate investigation and treatment of inter-current disease (to be reported in 
AE/SAE/concomitant medication parts of the e-CRF), 
- 
Stress the absolute need to be compliant to treatment, 
- 
Stress the importance of consistency in meals and insulin dosing, particularly during 
this time of poor glycemic control, 
- 
Monitor night time glucose, 
- 
Organize a specific interview with a Registered Dietician or other medically qualified 
person to stress on the absolute need to be compliant to diet and lifestyle 
recommendations, in particular with attention to awareness of the carbohydrate content 
of the meal and covering all snacks with a dose of rapid-acting insulin, 
- 
Schedule a FPG / HbA1c assessment at the next visit. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 40 
8.1.7 Reasons for treatment discontinuation  
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at 
any time. List of criteria for permanent treatment discontinuation are found in Section 10.3.3. 
Handling of patients after permanent treatment discontinuation is described in Section 10.3.4. 
8.2 
NONINVESTIGATIONAL MEDICINAL PRODUCT(S) 
Insulin glargine (Lantus), which is to be used as the mandatory background basal insulin therapy 
throughout the study, is considered NIMP. 
At randomization, all patients will be supplied with the appropriate number of disposable Lantus 
SoloSTAR pens specifically labeled for the use in the study when required by local regulations 
and needles (BD Ultra-Fine Needles 31 G x 5 mm; BD Ultra-Fine Needles 31 G x 8 mm). 
These will be dispensed at all subsequent on-site visits up to Visit 11 (Week 40) included. Patients 
will be trained by the study staff at the site on the use of the injection devices and needles, 
administration techniques and storage conditions used in this study in addition to being provided 
with instruction materials. 
Similar to IMP, for the duration of the study, the patients will be required to use the NIMP study 
drug pens and needles supplied by the Sponsor. Different needle lengths supplied may be used 
interchangeably. In countries where the BD Ultra-Fine needle is not available, the smallest bore 
BD needle available will be used. 
Each Lantus SoloSTAR pen contains 3 mL of solution with a total of 300 units of insulin glargine. 
Doses can be set in increments of 1 U up to a maximum single injection of 80 U. If a dose greater 
than 80 units is required, it will be given as two or more consecutive SC injections at the same 
time with the daily dose split in equal or close to equal doses.  
Lantus will be injected once daily SC consistent with the local label. The time of injection 
(hh:mm) will be fixed at randomization (Visit 3, Baseline) according to patient and site 
preference.  
 
The area for the injection sites for Lantus injection should be different from that of the IMP so 
that any injection site reactions can be attributed specifically to the IMP or NIMP. The injection 
area is recorded in the e-CRF at each study visit. 
Mixing of Lantus with other insulin is not allowed, and nor is dilution. 
8.2.1 Starting dose of noninvestigational medicinal product (Lantus) 
Starting dose of Lantus at randomization will be the same as the last dose of insulin glargine 
100 U/mL or insulin detemir prior to baseline visit or at the discretion of the Investigator, taking 
into consideration the actual glycemic control and usual doses of basal insulin needed to manage 
diabetes mellitus. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 41 
8.2.2 Dose adjustment of noninvestigational medicinal product (Lantus) 
Doses of Lantus will be adjusted to achieve glycemic targets without hypoglycemia. Changes in 
the Lantus dose are based on fasting prebreakfast SMPG measurements using the glucometer 
provided for this study. Pre-prandial SMPG measurements will be taken into account also. 
The recommended target range for fasting, pre-prandial plasma glucose SMPG is 4.4 to 
7.2 mmol/L (80 to 130 mg/dL). This target range may be adapted for individual patients, if 
deemed necessary, (eg, due to age, comorbid conditions, individual patient considerations) so that 
an individual target range may be appropriate for individual patients. The individual targets for 
fasting SMPG will be recorded in source documents. 
The Lantus dose can be increased, if the median of fasting, pre-prandial plasma glucose over the 
previous 3 to 4 days is greater than the recommended target range of 4.4 to 7.2 mmol/L 
(80 to 130 mg/dL), or the individual pre-specified individual fasting SMPG target as recorded in 
source, and there has been no evidence of relevant hypoglycemia. The increase of the Lantus dose 
should not exceed 10% of the daily dose of Lantus (8). The Investigator may choose to change 
rapid-acting insulin doses instead and a change in basal insulin is not required by the protocol. 
Whenever the basal insulin dose is changed, the rapid-acting insulin doses need to be reviewed to 
avoid hypoglycemia. 
Doses of Lantus may be reduced or modified at any time for hypoglycemia. Patients who 
experienced mild to moderate hypoglycemia as a result of a missed meal, unusual exercise or 
alcohol use will be counseled on the correction of those behaviors and will not have their insulin 
dose decreased. 
Glycemic excursions related to inter-current illness should be primarily treated with rapid-acting 
insulin.  
8.3 
BLINDING PROCEDURES 
8.3.1 Methods of blinding 
SAR341402 in the SAR341402 SoloSTAR pen and the control drug, NovoLog/NovoRapid in the 
NovoLog/NovoRapid FlexPen are distinguishable and so this study is an open-label design. 
Administration of SAR341402/NovoLog/NovoRapid throughout the trial is to be open-label. 
Potential bias will be reduced by the following steps: 
• The specific treatment to be taken by a participant will be assigned using an interactive 
response technology (IRT) system. 
• HbA1c, FPG, and AIAs are determined in central laboratories blinded to the treatment 
received. 
• The study team will review data including the primary efficacy parameter in descriptive 
statistics without treatment assignment during data review meetings. 
• Members of the study team may review compliance with dosing and titration blinded to 
treatment; monitoring team is not blinded when reviewing. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 42 
• Measures will be undertaken to minimize that the treatment arm is not disclosed to the 
operational study team. 
• At Sponsor level, the unblinded treatment group allocation variable will be included in the 
clinical study database only at the time of 6-month database lock, to perform the 
corresponding analyses; summary results by treatment arm will therefore not be available 
to anyone before the last participant end of main 6-month period and corresponding 
database lock. 
• Medical monitor for insulin oversight will remain blinded to treatment arm. 
8.4 
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
The randomized treatment kit number list and NIMP kit number list are generated centrally by 
Sanofi. The IMPs and NIMPs are packaged in accordance with these lists.  
The Trial Supply Operation Manager provides the treatment kit number list and the 
Study Biostatistician provides the randomization scheme (including stratification, see Section 6.1) 
to the centralized treatment allocation (IRT) system. Then, the IRT generates the patient 
randomization list according to which it allocates treatment arms to the patients. 
The treatment kits, open-label boxes identified with treatment numbers, are allocated to the 
patients by the IRT using the treatment number of the boxes. 
At the screening visit the Investigator or designee calls the IRT for allocation of the patient 
number. The patient identification (patient number) is composed of 12-digit number containing 
the 3-digit country code, the 4-digit center code and the 5-digit patient chronological number 
(which is 00001 for the first patient screened in a center, 00002 for the second patient screened in 
the same center etc). 
Randomization ratio is 1:1, stratification will be done by geographical region (Europe, US, 
Japan), by type of diabetes mellitus (T1DM, T2DM [T2DM only for US]), by HbA1c obtained at 
the screening visit (<8.0%, ≥8.0%), and by prior use of NovoLog/NovoRapid (Yes, No). 
On Visit 3 (Day 1, Randomization), after all the baseline evaluations have been performed, the 
Investigator or designee has to call the IRT for the first treatment kit(s) allocation 
(randomization). Afterwards the IRT is called again each time a new treatment kit(s) allocation is 
necessary. 
A randomized patient is a patient who has been assigned to a randomized treatment arm by the 
IRT regardless whether the treatment kit was used or not. A patient cannot be randomized more 
than once in the study. Patients who need to be moved to another site will keep their number. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 43 
8.5 
PACKAGING AND LABELING 
The respective number of the study treatment will be packaged under the responsibility of Sanofi 
according to good manufacturing practice and local regulatory requirement. 
SAR341402, the active IMP, will be supplied in disposable SAR341402 SoloSTAR pens. 
The content of the labeling will be in accordance with the local regulatory specifications and 
requirements. 
Commercially available comparator NovoLog/NovoRapid and NIMP (Lantus) will be repackaged 
in study specific kits and relabeled with study specific labels in accordance with local regulatory 
specifications and regulations. 
Packaging is in accordance with the administration schedule. The content of the labeling is in 
accordance with the local regulatory specifications and requirements for both IMP and NIMP. 
8.6 
STORAGE CONDITIONS AND SHELF LIFE 
Investigators or Pharmacists are responsible for storing throughout the trial both the IMP (not in 
use SAR341402 or NovoLog/NovoRapid) and also NIMP (not in use Lantus) in a securely locked 
and safe place in accordance with local regulations and labeling specifications (eg, refrigerated 
storage), policies, and procedures. 
Control of storage conditions for IMP/NIMP provided by the Sponsor, especially control of 
temperature (eg, refrigerated storage) and information on in-use stability and instructions for 
handling the Sanofi IMP/NIMP will be managed according to the rules provided by the Sponsor. 
In-use pens of investigational medicinal product NovoLog/NovoRapid for use as mealtime insulin 
for this study and the mandatory basal insulin NIMP Lantus are to be stored by the patients in 
accordance with the storage conditions indicated on the label of each product. SAR341402 will be 
stored in accordance with the label for NovoLog/NovoRapid. 
8.7 
RESPONSIBILITIES 
The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the 
IMP and NIMP will be responsible for ensuring that the IMP and NIMP used in the clinical trial is 
securely maintained as specified by the Sponsor and in accordance with applicable regulatory 
requirements. 
All IMP will be dispensed in accordance with the Investigator's prescription and it is the 
Investigator's responsibility to ensure that an accurate record of IMP and NIMP issued and 
returned is maintained. 
Any quality issue noticed with the receipt or use of an IMP and NIMP (deficiency in condition, 
appearance, pertaining documentation, labeling, expiration date, etc) should be promptly notified 
to the Sponsor. Some deficiencies may be recorded through a complaint procedure. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 44 
A potential defect in the quality of IMP and NIMP may be subject to initiation of a recall 
procedure by the Sponsor. In this case, the Investigator will be responsible for promptly 
addressing any request made by the Sponsor, in order to recall IMP and eliminate potential 
hazards. 
Under no circumstances will the Investigator supply IMP or NIMP to a third party and allow the 
IMP or NIMP to be used other than as directed by this Clinical Trial Protocol or dispose of IMP 
or NIMP in any other manner. 
Investigators in this open-label study are reminded of the need to strictly follow dispensing 
guidelines using the IRT system in order to perform correct allocation of IMP at each 
dispensation. 
At each on-site visit after baseline as well as at the end of the treatment period, participants will 
take study drug with them to the site. It is important that sites: 
• Instruct patients to take with them all used, unused and in-use IMP/NIMP for each on-site 
visit. 
• Collect from patients all used, unused and in-use study treatments starting from Visit 5 
(Week 4) which is the first on site visit after randomization. 
• Be available to discuss the patient’s progress, dose regimens, and data from the study 
(hypoglycemic events, HbA1c) with future caregivers as needed. 
• Review patients’ prior regimens and give a reminder about follow-up care, no later than 
the visit prior to the end-of-treatment visit. 
• At end of treatment period: remind patients to arrange for follow-up care and supply of 
insulin from their physician, before the end of treatment visit. 
8.7.1 Treatment accountability and compliance 
At each visit, the Investigator or his/her delegate asks the patient about administered doses of IMP 
(SAR341402 or NovoLog/NovoRapid) and NIMP (Lantus). 
An adequate supply of labeled IMP and NIMP treatment kits with shelf life adequate to reach the 
next in-person visit will be provided at each on site visit starting with Visit 3 (Day1, baseline).  
Treatment kits (used, unused and in-use) are returned by the patient at each on-site visit. 
The Investigator or delegate has to inspect IMP and NIMP remaining in the returned kits are 
consistent with dose used. Discrepancies will be addressed to the patient for clarification of real 
treatment administration.  
The Investigator or delegate fills the Product Accountability Form per patient based on the 
used/unused IMP and NIMP kits returned. 
The monitor in charge of the study then checks the data entered on the IMPs administration page 
by comparing them with the IMPs that has been retrieved and the Product Accountability Form 
per patient. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 45 
Similar to use of IMP, patients have to record the administration of their mandatory background 
NIMP, Lantus, in the electronic patient diary.  
8.7.2 Return and/or destruction of treatments 
Investigational medicinal product and NIMP reconciliation must be performed at the site by the 
Investigator (or the Pharmacist) and the monitoring team using the Product Accountability Forms 
(at site level and patient level) countersigned by the Investigator (or the Pharmacist) and the 
monitoring team.  
The destruction is recommended to be performed at site depending on IMP/NIMP specificities 
and local requirements but IMP/NIMP can be returned to the Sponsor for destruction. 
The Investigator will not destroy any IMP or NIMP unless the Sponsor provides written 
authorization. A detailed treatment log of the destroyed IMP and NIMP will be established with 
the Investigator (or the pharmacist) and countersigned by the Investigator and the monitoring 
team.  
A potential defect in the quality of IMP or NIMP may initiate a recall procedure by the Sponsor. 
In this case, the Investigator will be responsible for promptly addressing any request made by the 
Sponsor, in order to recall IMP/NIMP and eliminate potential hazards. 
In case of a clear relationship of a SAE to NIMP, the batch number of the NIMP administered 
during the occurrence of the event has to be documented in the patient source. 
8.8 
CONCOMITANT MEDICATION 
A concomitant medication is any treatment received by the patient concomitantly to 
IMP treatment. 
Short term therapy (less than 10 days maximum) with either basal insulin or short acting insulin 
not specified in this study protocol such as may occur due to acute illness or surgery is allowed. 
8.8.1 Prohibited concomitant therapy 
The following drugs are not permitted during the screening period and the randomized open-label 
treatment periods: 
• Any glucose-lowering agents including injectable non-insulin peptides such as Symlin® 
and GLP-1 receptor agonists other than the IMP, authorized insulin analog SAR341402 or 
NovoLog / NovoRapid and the background basal anti-diabetic therapy (Lantus). Patients 
on insulin lispro 100 U/mL are permitted to continue their mealtime insulins during the 
screening period until randomization. 
• Systemic glucocorticoids at doses greater than replacement for more than 10 days (topical 
or inhaled applications are allowed). 
• Insulin pump therapy. 
• Initiation of body weight loss drugs. 
• Any other investigational product (ie, participation in another clinical trial). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 46 
Patients with T2DM using OADs prior to the study may continue using them on stable dose 
except sulfonylureas, which must be discontinued at baseline and cannot be used during the study. 
There is no rescue therapy defined for this study. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 47 
9 
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT 
All biological efficacy and safety analysis will be performed by a Central Laboratory. Secondary 
assessments with SMPG will include analysis of 7-point SMPG profiles, including post meal 
excursions. Detailed information on samples drawing, management, and analysis will be provided 
in a specific manual. 
9.1 
PRIMARY ENDPOINT 
The primary endpoint is change in HbA1c (%) from baseline to Week 26. 
For assessment methods refer to Section 9.2.2.2.1. 
9.2 
SECONDARY ENDPOINTS 
9.2.1 Immunogenicity endpoints 
• Anti-SAR341402/NovoLog/NovoRapid antibody positive/negative status, titers and 
cross-reactivity to human insulin at each sampling visit up to Week 26, and during the 
extension period up to Week 52. 
• Treatment-induced, treatment-boosted and treatment-emergent (treatment induced plus 
treatment boosted) AIAs (2) during the main 6-month and the 12-month on-treatment 
periods (refer to Section 9.2.1.1 for definition of on-treatment periods). 
9.2.1.1 Observation period of immunogenicity variables 
• The 6-month on-treatment period is defined as the time from first injection of IMP up to 
Week 26 (Visit 9) or up to 1 day after the last injection of IMP whichever comes earlier. 
• The 12-month on-treatment period is defined as the time from the first injection of IMP up 
to 1 day after the last injection of IMP. 
9.2.1.2 Immunogenicity assessments 
For the assessment of immunogenicity the anti-SAR341402 / anti-NovoLog/NovoRapid antibody 
status (positive or negative), anti-SAR341402 / NovoLog/NovoRapid antibody titer at baseline 
and during the course of the clinical study as well as the cross-reactivity to human insulin will be 
evaluated.   
Blood samples for AIAs will be taken at 6 visits: Visit 3 (Day 1, baseline), Visit 5 (Week 4), 
Visit 7 (Week 12), Visit 9 (Week 26, Endpoint), Visit 11 (Week 40) and Visit 12 (Week 52, end 
of treatment) (see flowchart, Section 1.2). They will be determined in a blinded fashion at a 
centralized laboratory using a validated AIA binding assay. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 48 
In subjects who present with elevated AIA titers above baseline at endpoint and in whom the 
ARAC assesses AIA-mediated hypersensitivity reaction or effects on efficacy or safety, the 
increased AIA titers will be followed until return to baseline or until the ARAC decides that no 
further follow-up is deemed necessary. 
Detailed procedures for sample preparation, storage and shipment as well as exact AIA sampling 
times in relation to the last injection of mealtime insulin will be described in the specific 
laboratory manual. 
9.2.1.3 Immunogenicity variables definition 
The following definitions will be used to identify patients with a change in AIA response during 
the on-treatment period (2): 
• Patients with treatment-induced AIAs will be defined as patients with AIAs that developed 
de novo (seroconversion) following the IMP administration (ie, patients with at least one 
positive AIA sample at any time during the on-treatment period, in those patients without 
pre-existing AIA or with missing sample at baseline). 
• Patients with treatment-boosted AIAs will be defined as patients AIA positive at baseline 
that were boosted to a significant higher titer following the IMP administration 
(ie, patients with at least one AIA sample with at least a 4-fold increase in titers compared 
to baseline value at any time during the on-treatment period, in those patients with 
preexisting AIA). 
Patients with treatment-emergent AIA (Yes, No) will be derived as follows: 
• Patients with treatment-emergent AIAs (AIA incidence) will be defined as patients with 
treatment-induced or treatment-boosted AIAs. 
• Patients without treatment-emergent AIAs will be defined as patients without treatment 
induced or treatment-boosted AIAs. 
• Inconclusive patients (patients who cannot irrefutably be classified as patients without 
treatment-emergent AIAs) will not be included in the above categories and will be listed 
separately. 
Treatment-emergent AIAs at last on-treatment value (Yes, No) will be defined using the same 
definitions based on results obtained at the last on-treatment visit (ie, taking into account the 
closest value prior to the last dose of IMP). 
The peak titer will be defined as the maximal titer observed during the on-treatment period. For 
patients with treatment-induced and treatment-boosted AIAs, the kinetics of AIA response will be 
further classified as follows: 
• Transient AIA response, defined as a response detected only at one sampling time point 
during the on-treatment period (excluding the last sampling time point); or response 
detected at two or more sampling time points during the on-treatment period, where the 
first and last AIA-positive samples (irrespective of any negative samples in between) are 
separated by a period less than 16 weeks, and the patient’s last sampling time point is 
AIA-negative. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 49 
• Persistent AIA response, defined as a response detected at two or more sampling time 
points during the on-treatment period, where the first and last AIA-positive on-treatment 
sample (irrespective of any negative samples in between) are separated by at least 
16 weeks. 
• Indeterminate AIA response, defined as a response where only the last sampling time point 
is positive or the last 2 sampling time points are positive but separated by a period less 
than 16 weeks. 
9.2.2 Secondary efficacy endpoints 
• Change in HbA1c (%) from baseline to Week 52. 
At Week 26 and Week 52: 
• The percentage of patients with HbA1c <7% (HbA1c responders; Yes/No variable). 
Patients without assessment will be considered as failure. 
• Change from baseline in FPG. 
• Change from baseline in the mean 24-hour plasma glucose concentration, based on the  
7-point SMPG profiles. 
• Change from baseline in postprandial plasma glucose excursions (difference between  
2-hour postprandial and pre-prandial plasma glucose values at breakfast, lunch and 
dinner), based on the 7-point SMPG profiles. 
• Change from baseline in 7-point SMPG profiles per time-point. 
9.2.2.1 Observation period of efficacy variables 
• The 6-month randomized period is defined as the time from randomization up to Week 26 
(Visit 9). 
• The 12-month randomized period is defined as the time from randomization up to 
Week 52 (Visit 12). 
9.2.2.2 Efficacy assessment methods 
9.2.2.2.1 Hemoglobin A1c 
For the eligibility and efficacy assessments of the study, HbA1c is measured by a certified Level I 
“National Glycohemoglobin Standardization Program” central laboratory according to 
Section 1.2.  
9.2.2.2.2 Fasting plasma glucose 
Blood samples for FPG measurement are taken and measured at central laboratory according to 
Section 1.2. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 50 
9.2.2.2.3 Self-measured plasma glucose profiles and plasma glucose during symptomatic 
hypoglycemia 
At Visit 1 (Week -2, screening), the Investigator or a member of the investigational staff will 
provide patients with glucometer provided by the Sponsor including the corresponding supplies 
(needles, control solutions, test strips etc). Intensive training on the correct handling (including 
checks with the control solution of the glucose meter provided by the Sponsor) will be provided at 
the screening visit (Visit 1, Week -2) and baseline visit (Visit 3, Day 1). Regular refresher 
instructions will be provided at each visit throughout the study.  
All plasma glucose values collected in the study, including during the screening period to 
document compliance and including 7-point profiles for endpoint analysis and fasting 
prebreakfast SMPGs and 3- or 4-point profiles that are used for self-adjustment of the insulin 
dose, have to be measured by the patient using the sponsor-provided glucometer. Patients will be 
provided with an electronic diary in order to record their SMPG and complete the 3-4 point or 
7-point SMPG profiles, insulin doses, and hypoglycemic events including symptoms of 
hypoglycemia. 
The patients will be instructed to bring the glucometers provided by the Sponsor to each on-site 
visit. The glucometers should be calibrated according to manufacturer’s instructions and the 
investigational site should also check regularly the glucometers using the provided control 
solutions for data validity.  
The electronic diary needs to be brought to each visit. Detailed information regarding the Web 
based portal and other software support is provided at the screening visit. 
To ensure safety when there are technical problems with the glucometer provided by the Sponsor, 
patients are to contact the site and the e-diary helpdesk immediately and should use an alternative 
meter until resolved. 
All SMPG values will be used by the Investigator to monitor glycemic control, for dosage 
adjustment of meal related rapid-acting insulin (SAR341402/NovoLog/NovoRapid) and for 
titration of basal insulin (Lantus) throughout the trial.  
SMPG measurements are scheduled as follows: 
• 7-point SMPGs (fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch, 
pre- and 2 hours after dinner, and at bedtime): on at least 2 days in the week before Visit 3 
(Baseline), Visit 7 (Week 12), Visit 9 (Week 26 ([Endpoint]), and Visit 12 (Week 52; 
End of treatment), measured in a single, 24-hour period; they must be recorded into the 
e-diary before the visit, reviewed by the Investigator and transferred into the clinical 
database. 
• SMPG to assist insulin titration/dosing (to include minimum 3- or 4-point SMPG to be 
recorded into the e-diary along with insulin dose and carbohydrate intake) is recommended 
daily during the first weeks of study treatment until reaching target ranges for SMPG, and 
thereafter on at least 3 days each week or more frequently as requested by the Investigator 
as specified in titration manual: 
- 
To assist titration of the basal insulin (Lantus): fasting (prebreakfast) SMPG, 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 51 
- 
To assist titration of SAR341402 or NovoLog/NovoRapid: either postprandial or  
next-meal preprandial (in the case of dinner, bedtime) SMPG will be used, depending 
on the preference of the Investigator and patient and consistent with standard of care. 
These SMPGs, supporting optimization of the basal and mealtime insulin dose are recommended 
to be recorded in the e-diary at least weekly; they will be uploaded in the e-diary web portal and 
for review by the site or the Sponsor (titration oversight working group) (see titration oversight 
manual). The results will be discussed between Investigator and patient during on site and 
unscheduled telephone visits at the discretion of the Investigator. 
For SMPG ≤3.9 mmol/L (≤70 mg/dL) transferred to the e-diary, the patient will be prompted to 
the hypoglycemic episode diary after the SMPG are transferred regardless if symptoms of 
hypoglycemia were present or not. 
7-point SMPG can also be used for titration oversight. 
• SMPG during episodes of symptoms of hypoglycemia: whenever the patients feel 
hypoglycemic symptoms, plasma glucose should be measured by the patient (or others, if 
applicable), if possible. 
For details please refer to Section 9.2.3.2.1.1. 
9.2.3 Safety endpoints 
The following safety parameters will be analyzed in the CSR (for the main  
6-month and 12-month on-treatment periods): 
• Hypoglycemia (according to ADA Workgroup on Hypoglycemia) (3, 4, 5). 
• AEs, SAEs. 
• Laboratory data: 
- 
Hematology: erythrocytes, hemoglobin, hematocrit, leukocytes, differential blood 
count (neutrophils, lymphocytes, monocytes, eosinophils, basophils) and platelets, 
- 
Clinical chemistry: electrolytes including sodium and potassium, renal function 
including creatinine and eGFR (MDRD), and liver function including ALT, AST, 
alkaline phosphatase (ALP) and total bilirubin (in case of values above the normal 
range, differentiation in conjugated and non-conjugated bilirubin), 
- 
Serum lipids: total cholesterol, high-density lipoprotein (HDL) cholesterol, 
low-density lipoprotein (LDL) cholesterol, and triglycerides (TG) (in fasting 
condition). 
• Injection site reactions, hypersensitivity reactions.  
• Vital signs: heart rate, and SBP and DBP. 
• Body weight. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 52 
9.2.3.1 Observation period for safety variables 
The observation period of safety data is divided into 3 main segments: 
• The pre-treatment period is defined as the time from informed consent up to the time of 
the first injection of IMP. 
• The 6-month on-treatment period is defined as the time from first injection of IMP up to 
Week 26 (Visit 9) or up to 1 day after the last injection of IMP whichever comes earlier. 
The 12-month on-treatment period is defined as the time from the first injection of IMP up 
to 1 day after the last injection of IMP. 
• The post-treatment period is defined as the time starting 1 day after last injection of IMP 
(after the on-treatment period). 
9.2.3.2 Safety assessment methods 
9.2.3.2.1 Hypoglycemia 
Hypoglycemia will be analyzed as incidence of patients (%) with at least one hypoglycemia event 
and number of hypoglycemia event per patient year of exposure. 
Hypoglycemia events will be categorized (3, 4, 5) as follows: 
• Severe hypoglycemia: Severe hypoglycemia is an event requiring 3rd party assistance of 
another person to actively administer carbohydrate, glucagon, or other resuscitative 
actions. These episodes may be associated with sufficient neuroglycopenia to induce 
seizure, unconsciousness or coma. Plasma glucose measurements may not be available 
during such an event, but neurological recovery attributable to the restoration of plasma 
glucose to normal is considered sufficient evidence that the event was induced by a low 
plasma glucose concentration. The definition of severe symptomatic hypoglycemia 
includes all episodes in which neurological impairment was severe enough to prevent 
self-treatment and which were thus thought to place patients at risk for injury to 
themselves or others. Note that “requires 3rd party assistance” means that the patient could 
not help himself or herself. Assisting a patient out of kindness, when assistance is not 
required, should not be considered a “requires assistance” incident. 
Severe hypoglycemia will be qualified as an SAE only if it fulfills SAE criteria. All 
events of seizure, unconsciousness or coma must be reported as SAEs. 
• Documented symptomatic hypoglycemia: Documented symptomatic hypoglycemia is an 
event during which typical symptoms of hypoglycemia are accompanied by a measured 
plasma glucose concentration of (≤3.9 mmol/L (≤70 mg/dL) (3). Clinical symptoms that 
are considered to result from a hypoglycemic episode are, eg, increased sweating, 
nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, 
headache, sleep disorder, confusion, seizures, unconsciousness, or coma. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 53 
• Asymptomatic hypoglycemia: Asymptomatic hypoglycemia is an event not accompanied 
by typical symptoms of hypoglycemia but with a measured plasma glucose concentration 
less than or equal to 3.9 mmol/L (70 mg/dL).   
• Probable symptomatic hypoglycemia: Probable symptomatic hypoglycemia is an event 
during which symptoms of hypoglycemia are not accompanied by a plasma glucose 
determination, but was presumably caused by a plasma glucose concentration less than or 
equal to 3.9 mmol/L (70 mg/dL); symptoms treated with oral carbohydrate without a test 
of plasma glucose.  
• Relative hypoglycemia: (recently termed “pseudo-hypoglycemia” [4]) is an event during 
which the person with diabetes reports any of the typical symptoms of hypoglycemia, and 
interprets the symptoms as indicative of hypoglycemia, but with a measured plasma 
glucose concentration greater than 3.9 mmol/L (70 mg/dL). 
Hypoglycemia events will be evaluated regardless the time of onset. 
In addition to the threshold of plasma glucose of less than or equal to 3.9 mmol/L (70 mg/dL), 
documented hypoglycemia with a measured plasma glucose concentration less than 
3.0 mmol/L (54 mg/dL) will also be analyzed (5). 
9.2.3.2.1.1 Self-measured plasma glucose during symptomatic hypoglycemia 
Whenever the patients feel hypoglycemic symptoms, plasma glucose should be measured by the 
patient (or others, if applicable), if possible. Patients should be instructed to measure plasma 
glucose levels prior to carbohydrate intake or administration of glucose whenever symptomatic 
hypoglycemia is suspected, unless safety considerations necessitate immediate 
carbohydrate/glucose rescue prior to confirmation. 
Exceptionally, and only during hypoglycemic events, plasma glucose may be recorded with other 
devices. 
Patients will then complete the hypoglycemic episode diary in their e-diary. Site will receive 
alerts from e-diary for all severe hypoglycemic events and will review for decision on any 
necessary measures to be taken such as dose reduction of IMP or NIMP. 
All hypoglycemia episodes will be documented by the patient on the hypoglycemic episode diary 
page of the e-diary as soon after the event as possible, so that this information can be reviewed in 
the web based portal by the site. This requires that the SMPG values related to hypoglycemia 
(measured with the glucometer and transferred to the e-diary) are linked to the appropriate 
hypoglycemic symptoms directly entered into the e-diary. 
9.2.3.2.2 Adverse events, serious adverse events 
All reported AEs and SAEs will be collected from the time of signed informed consent until the 
end of the study (defined as patient’s last visit planned per protocol or the resolution/stabilization 
of all SAE and AEs with pre-specified monitoring). All events will be managed and reported in 
compliance with all applicable regulations, and included in the final CSR. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 54 
All AEs and SAEs will be coded to a Lower Level Term (LLT), Preferred Term (PT), High Level 
Term (HLT), High Level Group Term (HLGT) and associated primary System Organ Class 
(SOC) using the version of MedDRA (Medical Dictionary for Regulatory Activities) currently in 
effect at the sponsor at the time of database lock. The occurrence of AEs and SAEs is recorded 
from the time of signed informed consent until the end of the study. 
For further details on AEs refer to Section 10.4. 
9.2.3.2.2.1 Adverse event observation periods 
If an AE/SAE is ongoing and not resolved by the end of the study observation period and leads to 
subsequent death of the patient, it will have to be reported. 
The AE observations will be classified per the observation periods of safety data as defined above 
into: 
• Pre-treatment AEs are AEs that developed or worsened or became serious during the 
pretreatment period. 
• Treatment-emergent AEs (TEAEs) are AEs that developed or worsened or became 
serious during the on-treatment period. 
• Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period. 
9.2.3.2.2.2 Death observation periods 
The death observations are per the observation periods defined above. In addition, after the 
post-treatment period, death related to IMP as well as death resulting from TEAE must be 
reported to the Sponsor. 
• Death on-study: deaths occurring during the on-study observation period. 
• Death on-treatment: deaths occurring during the on-treatment period. 
• Death post study: deaths occurring after the end of study. 
9.2.3.2.3 Laboratory safety variables 
The clinical laboratory data collected consist of blood analysis (including hematology, clinical 
chemistry and fasting lipids). Clinical laboratory values will be analyzed after conversion into 
standard international units. International units will be used in all listings and tables. 
Blood for assessment of laboratory safety variables in central laboratory will be collected at 
screening (Visit 1), Visit 9 (Week 26), and Visit 12 (Week 52). 
The following safety laboratory endpoints will be assessed: 
• Hematology at Visit 1 (Week -2), Visit 9 (Week 26), Visit 12 (Week 52): erythrocytes, 
hemoglobin, hematocrit, leukocytes, differential blood count (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils) and platelets. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 55 
• Clinical chemistry at Visit 1 (Week -2), Visit 9 (Week 26), Visit 12 (Week 52):  
- 
Electrolytes including sodium, potassium, 
- 
Renal function including creatinine and eGFR (MDRD), 
- 
Liver function including ALT, AST, alkaline phosphatase (ALP) and total bilirubin (in 
case of values above the normal range, differentiation in conjugated and 
nonconjugated bilirubin). 
• Serum lipids at Visit 1 (Week -2), Visit 9 (Week 26), Visit 12 (Week 52): total cholesterol, 
high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, 
and triglycerides (TG) (in fasting condition). 
The following additional safety laboratory assessments will be done: 
• Hepatitis serology to include HBs-Ag, HC-Ab at screening visit (Visit 1, Week -2). 
• Serum pregnancy test in WOCBP at screening and urine pregnancy test at most of the 
subsequent on-site visits will be performed. In the event of a positive urine pregnancy test, 
a confirmatory serum pregnancy test should be performed. Urine pregnancy tests can be 
performed more often if required by local law. 
• Serum follicle stimulating hormone (FSH) and estradiol (only in females requiring 
confirmation of postmenopausal status) at screening visit (Visit 1, Week -2). 
Note: Any abnormal laboratory value estimated as clinically significant by the Investigator should 
be immediately rechecked (whenever possible using the central laboratory) for confirmation 
before making a decision of permanent discontinuation of IMP for the concerned patient. Any 
confirmed laboratory abnormality estimated as clinically significant by the Investigator must be 
reported as an AE/SAE as applicable. 
9.2.3.2.4 Injection site reactions and hypersensitivity reactions 
If the Investigator or the patient recognizes any signs related to local reactions at the study drug 
injection site or potential hypersensitivity reactions, the event should be recorded in the e-CRF 
(for details refer to Section 10.6.2 and Section 10.6.3). 
If a patient reports an injection site or a hypersensitivity reaction between the on-site visits or 
during a phone call visit, it is recommended that the Investigator ask him/her to come to the study 
site on the same or the next day, so that the event can be properly assessed and reported 
(see also Section 10.6.3). 
9.2.3.2.5 Vital signs 
Vital signs parameters are heart rate, and SBP and DBP in sitting position. 
Determination of the screening BP and reference arm for BP measurements: At Visit 1, after 
the patient has rested comfortably for at least 10 minutes, BP is measured on both of the patient’s 
arms while the patient is in sitting position and then again after two minutes on both arms. The 
arm with the highest SBP will be determined at this visit, identifying the reference arm for future 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 56 
measurement throughout the study. The highest value will be recorded in the e-CRF 
(all BP values are to be recorded in the source data) as the BP to determine the reference arm. 
Additional measurements may be made to determine the screening SBP and DBP. Blood pressure 
measurements which are not the defined screening BP are not exclusionary.  
Blood pressure at all subsequent on-site visits should be measured when the patient is quiet and 
seated and with their determined reference arm outstretched in line with mid-sternum and 
supported. Measurement at all subsequent visits should be taken under standardized conditions, 
approximately at the same time of the day, on the reference arm, with the same device (after the 
patient has rested comfortably for at least five minutes), and the values are to be recorded in the 
e-CRF. Both SBP and DBP should be recorded. Devices for BP measurement should be regularly 
recalibrated according to manufacturers’ instructions. 
Heart rate will be measured at the time of the BP measurement in sitting position and recorded in 
the e-CRF.  
9.2.3.2.6 Height and body weight 
Height will be measured at screening visit (Visit 1, Week -2) when the patient’s shoes are off, 
feet together, and arms by the sides. Heels, buttocks and upper back should also be in contact with 
the wall when the measurement is made. 
Body weight should be obtained at 4 visits, screening visit (Visit 1, Week -2), Visit 3 (Day 1), 
Visit 9 (Week 26), and End of treatment Visit 12 (Week 52 and, if applicable, early treatment 
discontinuation) with the patient wearing undergarments or very light clothing and no shoes, and 
with an empty bladder. The floor surface on which the scale rests must be hard and should not be 
carpeted or covered with other soft material. The same scale should be used throughout the study, 
and calibrated on a regular basis as recommended by the manufacturer. The weight is read and 
recorded in the e-CRF and Source Data. Self-reported weights are not acceptable and patients 
must not read the scales themselves. 
9.2.3.2.7 Electrocardiogram  
A 12-lead ECG record will be performed locally at Visit 1 (Screening visit) and thereafter only 
when justified by the occurrence of an AE (see flowchart, Section 1.2).  
The 12-lead ECG should be performed after at least 10 minutes in supine position. The 
Investigator has to review the ECG and document his interpretation and sign and date on the 
ECG printout. In case of subsequent ECGs, each ECG trace is analyzed in comparison with the 
screening recorded trace. All original traces are kept as source data. 
In the e-CRF the assessment “normal” or “abnormal”/ ”clinically significant” or ”clinically not 
significant”, as determined by the Investigator, is collected and the ECG is kept in source. 
Note: Any abnormal ECG parameter should be immediately rechecked for confirmation before 
making a decision of permanent discontinuation of treatment with IMPs. If the abnormality is 
confirmed, the finding must be reported as an AE/SAE as applicable. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 57 
9.3 
OTHER ENDPOINTS 
9.3.1 Pharmacokinetics 
Pharmacokinetic assessment is not planned. 
9.3.2 Insulin dose 
All mealtime insulin doses and the basal insulin dose will be integrated into e-CRF from the 
e-diary record as follows:  
• For the 7 days prior to Baseline (Visit 3) and during the first 7 days after start of IMP.  
• For 2 days in the weeks prior to Visit 5 (Week 4), Visit 7 (Week 12), Visit 9 (Week 26), 
Visit 11 (Week 40) and Visit 12 (Week 52). 
9.4 
FUTURE USE OF SAMPLES 
Not applicable. 
9.5 
APPROPRIATENESS OF MEASUREMENTS  
The primary efficacy analysis will test non-inferiority of SAR341402 compared to 
NovoLog/NovoRapid in terms of change of HbA1c from baseline to Week 26. The 26-week 
duration of study treatment is considered to be sufficient for achieving steady state conditions of 
the MDI insulin regimen with SAR341402 or NovoLog/NovoRapid in combination with Lantus 
after randomization, enabling an adequate assessment of time-dependent changes in HbA1c and 
the concomitant risk of hypoglycemia. HbA1c reflects the average glycemia over several months 
and has strong predictive value for diabetes complications. For the eligibility and efficacy 
assessments of the study, HbA1c is measured by a certified level I “National Glycohemoglobin 
Standardization Program” (NGSP) central laboratory.  
HbA1c is accepted by regulatory agencies as primary endpoint to support a claim based on 
glycemic control (10, 11). 
Parameters defining secondary efficacy endpoints including percentage of patients reaching 
HbA1c targets, change in FPG, and change in mean 24-hour and postprandial glucose levels are 
all assessments of glycemic control that are recognized and accepted by regulatory agencies. 
Change in mean 24-hour and postprandial glucose levels are collected at Week 12, the end of the 
critical titration period, and at the endpoints at Week 26 and at Week 52. SMPG-related data are 
not collected at Week 40 during the comparative safety extension period. 
As a biological protein, insulin has the potential to be immunogenic. Therefore, immunogenicity 
will be assessed by evaluating anti-SAR341402/NovoLog/NovoRapid antibody positive/negative 
status and titers, as well as cross-reactivity to human insulin at various time points throughout the 
study. A single immunogenicity assay based on SAR341402 will be used to test samples from 
both SAR341402 and NovoLog/NovoRapid treated subjects. The immunoassay will detect all 
immunoglobulin isotypes and will be validated in accordance with recent recommendations 
(2, 12, 13). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 58 
All potential hypersensitivity or hypersensitivity-like events will be adjudicated by the members 
of an ARAC, who are blinded to the treatment and will also assess a potential association of the 
hypersensitivity or hypersensitivity-like event with treatment induced or treatment boosted AIAs. 
The ARAC members will further recommend a follow up of patients with increase of AIA titers 
above baseline at the end of the study. All the ARAC assessments will further strengthen the 
robustness of the clinical assessment of the immunogenicity of SAR341402 in comparison with 
NovoLog/NovoRapid. 
Safety will be evaluated by standard clinical and laboratory measurements, including safety 
parameters of special interest for an insulin product such as hypoglycemia, injection site reactions 
and potential hypersensitivity reactions. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 59 
10 
STUDY PROCEDURES 
10.1 
VISIT SCHEDULE 
The visit schedule and procedures/assessments listed in the “Study Flow Chart” (Section 1.2) are 
not repeated in this section. The aim of this section is to provide details on how some of the 
procedures/assessments have to be performed. 
This is an outpatient study and consists of 8 on-site visits and 5 phone-call visits. Additional, 
optional phone call visits to monitor and support the progress of insulin titration should be 
scheduled whenever considered necessary by the Investigator. 
All on-site visits should take place in the morning. The patients must be fasting for Visit 1 
(Week -2, screening), Visit 3 (Day 1, baseline), Visit 7 (Week 12), Visit 9 (Week 26, Endpoint), 
Visit 11 (Week 40), and at end of treatment assessment Visit 12 (Week 52) or at early 
discontinuation from IMP. Patient is required to come to the visit after a fasting period of at least 
8 hours: during this time, only water or tea without sugar or sweetener and without milk is 
allowed. No coffee, no other beverages; no injection of rapid-acting insulin at home are allowed. 
Patients do not need to come to other on-site titration visits fasting. 
Eight-hour delay must be respected between the last mealtime insulin dose and AIA sampling 
time for Visit 3 (Day 1, baseline), Visit 5 (Week 4), Visit 7 (Week 12), Visit 9 (Week 26 
Endpoint), Visit 11 (Week 40) and at end of treatment assessment Visit 12 (Week 52) or at early 
discontinuation from IMP. 
Visit window: Visit 2 should take place 7 days ±3 days after Visit 1 (screening). Visit 3 should 
occur 14 days ±3 days after Visit 1 (screening). From Visit 4 (Week 2) until the primary efficacy 
endpoint visit (Visit 9, Week 26), visits should occur within ±3 days, taking the baseline (Visit 3) 
visit day as a reference. Visits in the extension period, phone visit (Visit 10, Week 34), and on site 
visits (Visit 11, Week 40) to end of treatment (Visit 12, Week 52) may occur within ±5 days. 
Post treatment follow-up visit, (Visit 13, Week 52+1 day) may occur at +2 to 3 days in the event 
this visit falls on a weekend or holiday. 
If one visit date is changed, the next visit should occur according to the original schedule. 
For a complete list of procedures scheduled for each study visit please refer to the Study flowchart 
(Section 1.2). The aim of the sections of the “Visit schedule” in Section 1.2  as well as 
“Assessment methods” in (Section 9.2.1.1, Section 9.2.2.2 and Section 9.2.3.2) is to detail 
procedures to be performed. 
All data obtained during the trial visits are reviewed by the Investigator and SubInvestigators who 
are qualified in treatment of T1DM or T2DM (as appropriate) with MDI therapy and who are 
familiar with the study. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 60 
10.1.1 Screening period 
The duration of the screening period is 2 weeks from Visit 1 (Week -2) to Visit 3 (Week 0) and 
must be long enough to establish inclusion/exclusion criteria. 
Patients will be screened at Visit 1 after signature of the informed consent form. All laboratory 
tests measured at central laboratory needed for checking the exclusion criteria of the patients will 
be performed at Visit 1. Patients will be called at Visit 2 (Week -1), and patients who meet the 
inclusion criteria and have no exclusion criteria as noted in Section 7.1 and Section 7.2 will be 
randomized at Visit 3 (Day 1). 
If any of the laboratory parameters are not available upon the end of the screening period 
(eg, sample material damaged during transport etc) a retest can be performed. Retesting done by 
the Central Laboratory for quality purposes by the reference lab for HbA1c cannot be used for 
screening purposes. 
Patients can be re-screened one time before randomization in case of non-evaluable exclusion 
criteria (eg, not evaluable screening laboratory findings) or in case of a HbA1c out of the included 
range when there is an acute disease at the initial screening visit (Visit 1, Week-2) that is expected 
to affect the HbA1c. 
The IRT will be contacted at Visit 1 for notification of screening and for patient number 
allocation, before study related measures are performed. 
10.1.1.1 On-site Visit 1 (Week -2) screening visit 
The following procedures/assessments will be performed at the Visit 1 (Week -2): 
• Obtaining the informed consent: 
- 
The patient will receive verbal information concerning the aims and methods of the 
study, its constraints and risks and the study duration. Written information will be 
provided to the patient. Written informed consent must be signed by the patient and 
Investigator prior to any study-specific investigations.  
• IRT notified (allocation of patient number, registration of screening, collection of 
demographic information): 
- 
The patient number is composed of a 12-digit number containing the 3-digit country 
code, the 4-digit center code and the 5-digit patient chronological number (which is 
00001 for the first patient screened in a center, 00002 for the second patient screened 
in the same center etc). 
• Assessment of inclusion/exclusion criteria. 
• Demographics (age, gender, and ethnic origin). 
• Patient’s medical (including detailed cardiovascular) and surgical history as well as family 
history of diabetes in the immediate family. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 61 
• History of T1DM or T2DM treatment including documentation for diagnosis, of insulin 
treatment (including start date of first insulin treatment), documentation of current 
treatment and treatment in the last 6 months with insulin glargine (in the last 12 month 
with insulin detemir) and insulin lispro or NovoLog/NovoRapid (including start dates), 
duration, and of microvascular complications (eye, kidney) and their treatments, all of 
which must be in the source documentation prior to randomization. 
• History of T1DM or T2DM, supporting documentation for diagnosis, must be in source 
documentation prior to randomization. 
• Concomitant medication history. 
• Habits: alcohol habits and smoking status (during the last 12 months). 
• Physical examination. 
• Body height and weight, vital signs (determination of reference arm for BP; SBP, DBP, 
heart rate). 
• 12-lead ECG. 
• Laboratory testing by central laboratory: 
- 
HbA1c, 
- 
Safety laboratory test for hematology, clinical chemistry (please refer to 
Section 9.2.3.2.3), 
- 
Serum lipids (please refer to Section 9.2.3.2.3), 
- 
Hepatitis serology (HBs-Ag, HC-Ab), 
- 
Serum pregnancy test (β-human chorionic gonadotropin [β-HCG]) in WOCBP only, 
- 
FSH and estradiol in postmenopausal women only. 
• Report AE/SAE, hypersensitivity reactions and hypoglycemia if any. 
• E-diary and Sponsor provided glucometer dispensation: 
- 
Creation of the patient number provided by IRT in the e-diary web portal and in the 
allocated e-diary, 
- 
Dispensation of Sponsor provided glucometer, training materials and supplies, 
- 
Pairing of the e-diary with the glucometer, 
- 
Dispensation of e-diary, instruction on use and software support information, 
- 
Completion of the training session by the patient on the e-diary. 
• Routine review of diet and lifestyle counseling along with instructions on dosage  
self-adjustment including carbohydrate intake (when available) and review of correction 
scales. 
A time will be selected for the telephone Visit 2 (Week -1) in the screening period. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 62 
10.1.1.2 Screening telephone visit: Visit 2 (Week-1) +/- 3 days 
Patient is called by the Investigator or qualified designee at a scheduled time. If the call has been 
completed by site staff other than the Investigator, the Investigator has to be consulted if AE/SAE 
is suspected. This visit is a mandatory telephone visit, but can optionally be performed as clinical 
visit. 
• During the phone call, ask the patient: 
- 
Did you experience any new medical event, disease or symptom since the last visit? 
(Please pay attention to any possible hypoglycemic event or symptom, possible 
allergic or injection site reactions). 
- 
Did you experience any change in a pre-existing medical event or disease or symptom 
since the last visit? 
- 
Did you change or add any concomitant medication since the last visit?  
- 
Do you feel comfortable using the e-diary and glucometer or do you need more 
training? 
• Review patient diary through the e-diary web portal (StudyWorks): 
- 
Basal insulin (glargine or detemir) and mealtime NovoLog/NovoRapid or insulin 
lispro doses, 
- 
SMPG values, 
- 
Hypoglycemia if any. 
• Review any potential questions related to screening and inclusion/exclusion criteria. 
• Refresher instructions for use of glucometer, and routine review of diet and lifestyle 
counseling along with instructions on dosage self-adjustment including carbohydrate 
intake (when available) are provided. 
• Patients are reminded to record in their e-diary when they return for randomization: 
- 
On at least 2 days in the week before the baseline Visit 3: 7-point plasma glucose 
profile (7 values: fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after 
lunch, pre- and 2 hours after dinner, and at bedtime) measured in a single, 24-hour 
period, 
- 
Any SMPG related to hypoglycemia, symptoms of hypoglycemia, 
- 
All doses of NovoLog/NovoRapid or insulin lispro injected either prior to meal intake 
or immediately after meal intake, any corrective dose related to the SMPG on each day 
of the week preceding the baseline visit, 
- 
Daily dose of insulin glargine or insulin detemir 100 U/mL on each day of the week 
preceding the baseline visit. 
• An appointment is made at telephone Visit 2 for the randomization visit (Day 1). Patients 
are reminded to bring their glucometer and their e-diary to their visit and come to their 
randomization visit fasting. Eight-hour delay between injection of SAR341402 or 
NovoLog/NovoRapid and AIA sampling must be respected. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 63 
• Visit 2 must be confirmed in the e-diary web portal and Visit 3 date should be corrected if 
the scheduled appointment is different from the planned per protocol (Visit 1 + 14 days). 
10.1.2 Open-label randomized treatment period and comparative safety extension period 
(Week 0 to Week 52) 
The 26-week open-label randomized treatment period will last from Visit 3 (Week 0, Day 1, 
baseline) to Visit 9 (Week 26, primary endpoint). 
After completion of the 26-week open-label active-controlled treatment period and measurement 
of the primary efficacy endpoint at Visit 9 (Week 26), patients will enter the 26-week active 
controlled safety extension period. 
Patients meeting all inclusion criteria and no exclusion criteria during the screening period 
undergo assessment Visit 3 (Day 1) as described in the flowchart (Section 1.2).  
After these assessments the patients will be 1:1 randomized through the IRT in one of the two 
following treatment arms using the HbA1c from the screening visit: 
• SAR341402 (SAR341402 SoloSTAR) + Lantus once daily. 
• NovoLog/NovoRapid (NovoLog/NovoRapid FlexPen) + Lantus once daily. 
After randomization, patients will enter the 26-week open-label active-controlled treatment 
period, and receive their assigned treatment of SAR341402 (SAR341402 SoloSTAR) or 
NovoLog/NovoRapid (NovoLog/NovoRapid FlexPen) in addition to their once daily mandatory 
Lantus background therapy.  
During the treatment period, patients are to continue their SMPG with routine dosage adjustment 
of rapid-acting/prandial insulin at all meals.  
Self-measured plasma glucose and insulin doses are to be transferred to the clinical database or 
entered into the e-CRF during the treatment period Visit 3 to Visit 12 and will include: 
• On at least 2 days in the week before on-site visits (Visit 3, Visit 7, Visit 9, and Visit 12): 
7-point plasma glucose profile (7 values: fasting prebreakfast, 2 hours postbreakfast, 
pre-and 2 hours after lunch, pre- and 2 hours after dinner, and at bedtime) measured in a 
single, 24-hour period. 
• Any SMPG related to hypoglycemia, symptoms of hypoglycemia. 
• All mealtime insulin doses and the basal insulin dose 
- 
for the 7 days prior to Baseline (Visit 3) and during the first 7 days after start of IMP, 
- 
for the 2 days in the weeks prior to Visit 5 (Week 4), Visit 7 (Week 12), Visit 9 
(Week 26), Visit 11 (Week 40) and Visit 12 (Week 52). 
• In case of hypoglycemia: hypoglycemic episode diary completed in e-diary or on the 
hypoglycemic event information (e-diary) page in the e-CRF. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 64 
• In case of severe hypoglycemia: hypoglycemic episode diary completed in e-diary to 
include symptoms AND transfer of data to web portal ensuring automatic notification of 
the Investigator from the e-diary web portal so that the event can be properly assessed and 
reported and insulin dose be adjusted if needed. 
Self-measured plasma glucose and insulin doses are available in the web based portal.  
In case of permanent study treatment discontinuation before Visit 12 (Week 52), please refer to 
Section 10.3.2. In case of patients not meeting glycemic goals, please refer to Section 8.1.6. 
Patients are encouraged to continue IMP at least to Week 26, primary efficacy endpoint. Even if 
patients stop IMP, they are continued in the trial on their insulin regimen without IMP until at 
least Week 26. 
10.1.2.1 Baseline visit (Visit 3, Week 0/Day 1) 
Patients meeting all inclusion criteria and with no exclusion criteria at the end of the screening 
period (based on data collected at the screening Visit 1 [Week -2], at Visit 2 [Week -1] 
[if applicable] and Visit 3 [Week 0]) are eligible to be randomized and can participate in the 
study. Patients must have demonstrated the ability and willingness to use the e-diary during the 
screening period. 
For the complete list of procedures scheduled for this visit, please refer to the study flowchart 
(Section 1.2) and for detailed description of assessments (Section 9.2.2.2, Section 9.2.3.2). 
At this visit, the patient must return to the investigation site in the morning after an overnight fast 
(no less than 8 hours fasting) and not having injected their mealtime insulin at home. Eight-hour 
delay between injection of insulin lispro or insulin aspart and AIA sampling must be respected. 
Patients will come with the sponsor provided glucometer and the e-diary. 
Key procedures and assessments during the visit: 
• Body weight, vital signs (SBP and DBP, heart rate). 
• Laboratory testing done by central laboratory: 
- 
HbA1c, 
- 
FPG, 
- 
AIA, 
- 
C-peptide. 
• Urine pregnancy test in WOCBP. 
• Concomitant medications are reviewed. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 65 
• Patient e-diary is verified to ensure that no pending data are stored in the e-diary and if so, 
data should be transmitted. The e-diary data is reviewed in the vendor web portal by the 
Investigator or SubInvestigator who are qualified and familiar with the study and the 
following is validated in the clinical database: 
- 
On at least 2 days in the week before the baseline visit (Visit 3): 7-point plasma 
glucose profile (fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after 
lunch, pre- and 2 hours after dinner, and at bedtime) measured in a single, 24-hour 
period, 
- 
All doses of NovoLog/NovoRapid or insulin lispro injected either prior to meal intake 
or immediately after meal intake, including any corrective dose related to the SMPG 
on each day of the week prior to the baseline visit, 
- 
Doses of insulin glargine or insulin detemir 100 U/mL on each day of the week prior to 
the baseline visit, 
- 
Any SMPG related to hypoglycemia and symptoms of hypoglycemia. 
• Patients will be reminded to record daily dose of IMP and NIMP, including any corrective 
dose related to the SMPG on each day of the week after the baseline visit. 
• Additional SMPG, insulin dosage adjustment, and carbohydrate intake (when available) to 
assist the patient with insulin dosage self-adjustment is reviewed. 
• Training is repeated for use of glucometer, insulin pens and completion of the electronic 
diary as needed; instruction on the importance of timely completion of SMPG monitoring 
using the sponsor provided glucometer is provided. 
• AE/SAEs are collected and injection site reactions, hypersensitivity reactions, and 
hypoglycemic events are to be assessed and reported in the clinical database. 
• Review of inclusion/exclusion criteria. 
• IRT is called to randomize the patient if they still meet inclusion/exclusion criteria and 
after all baseline evaluations have been performed.  
• Visit occurrence is confirmed in the e-diary web portal. 
• Diet and lifestyle counseling is provided including assessment of food intake and how to 
adjust meal related rapid-acting insulin for changes in food intake. 
• Patients will be provided with kits containing pens for administration of IMP along with 
the instruction leaflet and corresponding supplies (needles, control solution, test strips 
etc.). A patient card, including emergency contact details and treatment arm will be 
provided to every patient who participates in the study. 
• Patients will be instructed by the study staff how to properly use the study drug pens; 
(NovoLog/NovoRapid FlexPen, SAR341402 SoloSTAR). 
• IMP administration will be explained to patients including communication of the starting 
IMP dose and dose self-adjustment requirements. Study medications until the next on-site 
visit are dispensed (NIMP [Lantus SoloSTAR] and IMP [NovoLog/NovoRapid FlexPen or 
SAR341402 SoloSTAR]). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 66 
• Investigators and their study staff are required to offer adequate training, thus enabling 
patients to successfully adjust their meal related boluses of IMP. The goal for all patients 
is to attain good glycemic control (recommended target 2 hour postprandial glucose value 
of <10 mmol/L (<180 mg/dL) while avoiding hypoglycemia or to a pre-prandial glucose 
target range of 4.4 to 7.2 mmol/L (80 to 130 mg/dL), for all of their meals [1]). 
• The target for titration of basal insulin is a FPG (fasting plasma glucose) is 4.4 to 
7.2 mmol/L (80 to 130 mg/dL). 
• Glycemic targets may be adapted for individual patients, if deemed necessary, eg, due to 
age, comorbid conditions, and individual patient considerations. The individual target will 
be documented in the source documents. Arrangements are made for contact between the 
Investigator or medically qualified designee and the patient is provided an appointment in 
4 weeks (Visit 5,Week4) to monitor insulin  doses for both Lantus and IMP 
(NovoLog/NovoRapid FlexPen or SAR341402 SoloSTAR). 
• Patients are instructed to return to the site for Visit 5 (Week 4) four weeks later, in the 
morning, and to bring used and in-use Lantus SoloSTAR and IMP (NovoLog/NovoRapid 
FlexPen or SAR341402 SoloSTAR), as well as the sponsor provided glucometer and the 
e-diary. 
10.1.2.2 On-site visits: Visit 5 (Week 4), Visit 8 (Week 20) +/- 3 days  
Key procedures and assessments during the visit: 
• Vital signs (SBP and DBP, heart rate). 
• Laboratory testing done by central laboratory Visit 5 (Week 4) only: 
- 
AIA (8-hour delay between injection of IMP and AIA sampling must be respected). 
• Concomitant medications are reviewed. 
• Diet and lifestyle counseling is provided including assessment of food intake and how to 
adjust meal related rapid-acting insulin for changes in food intake. 
• Patient data from the web based portal is reviewed and the following is transferred into the 
clinical database : 
- 
Any SMPG related to hypoglycemia and symptoms of hypoglycemia, 
- 
For Visit 5 (Week 4) only – on at least 2 days during the week before the visit:  
a) All doses of SAR341402/NovoLog/NovoRapid injected either prior to meal intake or 
immediately after meal intake, including any corrective dose related to the SMPG, 
b) Daily Lantus dose. 
• SMPG data are reviewed and patients instructed in adjustment of insulin doses; instruction 
on the importance of timely completion of SMPG monitoring using the sponsor provided 
glucometer is provided. 
• Compliance is checked with review of diary and web based portal. 
• Used and unused pens are counted and collected.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 67 
• Main area of injection for IMP and NIMP since last on-site visit is documented. 
• AE/SAEs are collected and injection site reactions, hypersensitivity reactions, and 
hypoglycemic events assessed and reported into the clinical database. Special attention has 
to be paid on severe hypoglycemia. 
• IRT is called. 
• Visit occurrence is confirmed in the e-diary web portal. 
• Doses of SAR341402/NovoLog/NovoRapid titration and dose self-adjustment 
requirements will be reviewed. 
• Study medications until the next on-site visit are dispensed (NIMP [Lantus SoloSTAR] 
and IMP [NovoLog/NovoRapid FlexPen or SAR341402 SoloSTAR]). 
• Patients are also instructed to return to the next on-site visit and to bring used and in-use 
Lantus SoloSTAR and IMP (NovoLog/NovoRapid FlexPen prefilled disposable pens or 
SAR341402 SoloSTAR), as well as the glucose meter and the diary. 
• At Visit 8, patients are reminded to come to their next visit fasting and to complete 
two 7-point profiles the week prior Visit 9. 
10.1.2.3 On-site visits: Visit 7 (Week 12) +/- 3 days and Visit 11 (Week 40) +/- 5 days 
Key procedures and assessments during the visit: 
• Vital signs (SBP and DBP, heart rate). 
• Laboratory testing done by central laboratory: 
- 
HbA1c, 
- 
FPG, 
- 
AIA (8-hour delay between injection of IMP and AIA sampling must be respected). 
• Urine pregnancy test done in WOCBP. 
• Diet and lifestyle counseling is provided including assessment of food intake and how to 
adjust meal related rapid-acting insulin for changes in food intake. 
• Concomitant medications are reviewed. 
• Patient diary is reviewed and the following is validated in the clinical database: 
- 
Visit 7: 
a) On at least 2 days in the week before the visit: 7-point plasma glucose profile 
(7 values: fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch,  
pre- and 2 hours after dinner, and at bedtime) measured in a single, 24-hour period, 
b) All doses of SAR341402/NovoLog/NovoRapid injected either prior to meal intake or 
immediately after meal intake, including any corrective dose related to the SMPG on 
the two 7-point profile days. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 68 
c) Daily Lantus dose on the two 7-point profile days. 
d) Any SMPG related to hypoglycemia and symptoms of hypoglycemia. 
- 
Visit 11: 
a) All doses of SAR341402/NovoLog/NovoRapid injected either prior to meal intake or 
immediately after meal intake, including any corrective dose related to the SMPG on 
2 days during the week prior to the visit, 
b) Daily Lantus dose on 2 days during the week prior to the visit, 
c) Any SMPG related to hypoglycemia and symptoms of hypoglycemia. 
• Additional SMPG, insulin dosage adjustment, and any carbohydrate counts (when 
available) are reviewed; instruction on the importance of timely completion of SMPG 
monitoring using the sponsor provided glucometer is provided. 
• Compliance is checked with review of diary and unused IMP. 
• Used and unused pens are collected. 
• Main area of injection for IMP and NIMP since last on-site visit is documented. 
• AE/SAEs are collected and injection site reactions, hypersensitivity reactions, and 
hypoglycemic events are to be assessed and reported in the clinical database. Special 
attention has to be paid on severe hypoglycemia. 
• IRT is called.  
• Visit occurrence is confirmed in the e-diary web portal. 
• Study medications until the next on-site visit are dispensed (NIMP (Lantus SoloSTAR) 
and IMP (NovoLog/NovoRapid FlexPen or SAR341402 SoloSTAR). 
• Arrangements are made for contact between the Investigator or medically qualified 
designee and the patient in 8 weeks at Visit 8 (Week 20) for Visit 7 or in 12 weeks at Visit 
12 (Week 52) for Visit 11 to monitor doses for both Lantus and IMP 
(NovoLog/NovoRapid FlexPen or SAR341402 SoloSTAR). 
• Patients are also instructed to return to the next on site visit-and to bring used and in-use as 
well as not used that may include expired Lantus SoloSTAR and IMP 
(NovoLog/NovoRapid FlexPen prefilled disposable pens or SAR341402 SoloSTAR), in 
addition to the sponsor provided glucose meter and the e-diary. At Visit 11, patients must 
be instructed to:  
- 
Return fasting. Eight-hour delay between injection of SAR341402 or 
NovoLog/NovoRapid and AIA sampling must be respected, 
- 
Complete two 7-point SMPG profiles the week prior to Visit 12. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 69 
10.1.2.4 Visit 9 (Week 26, primary efficacy endpoint) +/- 3 days 
Key procedures and assessments during the visit: 
• Laboratory testing done by central laboratory: 
- 
HbA1c, 
- 
FPG, 
- 
Safety laboratory test for hematology, clinical chemistry (please refer to 
Section 9.2.3.2.3), 
- 
Serum lipids (please refer to Section 9.2.3.2.3), 
- 
AIA (8-hour delay between injection of IMP and AIA sampling must be respected). 
• Urine pregnancy test in WOCBP. 
• Physical examination, vital signs and body weight are measured. 
• Concomitant medications are reviewed. 
• Diet and lifestyle counseling is provided including assessment of food intake and how to 
adjust meal related rapid-acting insulin for changes in food intake. 
• Patient diary is reviewed using the vendor web based portal and the following is validated 
in the clinical database: 
- 
On at least 2 days in the week before the Visit 9: 7-point plasma glucose profile 
(7 values: fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch,  
pre- and 2 hours after dinner, and at bedtime) measured in a single, 24-hour period, 
- 
All doses of SAR341402/NovoLog/NovoRapid injected either prior to meal intake or 
immediately after meal intake, including any corrective dose related to the SMPG on 
the two 7-point profile days, 
- 
Daily Lantus dose on the two 7-point profile days, 
- 
Any SMPG related to hypoglycemia and symptoms of hypoglycemia. 
• Additional SMPG, dosage adjustment, and any carbohydrate counts (when available) are 
reviewed; instruction on the importance of timely completion of SMPG monitoring using 
the sponsor provided glucometer is provided. 
• Compliance is checked with review of e-diary and unused IMP. 
• Used and unused pens are counted and collected. 
• Main area of injection for IMP and NIMP since last on-site visit is documented. 
• AE/SAEs are collected. Injection site reactions, hypersensitivity reactions, and 
hypoglycemia recording are to be assessed and reported. Special attention has to be paid 
on severe hypoglycemia. 
• IRT is called. 
• Visit occurrence is confirmed in the e-diary web portal. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 70 
• Study medications until the next on-site visit are dispensed (NIMP (Lantus SoloSTAR) 
and IMP (NovoLog/NovoRapid FlexPen or SAR341402 SoloSTAR). 
• Patients are instructed to schedule the Visit 10 phone visit and to schedule a return on-site 
visit, Visit 11, in the morning and to bring in all used and in-use, as well as not used pens 
that may include expired Lantus SoloSTAR and IMP (NovoLog/NovoRapid FlexPen 
prefilled disposable pens or SAR341402 SoloSTAR), in addition to the sponsor provided 
glucose meter and the e-diary. 
10.1.2.5 Telephone visits: Visit 4 (Week 2) +/-3 days, Visit 6 (Week 8) +/-3 days, Visit 10 
(Week 34) +/- 5 days; unscheduled telephone/fax/email visits 
Only at scheduled visits (Visit 4 [Week 2], Visit 6 [Week 8], and Visit 10 [Week 34]): 
• Patient diary is reviewed using the vendor web based portal and the following is validated 
in the clinical database: 
- 
Any SMPG related to hypoglycemia and symptoms of hypoglycemia, 
- 
Only at Visit 4: All doses of NovoLog/NovoRapid or SAR341402 injected either prior 
to meal intake or immediately after meal intake, any corrective dose related to the 
SMPG on each day of the week following the baseline visit, 
- 
Only at Visit 4: Daily dose of Lantus on each day of the week following the baseline 
visit, 
- 
Visit occurrence is confirmed in the e-diary web portal. 
• Patients are reminded that for their return (Visits 5, 7 and 9), 8-hour delay between 
injection of SAR341402 or NovoLog/NovoRapid and AIA sampling must be respected. 
• At Visit 6, patients are reminded to complete two 7-point profiles the week prior Visit 7.  
• At Visit 6 and 10, patients are reminded to come to their next visit fasting. 
During the phone call, ask the patient: 
• Did you experience any new medical event, disease or symptom since the last visit? 
(Please pay attention to any possible hypoglycemic event or symptom, possible allergic or 
injection site reactions). 
• Did you experience any change in a pre-existing medical event or disease or symptom 
since the last visit? 
• Did you change or add any concomitant medication since the last visit? 
• Did you have any technical difficulties with use of the e-diary or glucometer? 
Review with the patient: 
• Diet and lifestyle counseling. 
• Dosage self-adjustment for food and glucose out of goal range. 
• Correction/supplemental scales. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 71 
Instruct patients by: 
• Providing information on how to adjust dose according to their SMPG values. 
• Encourage patients to continue to measure required SMPG in the sponsor provided 
glucometer and complete the insulin doses and hypoglycemic form for all hypoglycemic 
events into the e-diary. 
Record in the clinical database: 
• Any changes to concomitant medication. 
• AE/SAE, injection site reaction, hypersensitivity, and hypoglycemia if any. Special 
attention has to be paid on severe hypoglycemia. 
Patient is called by the Investigator or qualified designee at a scheduled time. Patient may at the 
discretion of the Investigator, communicate SMPG and AE/SAE via email and fax, which are then 
placed into the source documents. 
10.1.2.6 End of treatment visit: Visit 12 (Week 52) +/- 5 days 
Key procedures and assessments during the visit: 
• Laboratory done via central laboratory: 
- 
HbA1c, 
- 
FPG, 
- 
Safety laboratory test for hematology, clinical chemistry (please refer to 
Section 9.2.3.2.3), 
- 
Serum lipids (please refer to Section 9.2.3.2.3), 
- 
AIA (8-hour delay between injection of IMP and AIA sampling must be respected). 
• Urine pregnancy test in WOCBP. 
• Physical examination, vital signs and body weight are measured. 
• Patient diary is reviewed by the site Investigator for concomitant medications. 
• Patient diary is reviewed using the vendor web based portal and the following is entered 
into the clinical database: 
- 
On at least 2 days in the week before the Visit 12: 7-point plasma glucose profile 
(7 values: fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch,  
pre- and 2 hours after dinner, and at bedtime) measured in a single, 24-hour period, 
- 
All doses of SAR341402/NovoLog/NovoRapid injected either prior to meal intake or 
immediately after meal intake, including any corrective dose related to the SMPG on 
the two 7-point profile days, 
- 
Daily Lantus dose on the two 7-point profile days, 
- 
Any SMPG related to hypoglycemia and symptoms of hypoglycemia. 
• Additional SMPG, insulin dosage adjustment, and any carbohydrate counts if available are 
reviewed by the site in the vendor web based portal. 
• Compliance is checked with review of diary/vendor web based portal and unused IMP. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 72 
• Counting/collecting used and unused pens. 
• Main area of injection for IMP and NIMP since last on-site visit is documented. 
• AE/SAEs, injection site reactions, hypersensitivity reactions, and hypoglycemic events are 
assessed and reported into the clinical database. Special attention has to be paid on severe 
hypoglycemia. 
• IRT is called to register end of treatment.  
• Visit occurrence is confirmed in the e-diary web portal, and the end of treatment 
information is entered. 
10.1.3 Post-treatment follow-up 
A post-treatment safety follow-up period will be performed 1 day after permanent discontinuation 
of the IMP.  
10.1.3.1 Post-treatment follow-up telephone visit: Visit 13 (Week 52 + 1 day) 
Following the last administration of IMP (SAR341402 or NovoLog/NovoRapid) either as 
scheduled at Visit 12 (Week 52) or prematurely with early end of IMP but with the assessments of 
Visit 12 (Week 52) the patient will be followed until at least Week 26, and a post-treatment 
follow-up should be scheduled. This is scheduled for all the patients 1 day after Visit 12 
(or 2 to 3 days in the event this visit falls on a weekend or holiday) for patients who complete the 
trial or 1 day after premature end of treatment visit (or 2 to 3 days in the event this visit falls on a 
weekend or holiday) for those who had premature end of treatment. This visit can be a phone call 
visit or an on-site visit in case of ongoing or new AE during the post-treatment period, if 
necessary. The patient is called by the Investigator or qualified designee at scheduled time.  
Concomitant medications, AE/SAEs, local reactions such as injection site reactions, 
hypersensitivity reactions, and hypoglycemia are reviewed by the site and reported in the clinical 
database at Visit 13. This will include the basal and mealtime insulins used post-trial including 
dose.  
IRT has to be called in order to register end of study. 
10.2 
DEFINITION OF SOURCE DATA 
10.2.1 Source data to be found in patient´s file 
Evaluations recorded in the e-CRF must be supported by appropriately signed source 
documentation related but not limited to the following: 
• Agreement and signature of informed consent form with the study identification. 
• Study identification (name). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 73 
• Patient number, confirmation of randomization, Treatment batch number (treatment arm), 
dates and doses of study medication administration. 
• Medical, surgical, diabetes history, including information on: 
- 
Demography, inclusion and exclusion criteria, 
- 
Last participation in a clinical trial, 
- 
Contraception method for WOCBP, 
- 
Previous and concomitant medication. 
• Dates and times of visits and assessments including examination results. 
• Vital signs, height, body weight, Laboratory reports, Investigation results (eg, ECG traces, 
imaging reports). 
• Adverse events and follow-up: 
- 
In case of SAE, the site should file in the source documents at least copies of the 
hospitalization reports and any relevant examination reports documenting the 
follow-up of the SAE. 
• Date of premature study discontinuation (if any) and reason. 
• Nursing notes. 
• Dietician’s notes. 
• Physician’s notes, to include 
- 
Initial insulin doses for basal insulin, meal related insulin which may include 
carbohydrate ratio and individualized goal ranges for glucose control. 
• Patient SMPG, insulin doses, and hypoglycemia event data will be stored on the vendor 
web based portal as electronic source available for the site. 
• For patients who are identified as outliers for severe hypoglycemia, patient and site 
retraining will be kept in source as well as any supporting clinical information as to 
underlying causes of the increased severe hypoglycemia. 
10.2.2 Source data verification requirements for screen failures 
For screen failure patients, the following source data must be verified: patient's identification 
details, the informed consent signed by the patient, the study identification (name), dates of study 
visits and the main reasons for screen failure. Data related to the AEs for screen failure patients 
will be checked against source documents. 
10.3 
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION  
The IMP should be continued whenever possible. In case the IMP is stopped, it should be 
determined whether the stop can be made temporarily; permanent IMP discontinuation should be 
a last resort. Any IMP discontinuation should be fully documented in the CRF. In any case, the 
patient should remain in the study as long as possible. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 74 
10.3.1 Temporary treatment discontinuation with investigational medicinal product(s) 
Temporary treatment discontinuation may be considered by the Investigator because of suspected 
AEs, see decision tree in Section 17. Reinitiating  treatment with the IMP will be done under close 
and appropriate clinical/and or laboratory monitoring once the Investigator will have considered 
according to his/her best medical judgment that the responsibility of the IMP in the occurrence of 
the concerned event was unlikely and if the selection criteria for the study are still met 
(Section 7.1, Section 7.2). 
It is in the interest of the patient to monitor plasma glucose during the temporary discontinuation 
period, therefore SMPG or other regular determination of plasma glucose is to be performed and 
documented. 
During any temporary treatment discontinuation, doses of alternative treatment used for plasma 
glucose control should be recorded by the Investigator in the concomitant medication page. 
Use of a different insulin during the time of temporary treatment discontinuation is recorded as 
concomitant medication (such as during a hospitalization) with the name and doses recorded in 
the e-CRF. 
10.3.2 Permanent treatment discontinuation with investigational medicinal product(s) 
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at 
any time. 
10.3.3 List of criteria for permanent treatment discontinuation 
The patients may withdraw from treatment with the IMP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision. All efforts should be made to 
document the reasons for treatment discontinuation and this should be documented in the e-CRF. 
The following reasons lead to permanent discontinuation: 
• At the patient’s own request, ie, withdrawal of consent for treatment. 
• If, in the Investigator's opinion, continuation with the administration of the study treatment 
would be detrimental to the patient's well-being. 
• Inter-current condition that requires permanent discontinuation of the study treatment 
(eg, laboratory abnormalities according to the decision tree in Section 17, Appendix B) as 
long as the abnormality persists and if the casual relationship of the concerned event and 
the IMP is possible according to the Investigator’s best medical judgment). 
• Pregnancy. 
• Specific request of the sponsor. 
Any abnormal laboratory value or ECG will be immediately rechecked for confirmation before 
making a decision of permanent discontinuation of the IMP for the concerned patient.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 75 
10.3.4 Handling of patients after permanent treatment discontinuation 
The assessments planned at end of treatment visit (Section 10.1.2.4 and Section 1.2) will be 
performed as soon as possible after the permanent discontinuation of treatment. 
All cases of permanent treatment discontinuation should be recorded by the Investigator in the 
appropriate pages of the e-CRF when considered as confirmed. Reason for discontinuation will be 
clearly specified and the newly prescribed rapid-acting insulin analogue will be recorded. 
After this end of treatment visit, the follow-up safety phone call will be performed 1 day 
(or 2 to 3 days in the event this visit falls on a weekend or holiday) after end of treatment visit. 
Afterwards, patients will be followed-up according to the study procedures specified in this 
protocol up to the scheduled date of study completion, to a minimum of Visit 9 (Week 26) (14) or 
up to recovery or stabilization of any AE to be followed-up as specified in this protocol, 
whichever comes last. 
Refer to e-CRF completion guidelines for description of how reasons for missing data are 
collected.  
10.3.5 Procedure and consequence for patient withdrawal from study  
The patients may withdraw from the study before study completion if they decide to do so, at any 
time and irrespective of the reason without any effect on their care. However, if patients no longer 
wish to take the IMP, they will be encouraged to remain in the study. 
The Investigators should discuss with them key visits to attend. The value of all their study data 
collected during their continued involvement will be emphasized as important to the public health 
value of the study. If possible, the patients are assessed using the procedure normally planned for 
the end-of-treatment visit (see Section 10.1.2.4 and Section 1.2). 
Patients who withdraw should be explicitly asked about the contribution of possible AEs to their 
decision to withdraw consent, and any AE information elicited should be documented. 
All study withdrawals must be recorded by the Investigator in the appropriate screens of the 
e-CRF and in the patient’s medical records. In the medical record, at least the date of the 
withdrawal and the reason should be documented. 
Withdrawal of consent for treatment should be distinguished from withdrawal of consent for 
follow-up visits and from withdrawal of consent for non-patient contact follow-up, eg, medical 
record checks. The site should document any case of withdrawal of consent. 
For patients who fail to return to the site, unless the patient withdraws the consent for follow-up, 
the Investigator should make the best effort to re-contact the patient (eg, contact patient’s family 
or private physician, review available registries or health care databases), and to determine his/her 
health status, including at least his/her vital status. Attempts to contact such patients must be 
documented in the patient’s records (eg, times and dates of attempted telephone contact, receipt 
for sending a registered letter). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 76 
The statistical analysis plan will specify how these patients lost to follow-up for their primary 
endpoints will be considered.  
Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their 
inclusion and treatment numbers must not be reused.  
10.4 
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.4.1 Definitions of adverse events  
10.4.1.1 Adverse event 
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. 
10.4.1.2 Serious adverse event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death, or, 
• Is life-threatening, or, 
Note: The term “life-threatening” in the definition of “serious” refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization, or, 
• Results in persistent or significant disability/incapacity, or, 
• Is a congenital anomaly/birth defect, 
• Is a medically important event, 
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization but may jeopardize the 
patient or may require medical or surgical intervention (ie, specific measures or corrective 
treatment) to prevent one of the other outcomes listed in the definition above. 
Note: The following list of medically important events is intended to serve as a guideline for 
determining which condition has to be considered a medically important event. The list is not 
intended to be exhaustive: 
• Intensive treatment in an emergency room or at home for: 
- 
Allergic bronchospasm, 
- 
Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc), 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 77 
- 
Convulsions (seizures, epilepsy, epileptic fit, absence, etc). 
• Development of drug dependence or drug abuse. 
• ALT >3 x ULN + total bilirubin >2 x ULN or asymptomatic ALT increase >10 x ULN. 
• Suicide attempt or any event suggestive of suicidality. 
• Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling). 
• Bullous cutaneous eruptions. 
• Cancers diagnosed during the study or aggravated during the study (only if judged 
unusual/significant by the Investigators in oncology studies). 
• Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study 
(only if judged unusual/significant by the Investigators in studies assessing specifically the 
effect of a study drug on these diseases). 
10.4.1.3 Adverse event of special interest 
An adverse event of special interest (AESI) is an AE (serious or non-serious) of scientific and 
medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and 
rapid communication by the Investigator to the Sponsor may be appropriate. Such events may 
require further investigation in order to characterize and understand them. Adverse events of 
special interest may be added, modified or removed during a study by protocol amendment. 
The AESI for this study: 
• ALT increase (refer to related flowchart and protocol appendices). 
• Pregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP/NIMP: 
- 
Pregnancy occurring in a female patient included in the clinical trial or in a female 
partner of a male subject entered in the clinical trial. It will be qualified as an SAE 
only if it fulfills one of the seriousness criteria (see Section 10.4.1.2 ), 
- 
In the event of pregnancy in a female participant, IMP should be discontinued, 
- 
Follow-up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outcome has been determined. 
• Symptomatic overdose with IMP/NIMP: 
- 
A symptomatic overdose (accidental or intentional) with the IMP/NIMP is an event 
suspected by the Investigator or spontaneously notified by the patient and resulting in 
clinical symptoms and/or signs and considered a “significant overdose” by the 
Investigator. It will be recorded in the e-CRF as an AESI with immediate notification 
“Symptomatic OVERDOSE (accidental or intentional)” in all cases and will be 
qualified as an SAE only if it fulfills the SAE criteria. 
• Of note, asymptomatic overdose (accidental or intentional) with the IMP/NIMP is defined 
as any “significant” overdose, without clinical symptoms and/or signs, either suspected by 
the Investigator or spontaneously notified by the patient (not based on accountability 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 78 
assessment). It will be recorded as an AESI “Asymptomatic OVERDOSE (accidental or 
intentional)” that does not require immediate notification. 
10.4.2 Serious adverse events waived from expedited regulatory reporting to regulatory 
authorities 
There are no waivers from expedited reporting of serious events to health authorities in this trial. 
10.4.3 General guidelines for reporting adverse events 
• All AEs, regardless of seriousness or relationship to IMP/NIMP, spanning from the 
signature of the informed consent form until the end of the study as defined by the 
protocol for that patient, are to be recorded on the corresponding page(s) or screen(s) 
included in the e-CRF. 
• Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. 
The Investigator should specify the date of onset, intensity, action taken with respect to 
IMP, corrective treatment/therapy given, additional investigations performed, outcome, 
and his/her opinion as to whether there is a reasonable possibility that the AE was caused 
by the IMP.  
• In this study, the required use of the mandatory background basal Lantus (NIMP) and use 
of IMP (SAR341402 or NovoLog/NovoRapid) may make it difficult to assess the causal 
relationship to the specific insulin, particularly for hypoglycemia. Global Safety Officer 
with input from other appropriate study team members will determine the causal 
relationship when it is not clearly provided by the Investigator. 
• The Investigator should take appropriate measures to follow all AEs until clinical recovery 
is complete and laboratory results have returned to normal, or until progression has been 
stabilized, or until death, in order to ensure the safety of the patients. This may imply that 
observations will continue beyond the last planned visit per protocol, and that additional 
investigations may be requested by the monitoring team up to as noticed by the Sponsor. 
• When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
• Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if:  
- 
Symptomatic and/or, 
- 
Requiring either corrective treatment or consultation, and/or, 
- 
Leading to IMP discontinuation or modification of dosing, and/or, 
- 
Fulfilling a seriousness criterion, and/or, 
- 
Defined as an AESI. 
Instructions for AE reporting are summarized in Table 1.  
10.4.4 Instructions for reporting serious adverse events 
• In the case of occurrence of an SAE, the Investigator or any designees must immediately: 
- 
ENTER (within 24 hours) the information related to the SAE in the appropriate 
screens of the e-CRF; the system will automatically send a notification to the 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 79 
monitoring team after approval of the Investigator within the e-CRF or after a standard 
delay, 
- 
SEND (preferably by fax or e-mail) a photocopy of all examinations carried out and 
the dates on which these examinations were performed, to the representative of the 
monitoring team whose name, fax number, and email address appear on the Clinical 
Trial Protocol. Care should be taken to ensure that the patient's identity is protected 
and the patient's identifiers in the clinical trial are properly mentioned on any copy of a 
source document provided to the Sponsor. For laboratory results, include the 
laboratory normal ranges, 
- 
All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for laboratory data, concomitant 
medications, patient status, etc.) should be sent (by fax or e-mail) to the monitoring 
team within 24 hours of knowledge of the SAE. In addition, every effort should be 
made to further document any SAE that is fatal or life threatening within a week 
(7 days) of the initial notification, 
- 
A back-up plan (using a paper CRF process) is available and should be used when the 
e-CRF system does not work. 
• Any SAE brought to the attention of the Investigator at any time after the end of the study 
for the patient and considered by him/her to be caused by the IMP with a reasonable 
possibility, should be reported to the monitoring team. 
10.4.5 Guidelines for reporting adverse events of special interest  
For AESIs, the Sponsor must be informed immediately (ie, within 24 hours), as per SAE 
notification guidelines described in Section 10.4.4, even if not fulfilling a seriousness criterion, 
using the corresponding pages of the CRF (to be sent) or screens in the e-CRF.  
10.4.5.1 Reporting of adverse events of special interest with immediate notification 
For AESIs with immediate notification, the Sponsor will be informed immediately (ie, within 
24 hours), as per the SAE notification instructions described in Section 10.4.4, even if not 
fulfilling a seriousness criterion, using the corresponding pages in the CRF (to be sent) or screens 
in the e-CRF.  
10.4.5.2 Reporting of adverse events of special interest without immediate notification 
Asymptomatic overdose (accidental or intentional) with the IMP/NIMP is defined as any 
“significant” overdose, without clinical symptoms and/or signs, either suspected by the 
Investigator or spontaneously notified by the patient (not based on accountability assessment). 
It will be recorded as an AE “Asymptomatic OVERDOSE (accidental or intentional)”. 
10.4.6 Guidelines for management of specific laboratory abnormalities 
Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in 
Appendix B.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 80 
The following laboratory abnormalities should be monitored, documented, and managed 
according to the related flow chart in protocol appendices:  
• Neutropenia. 
• Thrombocytopenia. 
• Increase in ALT. 
• Acute renal insufficiency. 
• Suspicion of rhabdomyolysis. 
Table 1 - Summary of adverse event reporting instructions 
Case Report Form completion 
Event category 
Reporting 
timeframe 
Specific events in this 
category 
AE 
form 
Safety  
Complementary 
Form 
Other 
specific 
forms 
Adverse event  
(non-SAE, non-AESI)   
Routine 
Any AE that is not SAE or AESI 
 
Yes 
No 
No 
Adverse event  
Routine 
Allergic or allergic-like 
Yes 
No 
Yes 
Serious adverse 
event (non-AESI or 
AESI) 
Expedited (within 
24 hours) 
Any AE meeting seriousness criterion 
per Section 10.4.1.2 
Yes 
Yes 
No 
Adverse event of 
special interest  
Expedited (within 
24 hours) 
Pregnancy 
Yes 
No 
Yes 
 
 
Symptomatic overdose with IMP/NIMP 
Yes 
Yes 
No 
 
 
ALT ≥3 x ULN or ALT >2 x baseline if 
baseline ALT ≥ULN 
Yes 
Yes 
Yes 
 
10.5 
OBLIGATIONS OF THE SPONSOR 
During the course of the study, the Sponsor will report in an expedited manner: 
• All SAEs that are both unexpected and at least reasonably related to the IMP (suspected 
unexpected serious adverse reaction [SUSAR]), to the health authorities, Independent 
Ethics Committees (IECs)/Institutional Review Boards (IRBs) as appropriate and to the 
Investigators. 
• All SAEs that are both expected and at least reasonably related to the IMPs to the health 
authorities, according to local regulations. 
• The following AESIs to the Health Authorities 
- 
Pregnancy, 
- 
Symptomatic overdose with IMP/NIMP, 
- 
ALT >3 x ULN or ALT >2 x baseline if baseline ALT ≥ ULN. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 81 
Adverse events that are considered expected will be specified by the reference safety information 
(Investigator’s Brochure).  
As this is an open label study, no un-blinding of SUSARs is necessary. 
The Sponsor will report all safety observations made during the conduct of the trial in the CSR. 
10.6 
SAFETY INSTRUCTIONS 
10.6.1 Hypoglycemia 
Severe symptomatic hypoglycemia 
• Severe symptomatic hypoglycemia is an event requiring assistance of another person to 
actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes 
may be associated with sufficient neuroglycopenia to induce seizure, unconsciousness or 
coma. Plasma glucose measurements may not be available during such an event, but 
neurological recovery attributable to the restoration of plasma glucose to normal is 
considered sufficient evidence that the event was induced by a low plasma glucose 
concentration.  
• The definition of severe symptomatic hypoglycemia includes all episodes in which 
neurological impairment was severe enough to prevent self-treatment and which were thus 
thought to place patients at risk for injury to themselves or others. 
• Note that “requires assistance” means that the patient could not help himself or herself. 
Assisting a patient out of kindness, when assistance is not required, should not be 
considered a “requires assistance” incident. 
• Severe symptomatic hypoglycemia will be qualified as an SAE only if it fulfills SAE 
criteria. All events of seizure, unconsciousness or coma must be reported as SAEs. 
• If a participant reports a severe hypoglycemia between the on-site visits or during a phone 
call visit, the Investigator should ask him/her to come to the study site on the same or the 
next day, so that the event can be properly assessed and reported. 
For description of all other hypoglycemia event types and discussion of endpoints related to 
hypoglycemia, see Section 9.2.3.2.1. 
10.6.2 Injection site reactions  
In case the Investigator or the patient recognizes any sign related to local non-allergic reactions at 
the study drug injection site (Section 9.2.3.2.4), this should be recorded on the AE page in the 
e-CRF.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 82 
10.6.3 Hypersensitivity reactions 
In case a patient experiences an event identified as a potential hypersensitivity reaction 
(an allergic reaction or an allergic-like reaction), this has to be reported as an AE and recorded in 
the e-CRF on the AE page; additional information is collected on the specific allergic reaction 
complementary forms. Allergic reaction or possible allergic reaction will be adjudicated by the 
ARAC (Section 6.4).  
If a participant reports a hypersensitivity reaction between the on-site visits or during a phone call 
visit, it is recommended that the Investigator ask him/her to come to the study site on the same or 
the next day as clinically appropriate, so that the event can be properly assessed and reported. 
Virtually all symptoms listed on the allergic reaction complementary form are possible adverse 
reactions that may be allergic in nature and may need to be addressed after medical judgment, 
excluding another etiology than allergy. 
Sometimes transient injection site reactions, irritant in nature may occur requiring no intervention 
and are of dubious significance. These reactions would not be considered to be allergic reactions. 
Adverse events that are obviously not of allergic origin (eg, local injection site reactions) should 
not be recorded on the Allergic Reaction Complementary Form. 
10.6.4 SMPG 
Safety instructions are provided for SMPG in Section 9.2.2.2.3 and Section 9.2.3.2.1.1. 
10.6.5 Follow-up of laboratory abnormalities 
Decision trees for the management of certain laboratory abnormalities are provided in Section 17, 
Appendix B. Assessment of General Safety Laboratory data is provided in Section 9.2.3.2.3. 
In subjects in whom the ARAC assesses AIA-mediated hypersensitivity reaction or 
insulin resistance, the increased AIA titers will be followed until return to baseline or until ARAC 
decides that no further follow-up is deemed necessary. 
10.6.6 Other 
Assessment of vital signs is noted in Section 9.2.3.2.5 and of ECG in Section 9.2.3.2.7. 
10.7 
ADVERSE EVENTS MONITORING 
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final CSR. 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 83 
11 
STATISTICAL CONSIDERATIONS 
11.1 
DETERMINATION OF SAMPLE SIZE 
The sample size calculations are performed based on the primary endpoint, change in HbA1c from 
baseline to Week 26 (in %). 
A sample size of 580 patients (290 patients per arm; approximately 480 T1DM patients 
[230 patients in the US using NovoLog and 250 patients in countries using NovoRapid] and 
100 T2DM patients [all in the US using NovoLog]) will ensure that the upper bound of the 
2-sided 95% confidence interval (CI) for the adjusted mean difference between SAR341402 and 
NovoLog/NovoRapid would not exceed a non-inferiority margin of 0.3% HbA1c with at least 
95% power. This sample size will also ensure that the lower bound of this 2-sided 95% CI would 
not be below -0.3% HbA1c with at least 95% power, thus will provide at least 90% power to show 
both non-inferiority of SAR341402 over NovoLog/NovoRapid (primary analysis) and inverse 
non-inferiority of NovoLog/NovoRapid over SAR341402 (secondary analysis).  These 
calculations assume a common standard deviation (SD) of 1.0% and a true difference in HbA1c 
between the treatment groups of zero. 
An exploratory analysis of the percentage of patients with treatment-emergent AIAs 
(AIA incidence) will be performed to compare the immunogenicity of SAR341402 versus 
NovoLog/NovoRapid. The sample size of 580 patients would ensure that the 2-sided 90% CI for 
the adjusted risk difference between SAR341402 and NovoLog/NovoRapid would be included 
within the [-10%; 10%] interval with at least 68% power. This calculation assumes a true risk 
difference between the treatment groups of zero and a maximum AIA incidence of 30% 
(in previous Sanofi clinical studies performed with rapid-acting insulin analogs, AIA incidence in 
the range of 15-20% were observed at 6 months). The power calculations are presented in Table 2. 
Table 2 - Power calculation based on the percentage of patients with treatment-emergent AIAs 
Percentage of patients with treatment-emergent AIAs 
10% 
20% 
30% 
Power for N=580 (290/arm) 
97% 
82% 
68% 
 
To reach this number of 580 patients randomized for the 6-month comparative efficacy and safety 
period, calculations were made using the nQuery Advisor® Software Version 7.0. 
11.2 
DISPOSITION OF PATIENTS 
The total number of patients for each of the following categories will be presented. 
• Screened: all patients who have originally met inclusion criteria and have signed the 
informed consent. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 84 
• Screen failure patients and reason for screen failure. 
• Randomized:  all screened patients with a treatment arm allocated and recorded in the IRT 
database, regardless of whether the treatment was used or not. 
• Safety population (Section 11.3.2), presented as treated. 
• Treated but not randomized patients. 
• Randomized but not treated patient. 
• The intent-to-treat (ITT) population (Section 11.3.1.1), analyzed as randomized. 
• The per protocol population (Section 11.3.1.2), analyzed as randomized. 
• The randomization strata (geographical region [Europe, US, Japan], type of diabetes 
[T1DM, T2DM], screening HbA1c categories [<8%, ≥8%], and prior use of 
NovoLog/NovoRapid [Yes, No]) assigned by IRT will be summarized. The discrepancy 
between the stratum assigned by IRT and the information reported on CRF will be listed 
for all randomized patients. 
• Disposition for the main 6-month period: 
- 
Patients who completed the main 6-month treatment period (patients who have 
performed Visit 9 [Week 26] and who did not permanently discontinue treatment 
before Visit 9 [Week 26]), 
- 
Patients who permanently discontinued the IMP during the main 6-month treatment 
period, and the reasons for permanent treatment discontinuation, 
- 
Patient’s decision for treatment discontinuation during the main 6-month period, 
- 
Patients who completed the main 6-month study period (patients who have performed 
Visit 9 [Week 26]), 
- 
Patients who prematurely discontinued the study during the main 6-month period, and 
the reasons for premature study discontinuation, 
- 
Status at last study contact of patients who prematurely discontinued the treatment 
during the main 6-month period. 
• Disposition for the 12-month period: 
- 
Patients who completed the 12-month treatment period including 6-month extension 
(patients who have performed Visit 12 [Week 52] and who did not permanently 
discontinue treatment before Visit 12 [Week 52]), 
- 
Patients who permanently discontinued the IMP during the 12-month treatment period, 
and the reasons for permanent treatment discontinuation, 
- 
Patient’s decision for treatment discontinuation during the 12-month period, 
- 
Patients who completed the main 12-month study period (patients who have performed 
Visit 12 [Week 52]), 
- 
Patients who prematurely discontinued the study during the 12-month period, and the 
reasons for premature study discontinuation, 
- 
Status at last study contact. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 85 
For all categories of patients (except for the screened and nonrandomized categories), percentages 
will be calculated using the number of randomized patients as denominator for each treatment 
group. 
Patients with the following deviations will be identified and described in separate listings: 
• Treated but not randomized. 
• Randomized but not treated. 
• Randomized but not treated as randomized. 
A list of patients prematurely discontinued from the IMP, along with reasons for discontinuation, 
will be provided. 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any population.  Their safety data will be listed separately. 
11.3 
ANALYSIS POPULATIONS 
11.3.1 Efficacy populations 
11.3.1.1 Intent–to-treat population 
The primary efficacy population will be the ITT population, which includes all randomized 
patients, irrespective of compliance with the study protocol and procedures. 
Patients will be analyzed for efficacy analyses in the treatment group to which they are 
randomized. 
11.3.1.2 Per protocol population 
The Per Protocol population is a subset of the ITT population, which includes all randomized and 
exposed patients, who do not permanently discontinue IMP allocated by randomization during the 
main 6-month period, who perform Week 26 and who do not present major or critical protocol 
deviations that could impact the analysis during the main 6-month period. The major and critical 
protocol deviations will be detailed in the SAP. 
11.3.2 Safety population 
The safety population is defined as all randomized patients who receive at least one dose of IMP, 
analyzed according to the treatment actually received. 
Patients will not be considered exposed if there is documented evidence that patients have not 
taken the IMP: 
• If a patient is dispensed IMP and is lost to follow-up without any documented evidence 
whether or not the patient took IMP, the patient will be considered exposed and included 
in the safety population. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 86 
• Randomized patients for whom it is unclear whether they took the study medication will 
be included in the safety population as randomized. 
In addition: 
• Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately. 
• For patients receiving more than one study treatment during the trial, the patient will be 
analyzed in the treatment group in which he/she was treated longer. 
11.3.3 Anti-insulin antibody population 
The AIA population is defined as all patients from the safety population with at least one 
AIA sample available for analysis (sample collected at least 8 hours after the last administration 
of mealtime insulin) during the on-treatment period, analyzed according to the treatment actually 
received. 
11.4 
STATISTICAL METHODS 
Unless specified otherwise, all analyses will be presented pooling NovoLog and NovoRapid in the 
comparator group. Specific subgroup analyses will be performed by type of comparator used 
(NovoLog in the US, NovoRapid in other countries). 
11.4.1 Extent of study treatment exposure 
The extent of study treatment exposure will be assessed and summarized by actual treatment 
received within the safety population. 
11.4.1.1 Extent of investigational medicinal product exposure 
The extent of IMP exposure will be assessed by the duration of the open-label IMP exposure.  
The duration of exposure during the study will be the total number of days of administration of 
IMP, ignoring temporary drug discontinuation.  
The duration of exposure to the open-label IMP during the study is defined as:  
(Date of the last IMP administration – date of the first IMP administration) + 1. 
Duration of IMP exposure will be summarized descriptively as a quantitative variable (number, 
mean, SD, median, minimum, and maximum). The number (n) and proportion (%) of patients 
exposed to the open-label IMP during the study will be presented by specific time periods for each 
treatment group in the safety population. 
The time periods of interest for the main 6-month on-treatment period are grouped as follows:  
• Up to 4 weeks, 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 87 
• >4 to 8 weeks, 
• >8 to 12 weeks, 
• >12 to 20 weeks, 
• >20 to 25 weeks, 
• >25 to 26 weeks, 
• >26 weeks. 
The time periods of interest for the 12-month on-treatment period are grouped as follows:  
• Up to 4 weeks, 
• >4 to 8 weeks, 
• >8 to 12 weeks, 
• >12 to 20 weeks, 
• >20 to 26 weeks, 
• >26 to 34 weeks, 
• >34 to 40 weeks, 
• >40 to 51 weeks, 
• >51 to 52 weeks, 
• >52 weeks. 
In addition, the cumulative duration of exposure is also described using the same time periods. 
11.4.1.2 Daily insulin doses 
The daily insulin doses (basal, mealtime, total) will be described at each visit, as well as the 
changes from baseline (in U and U/kg). 
11.4.2 Analyses of efficacy endpoints 
11.4.2.1 Analysis of primary efficacy endpoint(s) 
11.4.2.1.1 Primary efficacy analysis 
First step analysis: 
The statistical test for non-inferiority assessment of SAR341402 versus NovoLog/NovoRapid on 
the primary efficacy endpoint (change in HbA1c from baseline to Week 26 as defined in 
the Section 9.1) will be one-sided, with alpha level of 0.025 and using a non-inferiority margin of 
0.3% HbA1c. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 88 
The baseline value is defined as the last available value up to the date of randomization. 
The primary endpoint will be analyzed in the ITT population using all post-baseline data available 
during the main 6-month randomized period (ITT estimand). 
The analysis for change in HbA1c should account for missing data in a fashion consistent with 
what the measurement would have been, had it been measured. The behavior of missing data for 
those patients who are off-treatment is not expected to be the same as that of observed data for 
those patients who are on-treatment in the same treatment arm. It may not be appropriate to 
represent the missing data from patients who do not adhere to therapy by the data from those 
patients on the same arm who adhere to therapy.  
A multiple imputation approach will be used where missing data from patients who do not adhere 
to IMP will be represented by the data from those patients in the same treatment group who also 
do not adhere to IMP but have the measurement for the primary endpoint. Details of the proposed 
multiple imputation analysis in two parallel parts (according the status of the patients), are 
provided below: 
1. Missing data in patients who prematurely discontinued IMP during the main 6-month 
randomized period will be imputed using a model estimated solely from data observed in 
other patients who discontinued IMP during the main 6-month randomized period but have 
the measurement for the primary endpoint at Week 26. Due to the anticipated small 
number of these latter patients, a basic imputation model will be built, including only the 
randomized treatment group as predictor. Missing data will be imputed using the 
regression method. 
2. Missing data in patients who completed the main 6-month treatment period will be 
imputed separately, using a model estimated solely from data observed in other patients 
who completed the main 6-month treatment period and have the measurement for the 
primary endpoint at Week 26. Since in general, the missing pattern will not be monotone, 
a two-step approach will be used: 
• Step 1: the Markov Chain Monte Carlo (MCMC) method will be used in conjunction with 
the IMPUTE=MONOTONE option to create an imputed data set with a monotone missing 
pattern. The imputation model will include the continuous fixed covariates of the baseline 
HbA1c value as well as the changes from baseline in HbA1c at Week 12 and Week 26. 
• Step 2: using the monotone data set from step 1, missing data will be imputed using the 
regression method. The imputation model will include the fixed categorical effects of the 
treatment group, the randomization strata geographical region and type of diabetes 
(Europe T1DM, US T1DM, US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%) 
(except when analyzing the change in HbA1c) and prior use of NovoLog/NovoRapid 
(Yes, No), as well as the continuous fixed covariates of the baseline HbA1c value and the 
changes from baseline in HbA1c at Week 12 and Week 26. 
Missing values will be imputed 10 000 times. Completed datasets from the two parts detailed 
above will be combined into a single dataset. Each completed dataset will be analyzed using an 
analysis of covariance (ANCOVA) of the change in HbA1c from baseline to Week 26, including 
the fixed categorical effects of treatment group (SAR341402, NovoLog/NovoRapid), the 
randomization strata geographical region and type of diabetes (Europe T1DM, US T1DM, 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 89 
US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%) (except when analyzing the change in 
HbA1c) and prior use of NovoLog/NovoRapid (Yes, No), as well as the continuous fixed 
covariate of baseline value. Results from the 10 000 analyses will be combined using Rubin's 
formula. 
The adjusted least squares (LS) mean of the change in HbA1c from baseline to Week 26 for each 
treatment group (SAR341402, NovoLog/NovoRapid) will be estimated, as well as the 
between-group LS mean difference of SAR341402 versus NovoLog/NovoRapid, with the 
corresponding standard errors and 2-sided 95% CIs. 
Non-inferiority will be demonstrated if the upper bound of the 2-sided 95% CI of the difference 
between SAR341402 and NovoLog/NovoRapid on the ITT population is <0.3%. 
Second step analysis: 
If non-inferiority of SAR341402 over NovoLog/NovoRapid is demonstrated, using a hierarchical 
step-down testing procedure, the following additional analysis will be performed (not as primary 
objective): the inverse non-inferiority (of NovoLog/NovoRapid over SAR341402) will be tested 
looking at the lower bound of the 2-sided 95% CI of the difference between SAR341402 and 
NovoLog/NovoRapid in the ITT population. Non-inferiority of NovoLog/NovoRapid over 
SAR341402 will be demonstrated if the lower bound is >-0.3%.  
If SAR341402 is shown to be non-inferior to NovoLog/NovoRapid and NovoLog/NovoRapid 
non-inferior to SAR341402, similar efficacy (equivalence) of SAR341402 and 
NovoLog/NovoRapid will be assumed. 
11.4.2.1.2 Sensitivity analysis 
Sensitivity analyses will be conducted to describe the missing data frequency and pattern and 
assess the robustness of primary efficacy analysis with regard to missing data. 
11.4.2.1.3 Supportive analysis 
In the case the per-protocol population will represent less than 95% of the ITT population, a 
supportive analysis may be conducted on the primary efficacy analysis to evaluate the robustness 
of the conclusion when excluding the patients that may increase the chance of reaching non 
inferiority conclusion. Details will be provided in the SAP. 
11.4.2.1.4 Additional analysis 
Analyses on the primary efficacy endpoint will be presented for the subgroups comparing 
SAR341402 with NovoLog in patients randomized in the US (approximately 330 patients, 
230 with T1DM and 100 with T2DM) and comparing SAR341402 and NovoRapid in regions 
using NovoRapid (approximately 250 patients with T1DM). The analysis will be performed using 
a similar multiple imputation approach in two parts, as for the primary efficacy endpoint, followed 
by a similar ANCOVA model (as described in Section 11.4.2.1.1) adding the corresponding 
subgroup factor and subgroup factor-by-treatment interaction. The randomization strata of 
geographical region (Europe, Japan, US) and Type of diabetes (T1DM, T2DM) will not be 
included in the model.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 90 
Least square means difference of SAR341402 versus NovoLog and SAR341402 versus 
NovoRapid at Week 26 will be provided, as well as the corresponding SEs and 95% CI, within 
each subgroup. The significance level of the treatment-by-subgroup factor interaction term will 
also be provided for descriptive purpose. Forest plots will be provided. 
Additionally, the James-Stein (J-S) shrinkage estimator may be used to evaluate the treatment 
effect in each subgroup defined by type of comparator, with a different approach (15). 
This estimate is derived from the overall and subgroup treatment effect estimates in order to use 
all study information (including information collected in the other subgroup). Details will be 
provided in the statistical analysis plan. 
Explorative analyses will be performed on the primary endpoint to summarize the treatment 
effects across subgroups defined by baseline and screening factors, such as: category of age 
(<65, [65 to 75] and ≥75 years of age), baseline BMI (<30 and ≥30 kg/m²), randomization strata 
(geographical region [Europe, US, Japan], type of diabetes [T1DM, T2DM], screening HbA1c 
categories [<8%, ≥8%] and prior use of NovoLog/NovoRapid [Yes, No]) and type of comparator 
(NovoLog and NovoRapid). Subgroup analyses will be detailed in the SAP. 
11.4.2.2 Analyses of secondary efficacy endpoints 
All secondary efficacy endpoints (as defined in Section 9.2.2) will be analyzed in the 
ITT population, for descriptive purpose only (no formal statistical testing). Separate analyses will 
be performed for the main 6-month and the 12-month periods. 
All continuous secondary efficacy endpoints will be analyzed using a similar multiple imputation 
approach in two parts, as for the primary efficacy endpoint, followed by a similar ANCOVA 
model (as described in Section 11.4.2.1). 
The categorical secondary endpoint (HbA1c responders) will be analyzed using a logistic 
regression model adjusted on the randomization strata of geographical region and type of diabetes 
(Europe T1DM, US T1DM, US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%), and prior 
use of NovoLog/NovoRapid (Yes, No). Patients without assessment at Week 26 (or Week 52 for 
the analysis at Week 52) will be considered as failure. 
11.4.2.3 Multiplicity considerations 
11.4.2.3.1 Primary Endpoint 
A hierarchical step-down testing procedure is applied to test the non-inferiority of 
NovoLog/NovoRapid over SAR341402 only if the non-inferiority of SAR341402 over 
NovoLog/NovoRapid is demonstrated (primary comparison). 
11.4.2.3.2  Secondary Endpoints 
No multiplicity adjustment will be made as no formal statistical testing will be done on secondary 
endpoints. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 91 
11.4.3 Analyses of safety data 
Safety analyses will be presented by treatment group for the main 6-month and the 12-month  
on-treatment periods on safety endpoints (defined in Section 9.2.3). 
All safety analyses will be descriptive and performed on the Safety population using the following 
common rules: 
• The baseline value is defined as the last available value prior to the first injection of IMP. 
The following definitions will be applied to laboratory parameters and vital signs: 
• The Potentially Clinically Significant Abnormality (PCSA) values are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests, and vital signs. 
• PCSA criteria will determine which patients had at least one PCSA during the 
on-treatment period, taking into account all evaluations performed during the on-treatment 
period, including non-scheduled or repeated evaluations. The number of all such patients 
will be the numerator for the on-treatment PCSA percentage. 
11.4.3.1 Hypoglycemia 
Proportions of patients with at least one hypoglycemia event will be presented for any 
hypoglycemia and by type of event (see Section 9.2.3.2.1) for each treatment group on the safety 
population. 
Incidences of hypoglycemia per patient year will be computed as: 365.25 x (number of episodes 
of hypoglycemia)/(number of days exposed) and summarized for any hypoglycemia and by type 
of event for each treatment group.  
For exploratory purpose, odds-ratios and rate ratios of hypoglycemia event may be provided for 
SAR341402 versus NovoLog/NovoRapid, overall and for some categories of hypoglycemia. 
Details will be provided in the SAP. 
Exploratory analyses will be performed by subgroups defined by baseline and screening factors, 
such as: category of age (<65, [65 to 75] and ≥75 years of age), baseline BMI (<30 and 
≥30 kg/m²), randomization strata and type of comparator (NovoLog and NovoRapid). Further 
subgroup analyses may be performed if deemed necessary for interpretation of results. 
Further analyses over time or by time of the day may be performed if appropriate. 
11.4.3.2 Injection site reactions and hypersensitivity reactions 
Injection site and hypersensitivity reactions will be identified by MedDRA search (list of 
MedDRA terms will be specified in the SAP). 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 92 
Number (n) and proportion (%) of patients with related event will be summarized by treatment 
group as appropriate. Events adjudicated as possible hypersensitivity reactions by ARAC will also 
be described. 
11.4.3.3 Adverse events 
Adverse event incidence tables will present by SOC (sorted by internationally agreed order), 
HLGT, HLT and PT (sorted in alphabetical order) for each treatment group, the number (n) and 
percentage (%) of patients experiencing an AE. Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase. The denominator 
for computation of percentages is the safety population within each treatment group. 
Adverse event incidence table will be provided by treatment group for all types of TEAEs: all 
TEAEs, all treatment emergent SAEs, all TEAEs leading to permanent treatment discontinuation 
and all TEAEs leading to death.  
Death 
The following deaths summaries will be generated on the safety population: 
• Number (n) and proportion (%) of patients who died by study period (TEAE, on-study, 
post-study) and reasons for death. 
• A listing of all deaths. 
11.4.3.4 Analyses of laboratory variables 
Descriptive statistics will be used to summarize results of laboratory parameters, including the 
summary of incidence of PCSAs at any time during the main 6-month and 12-month on-treatment 
periods. 
11.4.3.5 Analyses of vital sign variables 
Descriptive statistics will be used to summarize results of vital signs, including the summary of 
incidence of PCSAs at any time during the main 6-month and 12-month on-treatment periods by 
treatment group. 
11.4.3.6 Drug-induced liver injury 
The liver function tests, namely AST, ALT, ALP and total bilirubin are used to assess possible 
drug induced liver toxicity. The proportion of patients with PCSA values will be displayed by 
treatment group for each parameter.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 93 
Listing of possible Hy’s Law cases will be identified and provided by treatment group 
(eg, subjects with any elevated ALT >3 x ULN, and associated with an increase in bilirubin 
>2 x ULN) with: ALT, AST, ALP, total bilirubin  and the following complementary parameters 
(if available): conjugated bilirubin and prothrombin time / International normalized ratio (INR), 
creatine phosphokinase (CPK), serum creatinine, complete blood count.  
The incidence of liver related TEAEs will be summarized by treatment group. The selection of 
PTs will be based on standardized MedDRA query (SMQ) Hepatic disorder. 
11.4.4 Analysis of immunogenicity data 
The analyses of immunogenicity data will be descriptive (no formal statistical testing) and based 
on the AIA population. Analyses will be presented separately for the main 6-month and the  
12-month on-treatment periods. 
Number and percentage of patients with anti-SAR341402/NovoLog/NovoRapid antibody positive 
and antibody negative samples will be summarized by treatment group and visit and at the last  
on-treatment value. 
On the group of patients with anti-SAR341402/NovoLog/NovoRapid antibody positive sample at 
a given visit, anti-SAR341402/NovoLog/NovoRapid antibody titers will be summarized using 
quantitative descriptive statistics, and the number and percentage of patients with cross-reactivity 
to human insulin will be provided.  
The number and percentage of patients will be provided by treatment group for each of the 
following categories: 
• Patients with treatment-induced AIAs. 
• Patients with treatment-boosted AIAs. 
• Patients with treatment-emergent AIA (AIA incidence). 
• Patients without treatment-emergent AIA.  
• Patients with pre-existing AIAs or treatment-induced AIAs (AIA prevalence). 
For exploratory purposes, the difference between SAR341402 and NovoLog/NovoRapid in the 
percentage of patients with treatment-emergent AIAs (AIA incidence) will be provided with 
associated 2-sided 90% CI. Results will be obtained by fitting a binomial regression model with 
an identity-link function. The model will include fixed categorical effects for treatment, the 
randomization strata of geographical region and type of diabetes (Europe T1DM, US T1DM, 
US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%), and prior use of NovoLog/NovoRapid 
(Yes, No). The risks within each treatment group and risk difference will be provided with their 
90% CIs using the adjusted LS mean estimates of the treatment effect. 
For patients with treatment-induced and treatment-boosted AIAs, the kinetics of AIA response 
(transient, persistent, or indeterminate AIA response as defined in Section 9.2.1.3) will be further 
summarized using number and percentage of patients, and the peak titer will be described using 
median, Q1 and Q3. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 94 
Exploratory analyses will be performed by subgroups defined by baseline and screening factors, 
such as: category of age (<65, [65 to 75] and ≥75 years of age), baseline BMI (<30 and 
≥30 kg/m²), randomization strata (geographical region [Europe, US, Japan], type of diabetes 
[T1DM, T2DM], screening HbA1c categories [<8%, ≥8%] and prior use of NovoLog/NovoRapid 
[Yes, No]) and type of comparator (NovoLog and NovoRapid). Further subgroup analyses may be 
performed if deemed necessary for interpretation of results. Details will be provided in the SAP. 
Subgroup analyses and/or scatterplots will be conducted to assess the relationship between 
immunogenicity endpoints and efficacy/safety assessments. Listings will be provided for patients 
with high AIA titers (AIA outliers). Change in HbA1c from baseline to Week 26 and Week 52, 
hypoglycemia, injection site reactions, hypersensitivity reactions, TEAE and SAEs will be  
summarized by treatment-emergent AIA (Yes, No) and treatment-emergent AIA at last 
on-treatment value (Yes, No). The relationship between the AIA titer and the efficacy and safety 
will be explored using scatter plot of maximal titer during the main 6-month and the 12-month 
on-treatment periods versus change in HbA1c from baseline to Week 26 and Week 52, total 
insulin dose, hypoglycemia, injection site reactions and hypersensitivity reactions. 
Further analyses may be performed if appropriate. 
11.4.5 Analyses of pharmacokinetic and pharmacodynamic variables 
Not applicable. 
11.5 
INTERIM ANALYSIS 
No interim analysis is planned.  
This controlled open-label study will not to be early terminated with a positive claim for efficacy 
or safety. The primary analysis of the efficacy and safety will be performed on the data collected 
during the main 6-month comparative efficacy and safety period. The timing of this analysis is 
when the last randomized patient has completed the Week 26 (Visit 9) visit. The results of the 
primary analysis will not be used to change the conduct of the ongoing study in any aspect. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 95 
12 
ETHICAL AND REGULATORY CONSIDERATIONS 
12.1 
ETHICAL AND REGULATORY STANDARDS 
This clinical trial will be conducted by the Sponsor, the Investigator, and delegated Investigator 
staff and SubInvestigator, in accordance with consensus ethics principles derived from 
international ethics guidelines, including the Declaration of Helsinki, and the International 
Council for Harmonisation (ICH) guidelines for good clinical practice (GCP), all applicable laws, 
rules and regulations. 
This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later 
than 21 days after the first patient enrollment, in compliance with applicable regulatory 
requirements and with Sanofi public disclosure commitments.  
12.2 
INFORMED CONSENT 
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the patient of all 
pertinent aspects of the clinical trial including the written information giving approval/favorable 
opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest 
extent possible about the study, in language and terms they are able to understand. 
Prior to a patient’s participation in the clinical trial, the written informed consent form should be 
signed, name filled in and personally dated by the patient or by the patient’s legally acceptable 
representative, and by the person who conducted the informed consent discussion. A copy of the 
signed and dated written informed consent form will be provided to the patient.  
The informed consent form used by the Investigator for obtaining the patient's informed consent 
must be reviewed and approved by the Sponsor prior to submission to the appropriate Ethics 
Committee (IRB/IEC) for approval/favorable opinion. 
If the race/ethnic origin of the patients will be collected in the clinical trial, the scientific 
justification should be specified. 
12.3 
HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT 
ETHICS COMMITTEE (IRB/IEC)  
As required by local regulation, the Investigator or the Sponsor must submit this Clinical Trial 
Protocol to the health authorities (competent regulatory authority) and the appropriate 
Ethics Committee (IRB/IEC), and is required to forward to the respective other party  a copy of 
the written and dated approval/favorable opinion signed by the Chairman with Ethics Committee 
(IRB/IEC) composition. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 96 
The clinical trial (study number, Clinical Trial Protocol title and version number), the documents 
reviewed (Clinical Trial Protocol, informed consent form, Investigator’s Brochure with any 
addenda, Investigator’s curriculum vitae [CV], etc) and the date of the review should be clearly 
stated on the written (IRB/IEC) approval/favorable opinion. 
The IMP will not be released at the study site and the Investigator will not start the study before 
the written and dated approval/favorable opinion is received by the Investigator and the Sponsor. 
During the clinical trial, any amendment or modification to the Clinical Trial Protocol should be 
submitted to the health authorities (competent regulatory authority), as required by local 
regulation, in addition to the Ethics Committee (IRB/IEC) before implementation, unless the 
change is necessary to eliminate an immediate hazard to the patients, in which case the health 
authorities (competent regulatory authority) and the IRB/IEC should be informed as soon as 
possible. It should also be informed of any event likely to affect the safety of patients or the 
continued conduct of the clinical trial, in particular any change in safety. All updates to the 
Investigator’s Brochure will be sent to the Ethics Committee (IRB/IEC) and to health authorities 
(competent regulatory authority), as required by local regulation. 
A progress report is sent to the Ethics Committee (IRB/IEC) at least annually and a summary of 
the clinical trial’s outcome at the end of the clinical trial. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 97 
13 
STUDY MONITORING 
13.1 
RESPONSIBILITIES OF THE INVESTIGATOR(S) 
The Investigator is required to ensure compliance with all procedures required by the Clinical 
Trial Protocol and with all study procedures provided by the Sponsor (including security rules). 
The Investigator agrees to provide reliable data and all information requested by the Clinical Trial 
Protocol (with the help of the CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives. 
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred. 
The Investigator may appoint such other individuals as he/she may deem appropriate as 
SubInvestigators to assist in the conduct of the clinical trial in accordance with the Clinical Trial 
Protocol. All SubInvestigators shall be appointed and listed in a timely manner. 
The SubInvestigators will be supervised by and work under the responsibility of the Investigator. 
The Investigator will provide them with a copy of the Clinical Trial Protocol and all necessary 
information. 
13.2 
RESPONSIBILITIES OF THE SPONSOR 
The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable 
steps to ensure the proper conduct of the clinical trial as regards ethics, Clinical Trial Protocol 
compliance, and integrity and validity of the data recorded on the CRFs. Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, 
scientific, technical and regulatory quality in all aspects of the clinical trial. 
At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the monitoring team to review study progress, 
Investigator and patient compliance with Clinical Trial Protocol requirements and any emergent 
problems. These monitoring visits will include but not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient 
compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of 
data. 
13.3 
SOURCE DOCUMENT REQUIREMENTS 
According to the ICH GCP, the monitoring team must check the CRF entries against the source 
documents, except for the pre-identified source data directly recorded in the CRF. The informed 
consent form will include a statement by which the patient allows the Sponsor’s duly authorized 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 98 
personnel, the ethics committee (IRB/IEC), and the regulatory authorities to have direct access to 
original medical records which support the data on the CRFs (eg, patient's medical file, 
appointment books, original laboratory records, etc). These personnel, bound by professional 
secrecy, must maintain the confidentiality of all personal identity or personal medical information 
(according to confidentiality and personal data protection rules). 
13.4 
USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST 
It is the responsibility of the Investigator to maintain adequate and accurate e-CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All e-CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data. 
Should a correction be made, the corrected information will be entered in the e-CRF overwriting 
the initial information. An audit trail allows identifying the modification.  
Data are available within the system to the Sponsor as soon as they are entered in the e-CRF. 
The computerized handling of the data by the Sponsor may generate additional requests (DRF) to 
which the Investigator is obliged to respond by confirming or modifying the data questioned. The 
requests with their responses will be managed through the e-CRF. 
In this trial, SMPG data from the glucometer and insulin dose and hypoglycemic events entered 
into the e-diary will be available on a vendor web based portal for review. Data for endpoint 
analysis will be captured in the clinical database. At the end of trial, data in the web based portal 
will be stored and then will later be destroyed according to local regulation. 
13.5 
USE OF COMPUTERIZED SYSTEMS 
The complete list of computerized systems used for the study is provided in a separate document 
which is maintained in the Sponsor and Investigator study files. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 99 
14 
ADDITIONAL REQUIREMENTS 
14.1 
CURRICULUM VITAE 
A current copy of the CV describing the experience, qualification and training of each Investigator 
and SubInvestigator will be signed, dated and provided to the Sponsor prior to the beginning of 
the clinical trial. 
14.2 
RECORD RETENTION IN STUDY SITES 
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents. 
The Investigator should retain the study documents at least 15 years after the completion or 
discontinuation of the clinical trial. 
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required. 
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the clinical trial completion or discontinuation. 
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee.  
14.3 
CONFIDENTIALITY 
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the clinical trial, including, but not limited to, the Clinical Trial 
Protocol, personal data in relation to the patients, the CRFs, the Investigator's Brochure and the 
results obtained during the course of the clinical trial, is confidential, prior to the publication of 
results. The Investigator and any person under his/her authority agree to undertake to keep 
confidential and not to disclose the information to any third party without the prior written 
approval of the Sponsor. 
However, the submission of this Clinical Trial Protocol and other necessary documentation to the 
ethics committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality. 
The SubInvestigators shall be bound by the same obligation as the Investigator. The Investigator 
shall inform the SubInvestigators of the confidential nature of the clinical trial. 
The Investigator and the SubInvestigators shall use the information solely for the purposes of the 
clinical trial, to the exclusion of any use for their own or for a third party's account. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 100 
14.4 
PROPERTY RIGHTS 
All information, documents and IMP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor. 
The Investigator shall not and shall cause the delegated Investigator staff /SubInvestigator not to 
mention any information or the Product in any application for a patent or for any other intellectual 
property rights. 
All the results, data, documents and inventions, which arise directly or indirectly from the clinical 
trial in any form, shall be the immediate and exclusive property of the Sponsor. 
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the clinical trial. 
As the case may be, the Investigator and/or the SubInvestigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents. 
14.5 
DATA PROTECTION 
• The patient's personal data, which are included in the Sponsor database shall be treated in 
compliance with all applicable laws and regulations. 
• When archiving or processing personal data pertaining to the Investigator and/or to the 
patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
• The Sponsor also collects specific data regarding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor’s databases, 
shall be treated by both the Sponsor and the Investigator in compliance with all applicable 
laws and regulations. 
Subject race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, Not Reported, Unknown) or ethnicity (Hispanic or 
Latino, Not Hispanic or Latino, Not Reported, Unknown) will be collected in this study because 
these data are required by several health authorities (eg, on African American population for 
FDA, on Asian population for the PMDA in Japan or S-FDA in China).  
The data collected in this study will only be used for the purpose(s) of the study and to document 
the evaluation of the benefit/ risk ratio, efficacy and safety of the product(s). They may be further 
processed if they have been anonymized. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 101 
14.6 
INSURANCE COMPENSATION 
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship. This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from any 
obligation to maintain their own liability insurance policy. An insurance certificate will be 
provided to the IECs/IRBs or regulatory authorities in countries requiring this document.  
14.7 
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES 
For the purpose of ensuring compliance with the Clinical Trial Protocol, GCP, and applicable 
regulatory requirements, the Investigator should permit auditing by or on the behalf of the 
Sponsor and inspection by regulatory authorities. 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information. 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents. 
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections. 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor. 
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections. 
14.8 
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE 
14.8.1 By the Sponsor  
The Sponsor has the right to terminate the participation of either an individual site or the study at 
any time, for any reason, including but not limited to the following:  
• The information on the product leads to doubt as to the benefit/risk ratio. 
• Patient enrollment is unsatisfactory. 
• The Investigator has received from the Sponsor all IMP, means, and information necessary 
to perform the clinical trial and has not included any patient after a reasonable period of 
time mutually agreed upon. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 102 
• Noncompliance of the Investigator or SubInvestigator, delegated staff with any provision 
of the Clinical Trial Protocol, and breach of the applicable laws and regulations or breach 
of the ICH GCP. 
• The total number of patients are included earlier than expected. 
In any case the Sponsor will notify the Investigator of its decision by written notice. 
14.8.2 By the Investigator 
The Investigator may terminate his/her participation upon thirty (30) days' prior written notice if 
the study site or the Investigator for any reason becomes unable to perform or complete the 
clinical trial.  
In the event of premature discontinuation of the study or premature close-out of a site, for any 
reason whatsoever, the appropriate IRB/IEC and regulatory authorities should be informed 
according to applicable regulatory requirements. 
14.9 
CLINICAL TRIAL RESULTS 
The Sponsor will be responsible for preparing a CSR and to provide a summary of study results to 
the Investigator. 
14.10 PUBLICATIONS AND COMMUNICATIONS 
The Investigator undertakes not to make any publication or release pertaining to the study and/or 
results of the study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
As the study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, a primary presentation or publication of the study results based on global 
study outcomes shall be sought. However, if no multicenter publication is submitted, underway, 
or planned within twelve (12) months of the completion of this study at all sites, the Investigator 
shall have the right to publish or present independently the results of this study in agreement with 
other Investigators and stakeholders. The Investigator shall provide the Sponsor with a copy of 
any such presentation or publication for review and comment at least 30 days in advance of any 
presentation or submission for publication. In addition, if requested by the Sponsor, any 
presentation or submission for publication shall be delayed for a limited time, not to exceed 
90 days, to allow for filing of a patent application or such other justified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary rights.  
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s). 
The Sponsor has the right at any time to publish the results of the study. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 103 
15 
CLINICAL TRIAL PROTOCOL AMENDMENTS 
All appendices attached hereto and referred to herein are made part of this Clinical Trial Protocol. 
The Investigator should not implement any deviation from, or changes to the Clinical Trial 
Protocol without agreement by the Sponsor and prior review and documented approval/favorable 
opinion from the IRB/IEC and/or notification/approval of health authorities (competent regulatory 
authority) of an amendment, as required by local regulation, except where necessary to eliminate 
an immediate hazard(s) to clinical trial patients, or when the change(s) involves only logistical or 
administrative aspects of the trial. Any change agreed upon will be recorded in writing, the 
written amendment will be signed by the Investigator and by the Sponsor and the signed 
amendment will be filed with this Clinical Trial Protocol. 
Any amendment to the Clinical Trial Protocol requires written approval/favorable opinion by the 
IRB/IEC prior to its implementation, unless there are overriding safety reasons. 
In case of substantial amendment to the Clinical Trial Protocol, approval from the health 
authorities (competent regulatory authority) will be sought before implementation. 
In some instances, an amendment may require a change to the informed consent form. 
The Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised 
informed consent form prior to implementation of the change and patient signature should be 
re-collected if necessary. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 104 
16 
BIBLIOGRAPHIC REFERENCES 
1. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 
2017 Jan;40(Suppl 1):S1-S135. 
2. Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. American 
Association of Pharmaceutical Scientists. Assessment and reporting of the clinical 
immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical 
recommendations. AAPS J. 2014 Jul;16(4):658-73. 
3. American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting 
Hypoglycemia in Diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. 
4. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and 
Diabetes: A Report of a Workgroup of the  American Diabetes Association and the Endocrine 
Society. Diabetes Care. 2013;36(5):1384-95. 
5. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L 
(54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 
2017 Jan;40(1):155-157. 
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long-term complications in 
insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. 
7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Diabetes 
Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease 
in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53. 
8. Wolfsdorf, JI. Intensive diabetes management (4th ed). Alexandria, VA. American Diabetes 
Association. 2009:83-107. 
9. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In 
Standards of Medical Care in Diabetes, 2017. Diabetes Care 2017; 40(Suppl. 1):S64–S74. 
10. EMA. Guideline on clinical investigation of medicinal products in the treatment of diabetes 
mellitus. CPMP/EWP/1080/00 Rev.1. Committee for Medicinal Products for Human Use 
(CHMP). 2012:1-28. 
11. US Department of Health and Human Services, FDA, CDER. Guidance for Industry. Diabetes 
Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 
Contains Nonbinding Recommendations; Draft-Not for Implementation. FDA. February 
2008:1-34. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 105 
12. EMA. Guideline on Immunogenicity assessment of biotechnology-derived therapeutic 
proteins - Draft. EMEA/CHMP/BMWP/14327/2006 Rev. 1. Committee for Medicinal 
Products for Human Use (CHMP). 24 September 2015: 1-23. 
13. US Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research 
(CBER). Guidance for Industry. Scientific Considerations in Demonstrating Biosimilarity to a 
Reference Product. April 2015:1-24. 
14. Fleming TR. Addressing missing data in clinical trials. Ann Intern Med. 2011 Jan 
18;154(2):113-7. 
15. Quan H, Mao XZ, Chen J, Chung W, Shih J, Ouyang SP, et al. Multi-regional clinical trial 
design and consistency assessment of treatment effects. Statistics in Medicine. 2014; 33: 
2191-2205. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 106 
17 
APPENDICES 
Appendix A 
Guidance on contraceptive methods and collection of pregnancy 
information 
DEFINITIONS 
Nonreproductive potential 
1. Premenopausal female with 1 of the following: 
- 
Documented hysterectomy, 
- 
Documented bilateral salpingectomy, 
- 
Documented bilateral oophorectomy. 
3. Postmenopausal 
- 
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient, 
- 
Females on hormone replacement therapy (HRT) and whose menopausal status is in 
doubt will be required to use 1 of the highly effective contraception methods if they 
wish to continue their HRT during the study. Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrolment. 
Reproductive potential (WOCBP) 
A woman is considered of reproductive potential (WOCBP), ie, fertile, following menarche and 
until becoming postmenopausal unless permanently sterile. Permanent sterilization methods 
include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. 
CONTRACEPTIVE GUIDANCE 
Male subjects 
• Male subjects with heterosexual partners of reproductive potential (WOCBP) are eligible 
to participate if they agree to use the following during the protocol defined timeline: 
- 
Refrain from donating sperm,  
and 
- 
At least 1 of the following conditions applies: 
- 
Are and agree to remain abstinent from penile-vaginal intercourse on a long term 
and persistent basis, when this is their preferred and usual lifestyle. 
or 
- 
Agree to use a male condom plus an additional contraceptive method with a failure 
rate of < 1% per year (see table for female subjects). 
• Men with a pregnant or breastfeeding partner must agree to remain abstinent from  
penile-vaginal intercourse or use a male condom for the time defined in the protocol. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 107 
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctlya 
• Combined (estrogen- and progestogen-containing ) hormonal contraception associated with 
inhibition of ovulationb 
− Oral, 
− Intravaginal, 
− Transdermal. 
• Progestogen-only hormone contraception associated with inhibition of ovulationb 
− Oral, 
− Injectable. 
Highly Effective Methods That Are User Independent 
• Implantable progestogen-only hormone contraception associated with inhibition of ovulationb. 
• Intrauterine device (IUD). 
• Intrauterine hormone-releasing system (IUS). 
• Bilateral tubal occlusion. 
• Vasectomized partner. 
(Vasectomized partner is a highly effective contraceptive method provided that the partner is 
the sole sexual partner of the woman of childbearing potential and the absence of sperm has 
been confirmed. If not, an additional highly effective method(s) of contraception should be 
used. Spermatogenesis cycle is approximately 90 days.) 
• Sexual abstinence. 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the subject.) 
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations 
regarding the use of contraceptive methods for subjects participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraceptive 
method. In this case TWO highly effective methods of contraception should be used during the treatment period and for at least 
3 months after the last injection of study medication, covering more than 5 times the terminal half-life of the IMP after the last dose of 
study treatment. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 108 
Female subjects: 
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctlya 
• Combined (estrogen- and progestogen-containing ) hormonal contraception associated with 
inhibition of ovulationb 
− Oral, 
− Intravaginal, 
− Transdermal. 
• Progestogen-only hormone contraception associated with inhibition of ovulationb: 
− Oral, 
− Injectable. 
Highly Effective Methods That Are User Independent 
• Implantable progestogen-only hormone contraception associated with inhibition of ovulationb. 
• Intrauterine device (IUD). 
• Intrauterine hormone-releasing system (IUS). 
• Bilateral tubal occlusion. 
• Vasectomized partner. 
(Vasectomized partner is a highly effective contraceptive method provided that the partner is 
the sole sexual partner of the woman of childbearing potential and the absence of sperm has 
been confirmed. If not, an additional highly effective method(s) of contraception should be 
used. Spermatogenesis cycle is approximately 90 days.) 
• Sexual abstinence. 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the subject.) 
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations 
regarding the use of contraceptive methods for subjects participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraceptive 
method. In this case TWO highly effective methods of contraception should be used during the treatment period and for at least 
3 months after the last injection of study medication, covering more than 5 times the terminal half-life of the IMP after the last dose of 
study treatment. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 109 
COLLECTION OF PREGNANCY INFORMATION 
Male subjects with partners of reproductive potential who become pregnant 
• The Investigator will attempt to collect pregnancy information on any female partner of a 
male study subject who becomes pregnant while participating in this study. This applies 
only to subjects who receive study treatment. 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy.  
• Partner will also be followed to determine the outcome of the pregnancy. Information on 
the status of the mother and child will be forwarded to the Sponsor.  
• Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery 
date. Any termination of the pregnancy will be reported regardless of fetal status (presence 
or absence of anomalies) or indication for procedure.  
Female subjects who become pregnant  
• The Investigator will collect pregnancy information on any female subject, who becomes 
pregnant while participating in this study.  
• Information will be recorded on the appropriate form and submitted to the Sponsor within 
24 hours of learning of a participant's pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow-up information on participant and neonate, which will be forwarded to 
the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond 
the estimated delivery date.  
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.  
• Any pregnancy complication or elective termination of a pregnancy will be reported as an 
AE or SAE.  
• A spontaneous abortion is always considered to be an SAE and will be reported as such. 
• Any SAE occurring as a result of a post-study pregnancy which is considered reasonably 
related to the study treatment by the Investigator, will be reported to the Sponsor as 
described in Section 10.4.4. While the Investigator is not obligated to actively seek this 
information in former study subjects, he or she may learn of an SAE through spontaneous 
reporting.  
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 110 
Appendix B 
General guidance for the follow-up of laboratory abnormalities by 
Sanofi  
Neutrophils < 1500/mm3 or according to ethnic 
group
NEUTROPENIA
Repeat immediately a full blood count if value 
close to 1500/mm3
Neutrophils < 1500/mm3 confirmed 
with signs of infection  
Neutrophils < 1500/mm3 confirmed 
with no signs of infection  
1.
DISCONTINUE
Investigational Medicinal 
Product, hospitalization 
should be considered
2.
PERFORM biological 
investigations for infection
1.
DISCONTINUE
Investigational 
Medicinal Product
2.
INVESTIGATE for 
infection
In both situations
3.
INFORM the local monitor
4.
INVESTIGATE previous treatments particularly long-term, even a long time ago, 
exposure to toxic agents, e.g., benzene, X-rays, etc.
5.
PERFORM and collect the following investigations (results): 
•
RBC and platelet counts
•
Serology: EBV, (HIV), mumps, measles, rubella
6.
DECISION for bone marrow aspiration: to be taken in specialized unit
7.
COLLECT/STORE one sample following handling procedures described in PK 
sections (for studies with PK sampling) and freeze one serum sample (5 mL) on 
Day 1 (cessation of investigational medicinal product) and Day 5 (for further 
investigations)
8.
MONITOR the leukocyte count 3 times per week for at least one  week, then twice a 
month until it returns to normal
Note: 
•The procedures described in the above flowchart are to be discussed with the patient only in case 
the event occurs. If applicable (according to local regulations), an additional consent (e.g., for 
HIV testing) will only be obtained in the case the event actually occurs.
•For individuals of African descent, the relevant value of concern is <1000/mm3
 
Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Section 10.4.3 is met. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 111 
Platelets < 100 000/mm3 (rule out EDTA – induced 
pseudo-thrombocytopenia)
THROMBOCYTOPENIA
Repeat immediately the count (rule out EDTA 
anticoagulant in the sample)
Platelets  < 100 000/mm3 confirmed 
with bleeding  
Platelets  < 100 000/mm3 confirmed 
with no bleeding
1.
DISCONTINUE
Investigational Medicinal 
Product
2.
HOSPITALIZATION
should be considered
1.
DISCONTINUE
Investigational Medicinal 
Product
2.
INVESTIGATE for 
bleeding
In both situations
3.
INFORM the local Monitor
4.
QUESTION about last intake of quinine (drinks), alcoholism, heparin administration
5.
PERFORM or collect the following investigations: 
•
Complete blood count, schizocytes, creatinine
•
Bleeding time and coagulation test (fibrinogen, INR or PT, aPTT), Fibrin 
Degradation Product
•
Viral serology: EBV, HIV, mumps, measles, rubella
6.
COLLECT/STORE one sample following handling procedures described in PK 
sections (for studies with PK sampling) and freeze one serum sample (5 mL) on 
Day 1 (cessation of investigational medicinal product) and Day 5 (for further 
investigations)
7.
DECISION for bone marrow aspiration: to be taken in specialized unit
•
On Day 1 in the case of associated anemia and/or leukopenia
•
On Day 8 if platelets remain < 50 000/mm3
8.
MONITOR the platelet count every day for at least one week and then regularly 
until it returns to normal
Note: 
The procedures above flowchart are to be discussed with the patient only in case described in the 
the event occurs. If applicable (according to local regulations), an additional consent (e.g., for 
HIV testing) will only be obtained in the case the event actually occurs.
 
Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Section 10.4.3 is met. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 112 
INCREASE IN ALT
ALT > 3 ULN
Confirm ALT > 3 ULN
Retest within 72 hours of initial 
sample*
No
Yes
COMPLETE the specific CRF forms for 
„ALT Increase” and inform the 
Monitoring Team within 24 hours
Total Bilirubin > 2 ULN 
No
Yes
ALT > 5 ULN (if baseline ALT ≤ 2 ULN), or 
ALT >8 ULN (if baseline ALT > 2 ULN)
Continue IMP administration
No
Monitor LFTs every 72 hours
IMP administration can be continued as 
long as – under close monitoring –
conditions for permanent 
discontinuation or temporary 
interruption per protocol are not met
Yes
Permanent Discontinuation of IMP
In ANY CASE, FOLLOW the instructions listed in the box below: 
1.
INFORM the Site Monitor who will forward the information to the Study Manager
2.
INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or hypotension and/or episode of 
arrhythmia in the previous 72 hours; rule out muscular injury
3.
PERFORM the following tests:
- LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR
- CPK, serum creatinine, complete blood count
- Anti-HAV IgM, anti-HBc IgM (HBV-DNA if clinically indicated), anti-HCV and HCV RNA, anti-
CMV  IgM and anti-HEV IgM antibodies
- Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma
- Hepatobiliary ultrasonography (or other imaging investigations if needed)
4.
CONSIDER Auto-antibodies: antinuclear, anti-DNA, anti-smooth muscle, anti-LKM
5.
CONSIDER consulting with hepatologist
6.
CONSIDER patient hospitalisation if INR>2 (or PT<50%) and/or central nervous system disburbances suggesting hepatic 
encephalopathy
7.
MONITOR LFTs after discontinuation of IMP:
- As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to normal/baseline or clinical 
resolution.
8.
FREEZE serum sample (5ml x 2)
9.
In case of SUSPICION of GILBERT Syndrome, a DNA diagnostic test should be done
 
*If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.  
Note: 
• “Baseline” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the 
baseline visit. The algorithm does not apply to the instances of increase in ALT during screening. 
• See in Section 10.4 for guidance on safety reporting. 
• Normalization is defined as ≤ULN or baseline value, if baseline value is >ULN. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 113 
Rapid increase in serum creatinine over 150 µmol/L 
or rapid decrease in creatinine clearance below
50 mL/mn
ACUTE RENAL FAILURE
Can be rapidly reversed:
• By volume repletion
• Or relief of urinary tract 
obstruction (according to etiology)
Cannot be rapidly reversed: 
• Occurrence/aggravation of life 
threatening symptoms of ARF: anemia, 
hyperkalemia, hyperuricemia, metabolic 
acidosis, cardiac insufficiency, 
pulmonary edema, arrhythmia, DIC, etc.
• And/or predominant elimination of 
Investigational Medicinal Product by 
renal route
1.
Investigational Medicinal 
Product may be continued
2.
MONITOR serum creatinine 
until return to baseline level
1.
INFORM the local monitor
2.
DISCONTINUE
Investigational Medicinal Product 
administration
3.
HOSPITALIZATION should be 
considered and seek for nephrologic  
advice
4.
PERFORM the following 
examinations: 
•
BP, HR, hydration status, ECG
•
Blood count
•
Liver function tests + CPK
•
Biochemistry, including urea
•
Urinalysis
5.
COLLECT/STORE one sample 
following handling procedures 
described in PK sections (for studies 
with PK sampling) and freeze one 
serum sample (5 mL) on Day 1 
(cessation of investigational 
medicinal product)
6.
MONITOR renal function until 
return to baseline level (every day at 
the beginning, then every week)
 
Acute renal failure is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Section 10.4.3 is met. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 114 
If Increase in CPK (expressed in ULN)
> 3 ULN
Repeat immediately the count.
If confirmed, inform the local monitor and
INVESTIGATE for the origin:
- PERFORM:
•
ECG
•
CPK-MB -MM 
•
Troponin
•
Creatinine
•
Iono (k+, Ca2+)
•
Transaminases + Total and conjugated bilirubin
•
Myoglobin (serum and urines)
- COLLECT/STORE one sample following handling procedures described in PK sections (for 
studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of 
investigational medicinal product). 
- INTERVIEW the patient about a recent intensive muscular effort, trauma, convulsions, electrical 
injury, injury or stress to the skeletal muscle, multiple intramuscular injections, recent surgery, 
concomitant medications, consumption of alcohol, morphine, cocaine.
- SEARCH for alternative causes to cardiac or muscular toxicity, ie: stroke, pulmonary infarction, 
dermatomyositis or polymyositis, convulsions, hypothyroidism, delirium tremens, muscular 
dystrophies.
If either the cardiac origin or the 
rhabdomyolysis is confirmed or if CPK 
> 10 ULN:
1. DISCONTINUE Investigational 
Medicinal Product administration
2. MONITOR CPK every 3 days for the 
first week then once weekly until return 
to normal or for at least 3 months
3. HOSPITALIZATION should be 
considered
If the cardiac origin or the rhabdomyolysis is 
ruled out and if CPK ≤10 ULN:
MONITOR CPK every 3 days for the first week 
then once weekly until return to normal or for 
at least 3 months
Muscular symptoms (myalgia, pain, weakness, 
dark urines)
Systematic CPK assessment as per 
protocol
Perform CPK
SUSPICION OF RHABDOMYOLYSIS
 
Suspicion of rhabdomyolysis is to be recorded as an AE only if at least 1 of the criteria in the 
general guidelines for reporting AEs in Section 10.4.3 is met. 
(electronic 
 
 
 
3.0)


Amended Clinical Trial Protocol No. 02  
13-Dec-2017 
EFC15081 - insulin aspart 
Version number: 1 
Property of the Sanofi Group - strictly confidential 
Page 115 
Appendix C 
Country specific requirements 
Not applicable. 
(electronic 
 
 
 
3.0)


 
 
 
 
 
 
 
 
 
ELECTRONIC SIGNATURES 
 
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFC15081 Amended Protocol 02
Clinical Approval
19-Dec-2017 11:01 GMT+0100
Clinical Approval
19-Dec-2017 14:05 GMT+0100

SAP_001.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: QSD-002643 VERSION 6.0 (06-JUL-2016) 
Page 1 
STATISTICAL ANALYSIS PLAN 
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to 
NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin 
Glargine, with a 6-month Safety Extension Period 
SAR314102-EFC15081 
STATISTICIAN: 
Statistical Project Leader: 
DATE OF ISSUE: 28-Feb-2018 
Total number of pages: 
73 
(electronic 1.0)
NCT03211858


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 2 
TABLE OF CONTENTS 
STATISTICAL ANALYSIS PLAN ...................................................................................................................1 
TABLE OF CONTENTS..................................................................................................................................2 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS..........................................................................5 
1 
OVERVIEW AND INVESTIGATIONAL PLAN ................................................................................7 
1.1 
STUDY DESIGN AND RANDOMIZATION ......................................................................................7 
1.2 
OBJECTIVES...................................................................................................................................8 
1.2.1 
Primary objectives............................................................................................................................8 
1.2.2 
Secondary objectives.......................................................................................................................8 
1.3 
DETERMINATION OF SAMPLE SIZE.............................................................................................8 
1.4 
STUDY PLAN.................................................................................................................................10 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL................................11 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN .....................11 
2 
STATISTICAL AND ANALYTICAL PROCEDURES ....................................................................12 
2.1 
ANALYSIS ENDPOINTS ...............................................................................................................12 
2.1.1 
Demographic and baseline characteristics ....................................................................................12 
2.1.2 
Prior or concomitant medications...................................................................................................15 
2.1.3 
Efficacy endpoints..........................................................................................................................15 
2.1.3.1 
Primary efficacy endpoint(s) ..........................................................................................................16 
2.1.3.2 
Secondary efficacy endpoint(s)......................................................................................................16 
2.1.4 
Safety endpoints ............................................................................................................................16 
2.1.4.1 
Hypoglycemia.................................................................................................................................17 
2.1.4.2 
Adverse events variables...............................................................................................................18 
2.1.4.3 
Deaths............................................................................................................................................19 
2.1.4.4 
Laboratory safety variables............................................................................................................19 
2.1.4.5 
Vital signs variables .......................................................................................................................20 
2.1.4.6 
Electrocardiogram variables ..........................................................................................................20 
2.1.4.7 
Immunogenicity variables ..............................................................................................................20 
2.1.5 
Pharmacokinetic variables .............................................................................................................22 
2.1.6 
Pharmacodynamic/genomics endpoints ........................................................................................22 
2.1.7 
Quality-of-life endpoints .................................................................................................................22 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 3 
2.1.8 
Health economic endpoints............................................................................................................22 
2.2 
DISPOSITION OF PATIENTS .......................................................................................................22 
2.2.1 
Randomization and drug dispensing irregularities.........................................................................25 
2.3 
ANALYSIS POPULATIONS...........................................................................................................25 
2.3.1 
Efficacy populations .......................................................................................................................26 
2.3.1.1 
Intent–to-treat population ...............................................................................................................26 
2.3.1.2 
Per-protocol population..................................................................................................................26 
2.3.2 
Safety population ...........................................................................................................................27 
2.3.3 
Anti-insulin antibody population .....................................................................................................27 
2.4 
STATISTICAL METHODS .............................................................................................................27 
2.4.1 
Demographics and baseline characteristics ..................................................................................28 
2.4.2 
Prior or concomitant medications...................................................................................................28 
2.4.3 
Extent of investigational medicinal product exposure and compliance .........................................29 
2.4.3.1 
Extent of investigational medicinal product exposure....................................................................29 
2.4.3.2 
Compliance ....................................................................................................................................32 
2.4.4 
Analyses of efficacy endpoints.......................................................................................................32 
2.4.4.1 
Analysis of primary efficacy endpoint(s) ........................................................................................32 
2.4.4.2 
Analyses of secondary efficacy endpoints.....................................................................................38 
2.4.4.3 
Multiplicity issues ...........................................................................................................................39 
2.4.4.4 
Additional efficacy analysis(es)......................................................................................................40 
2.4.5 
Analyses of safety data..................................................................................................................40 
2.4.5.1 
Analyses of Hypoglycemia.............................................................................................................41 
2.4.5.2 
Analyses of adverse events ...........................................................................................................43 
2.4.5.3 
Deaths............................................................................................................................................45 
2.4.5.4 
Analyses of laboratory variables....................................................................................................46 
2.4.5.5 
Analyses of vital sign variables ......................................................................................................47 
2.4.5.6 
Analyses of electrocardiogram variables .......................................................................................47 
2.4.5.7 
Analyses of anti-insulin antibody data............................................................................................47 
2.5 
DATA HANDLING CONVENTIONS ..............................................................................................51 
2.5.1 
General conventions ......................................................................................................................51 
2.5.2 
Data handling conventions for efficacy variables...........................................................................52 
2.5.3 
Missing data...................................................................................................................................53 
2.5.4 
Windows for time points.................................................................................................................55 
2.5.5 
Unscheduled visits .........................................................................................................................56 
2.5.6 
Pooling of centers for statistical analyses......................................................................................56 
2.5.7 
Statistical technical issues .............................................................................................................56 
3 
INTERIM ANALYSIS .....................................................................................................................57 
4 
DATABASE LOCK........................................................................................................................58 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 4 
5 
SOFTWARE DOCUMENTATION .................................................................................................59 
6 
REFERENCES...............................................................................................................................60 
7 
LIST OF APPENDICES.................................................................................................................61 
APPENDIX A 
ANTI-DIABETIC DRUG ATC CODES .................................................................................62 
APPENDIX B 
STUDY FLOWCHART.........................................................................................................63 
APPENDIX C POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES CRITERIA ......................68 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 5 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
 
AEs: 
adverse events 
AIA: 
anti-insulin antibody 
ALP: 
alkaline phosphatase 
ALT: 
alanine aminotransferases 
ANCOVA: 
analysis of covariance 
ARAC: 
Allergic Reaction Assessment Committee 
AST: 
aspartate aminotransferases 
ATC: 
anatomical therapeutic chemical 
BMI: 
body mass index 
CI: 
confidence interval 
CLcr: 
creatinine clearance 
CONSORT: 
consolidated standards of reporting trials 
CSR: 
clinical study report 
DBP: 
diastolic blood pressure 
e-CRF: 
electronic case report form 
FPG: 
fasting plasma glucose 
GFR: 
glomerular filtration rate 
HbA1c: 
glycosylated hemoglobin A1c 
HLGT: 
high level group term 
HLT: 
high level term 
IMP: 
investigational medicinal product 
INR: 
international normalized ratio 
IRT: 
interactive response technology 
ITT: 
intent-to-treat 
KM: 
Kaplan-Meier 
LDL: 
low-density lipoprotein 
LLT: 
lower level term 
LPLV: 
last patient last visit 
LS: 
least squares 
MCMC: 
Markov Chain Monte Carlo 
MDRD: 
modification of diet in renal disease 
MedDRA: 
Medical Dictionary for Regulatory Activities 
NIMP: 
non-investigational medicinal product 
PCSA: 
potentially clinically significant abnormality 
PT: 
preferred term 
RBC: 
red blood cell 
ROW: 
rest of the world 
SAEs: 
serious adverse events 
SBP: 
systolic blood pressure 
SD: 
standard deviation 
SMPG: 
self-monitored plasma glucose 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 6 
SMQ: 
standardized MedDRA query 
SOC: 
system organ class 
T1DM: 
type 1 diabetes mellitus 
T2DM: 
type 2 diabetes mellitus 
TEAE: 
treatment-emergent adverse event 
ULN: 
upper limit of normal 
WHO-DD: 
World Health Organization-Drug Dictionary 
 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 7 
1 
OVERVIEW AND INVESTIGATIONAL PLAN   
This Statistical Analysis Plan (SAP) provides a comprehensive and detailed description of 
strategy and statistical technique to be used to realize the analysis of data for study SAR341402 / 
EFC15081. 
1.1 
STUDY DESIGN AND RANDOMIZATION 
This is a multicenter, multinational, open-label, randomized, active-controlled, 2-arm parallel 
group comparative Phase 3 study which will recruit outpatients with type 1 diabetes mellitus 
(T1DM) or with type 2 diabetes mellitus (T2DM [T2DM only for US]) of at least one year 
(12 months) duration and who have been on multiple daily injection (MDI) regimen using 
NovoLog/NovoRapid or insulin lispro 100 U/mL in the last 6 months prior to screening visit on 
top of insulin glargine (100 U/mL) in the last 6 months prior to screening visit or on top of 
Levemir (insulin detemir) in the last 12 months prior to screening visit and, comparing: 
• SAR341402 in combination with insulin glargine 100 U/mL (Lantus). 
• NovoLog/NovoRapid in combination with insulin glargine 100 U/mL (Lantus). 
The study will comprise a 6-month treatment period followed by a 6-month safety extension 
period. 
The study is open-label as injection devices, leaflets and other training material, and treatment kits 
are distinguishable from each other. 
Approximately 580 patients will be randomized from approximately 84 sites. The planned 
n=580 patients will be randomized to the rapid-acting insulins SAR341402 or 
NovoLog/NovoRapid in a 1:1 ratio at the end of the screening period. 
• Approximately 250 patients with T1DM will be randomized in the geographical region 
using NovoRapid (including Europe and Japan). 
• Approximately 330 patients, including 230 with T1DM and 100 with T2DM, will be 
randomized in the geographical region using NovoLog (all in the US). 
The number of patients with T1DM expected to be randomized in the US versus outside of the US 
may change owing to the recruitment potential at those regions.  
Randomization will be stratified by geographical region (Europe, US, Japan), by type of diabetes 
(T1DM, T2DM [T2DM only for US]), by glycosylated hemoglobin A1c (HbA1c) obtained at the 
screening visit (<8.0%, ≥8.0%), and by prior use of NovoLog/NovoRapid (Yes, No). 
The protocol-mandated background therapy is the basal insulin analogue insulin glargine, which 
will be continued throughout the study, including during the safety extension period. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 8 
1.2 
OBJECTIVES 
The primary objective will be assessed at the end of the main 6-month period, and the result will 
be presented in the 6-month clinical study report (CSR). 
The secondary objectives will be assessed for both the main 6-month and 12-month periods, and 
the results will be presented respectively in the 6-month and 12-month CSR. 
1.2.1 Primary objectives 
The primary objective of this study is to demonstrate non-inferiority of SAR341402 versus 
NovoLog/NovoRapid in HbA1c change from baseline to Week 26 in patients with T1DM or 
T2DM also using Lantus. 
1.2.2 Secondary objectives 
The secondary objectives of this study are: 
• To assess the immunogenicity of SAR341402 and NovoLog/NovoRapid in terms of 
positive/negative status and anti-insulin antibody (AIA) titers during the course of the 
study. 
• To assess the relationship of AIAs with efficacy and safety. 
• To assess the efficacy of SAR341402 and NovoLog/NovoRapid in terms of proportion of 
patients reaching HbA1c <7.0% and change in HbA1c, fasting plasma glucose (FPG), and 
self-monitored plasma glucose (SMPG) profiles from baseline to Week 26 and Week 52 
(only Week 52 for HbA1c). 
• To assess safety of SAR341402 and NovoLog/NovoRapid. 
1.3 
DETERMINATION OF SAMPLE SIZE 
The sample size calculation was performed based on the primary endpoint, change in HbA1c (%) 
from baseline to Week 26. 
A sample size of 580 patients (290 patients per arm; approximately 480 T1DM patients 
[230 patients in the US using NovoLog and 250 patients in countries using NovoRapid] and 
100 T2DM patients [all in the US using NovoLog]) will ensure that the upper bound of the 
2-sided 95% confidence interval (CI) for the adjusted mean difference between SAR341402 and 
NovoLog/NovoRapid would not exceed a non-inferiority margin of 0.3% HbA1c with at least 
95% power. This sample size will also ensure that the lower bound of this 2-sided 95% CI would 
not be below -0.3% HbA1c with at least 95% power, thus will provide at least 90% power to show 
both non-inferiority of SAR341402 over NovoLog/NovoRapid (primary analysis) and inverse 
non-inferiority of NovoLog/NovoRapid over SAR341402 (secondary analysis). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 9 
These calculations assume a common standard deviation (SD) of 1.0% and a true difference in 
HbA1c between the treatment groups of zero. 
The non-inferiority margin of 0.3% HbA1c for the adjusted mean difference between SAR341402 
and NovoLog/NovoRapid was chosen, as it is in line with recommendations by regulatory 
agencies including FDA, referring to a range of 0.3% to 0.4% (1), and the European Medicines 
Agency, suggesting the more stringent non-inferiority margin of 0.3% (2), and based on historical 
precedent for comparative insulin studies in which a 0.3% non-inferiority margin is often used.  
An exploratory analysis of the percentage of patients with treatment-emergent AIAs (AIA 
incidence) will be performed to compare the immunogenicity of SAR341402 versus 
NovoLog/NovoRapid. The sample size of 580 patients would ensure that the 2-sided 90% CI for 
the adjusted risk difference between SAR341402 and NovoLog/NovoRapid would be included 
within the [-10%; 10%] interval with at least 68% power. This calculation assumes a true risk 
difference between the treatment groups of zero and a maximum AIA incidence of 30% (in 
previous Sanofi clinical studies performed with rapid-acting insulin analogs, AIA incidence in the 
range of 15-20% were observed at 6 months). The power calculations are presented in Table 1 
below. 
Table 1 - Power calculation based on the percentage of patients with treatment-emergent AIAs 
Percentage of patients with treatment-emergent AIAs 
10% 
20% 
30% 
Power for N=580 (290/arm) 
97% 
82% 
68% 
To reach this number of 580 patients randomized for the 6-month comparative efficacy and safety 
period, calculations were made using the nQuery Advisor® Software Version 7.0. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 10 
1.4 
STUDY PLAN 
The following figure describes the design of the study: 
Figure 1 - Study design 
 
The study consists of: 
• A 2-week screening period, from signed informed consent to randomization. 
• A 26-week treatment period, from randomization to Visit 9 (Week 26). 
• A 26-week comparative safety extension period, from Visit 9 (Week 26) to the end of 
treatment visit (Visit 12, Week 52). 
• A 1-day follow-up period with a safety telephone visit 1 day after the end of treatment 
visit. 
In total, the study duration will be 54 weeks per patient (+ 1 day safety follow-up). 
The end of treatment is at Visit 12 (Week 52) after randomization. The end of the study is a 
follow-up contact (Visit 13) at the time of Week 52 plus 1 day. 
In case of premature permanent investigational medicinal product (IMP) discontinuation, patients 
will have as soon as possible a premature treatment discontinuation visit (recorded as Visit 
8000 in the clinical database) with the assessments normally planned at Visit 12 (Week 52), 
followed by a safety follow-up (recorded as Visit 8010 in the clinical database) 1 day after. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 11 
Afterwards, the patients will remain in the study until at least Visit 9 (Week 26), and will be 
followed-up according to the visits and assessments as planned in the protocol (except for the 
1-day safety post-treatment follow-up [Visit 13]). 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL  
This section summarizes major changes to the protocol statistical section with emphasis on 
changes after study start (after the first patient was enrolled). 
The protocol history table below gives the timing, rationale, and key details of major changes to 
the protocol statistical section. 
The first patient was randomized on 14-Aug-2017. There are no planned interim analyses. 
Table 2 - Protocol amendment statistical changes 
Amendment  
Number 
Date 
Approved 
Rationale 
Description of statistical changes 
2 
02-Nov-2017 
Simplification of hypoglycemia 
analyses 
Removal of evaluation of hypoglycemia 
events by the time of the day from the list of 
planned analyses. 
 
 
Clarification of disposition 
presentation 
Changes in planned presentation of patient 
disposition and in time periods of interest for 
extent of investigational medicinal product 
exposure. 
 
 
Simplification of hypoglycemia 
analyses 
Removal of analysis of hypoglycemia events 
by treatment period. 
 
3 
14-Dec-2017 
FDA Recommendation 
Additional exploratory statistical analyses of 
the percentage of patients with treatment 
emergent AIAs were included to further 
compare the immunogenicity of SAR341402 
versus NovoLog/NovoRapid. 
The sample size was increased from 500 to 
580 in order to increase the power for 
meeting both the primary analysis of non-
inferiority and the secondary analysis of 
inverse non inferiority on HbA1c, as well as 
to ensure reasonable power for the 
additional exploratory statistical analyses of 
AIAs. 
 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN 
Not applicable. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 12 
2 
STATISTICAL AND ANALYTICAL PROCEDURES 
2.1 
ANALYSIS ENDPOINTS 
2.1.1 Demographic and baseline characteristics 
The baseline value for efficacy variables is defined as the last available value obtained up to the 
date and time of randomization. 
The baseline value for safety variables will be the last available value prior to the first injection of 
IMP (SAR341402 or NovoLog/NovoRapid). For patients randomized and not treated, the baseline 
value is defined as the last available value obtained up to the date and time of randomization. 
All baseline safety and efficacy parameters (apart from those listed below) are presented along 
with the summary statistics in the safety and efficacy sections (Section 2.4.5 and Section 2.4.4). 
Demographic characteristics 
• Age (years) (calculated in the electronic case report form [e-CRF]), 
• Age group (<65, ≥65 to <75, ≥75 years of age), 
• Sex (Male, Female), 
• Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than One Race, Unknown or Not 
Reported), 
• Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown /Not Reported),  
• Regions (North America, Western Europe, Eastern Europe, Rest of the World [ROW]) / 
Countries, 
• Baseline body weight (kg), 
• Baseline body mass index (BMI, kg/m², calculated in the e-CRF), 
• Baseline BMI categories (kg/m²): <25, ≥25 to <30, ≥30 kg/m²,  
• Baseline estimated glomerular filtration rate (GFR, modification of diet in renal disease 
[MDRD] formula, mL/min/1.73m²), 
• Baseline estimated GFR categories (mL/min/1.73m²): ≥90, ≥60 to <90, ≥30 to <60, <30, 
• Randomization strata of geographical region (Europe, US, Japan), type of diabetes 
(T1DM, T2DM), screening HbA1c categories (<8%, ≥8%), and prior use of 
NovoLog/NovoRapid (Yes, No). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 13 
Medical and surgical history 
Medical and surgical history at baseline will be coded to a “lower level term (LLT)”, “preferred 
term (PT)”, “high level term (HLT)”, “high level group term (HLGT)”, and associated primary 
“system organ class (SOC)” using the version of Medical Dictionary for Regulatory Activities 
(MedDRA) currently in effect at Sanofi at the time of database lock. 
Medical history allergic and subject family history of allergy will also be recorded. 
Disease characteristics at baseline   
• Fasting C-peptides (nmol/L), 
• Fasting C-peptides (<0.023 nmol/L, ≥0.023 to <0.42 nmol/L, ≥0.42 nmol/L), 
• Type of diabetes (T1DM, T2DM), 
• Duration of diabetes (years), 
• Duration of diabetes (<10, ≥10 years), 
• Age (years) at onset of diabetes, 
• Duration of basal insulin treatment (years), 
• Duration of mealtime insulin treatment in patient life (years), 
• Previous basal insulin treatment: 
- 
Type (insulin glargine, insulin detemir), 
- 
Duration (years), 
• Previous mealtime insulin treatment within 6 months prior to screening: 
- 
Type (NovoLog/NovoRapid, Humalog/Liprolog, Both NovoLog/NovoRapid and 
Humalog/Liprolog), 
- 
Duration (years), 
• Diabetic complications at baseline: 
- 
Diabetic retinopathy (Yes, No, Unknown), including type (proliferative/non-
proliferative), 
- 
Diabetic neuropathy (Yes, No, Unknown), 
- 
Diabetic nephropathy (Yes, No, Unknown), 
• Family history of diabetes (Yes, No), 
• History of gestational diabetes for female (Yes, No). 
Any technical details related to computation, dates, and imputation for missing data are described 
in Section 2.5.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 14 
Baseline efficacy data 
All 7-point SMPG profiles will be reported by patient in e-diary, transferred to the dedicated 7-
point SMPG page in the e-CRF and reviewed by the investigator in dedicated items, or directly 
completed in another dedicated 7-point SMPG page in the e-CRF by the investigator. For the 
analyses, the investigator items will be used when available.  
The following baseline efficacy data will be provided: 
• HbA1c (% and mmol/mol), 
• FPG (mmol/L and mg/dL), 
• SMPG (mmol/L and mg/dL) from 7-point profiles measured on a 24-hour period (mean 
24-hour plasma glucose concentration, postprandial plasma glucose excursions, and value 
at each time-point as defined in Section 2.1.3.2). 
Insulin dose at baseline 
All insulin doses will be reported by patient in e-diary, transferred to the dedicated mealtime 
insulin and basal insulin pages in the e-CRF and reviewed by the investigator in dedicated items, 
or directly completed in another dedicated mealtime insulin and basal insulin pages in the e-CRF 
by the investigator. For the analyses, the investigator items will be used when available.  
The following baseline insulin doses will be provided: 
• Basal insulin daily dose at baseline (U and U/kg) = median of basal insulin daily doses 
during the 7 days before the day of first IMP, 
• Mealtime insulin daily dose at baseline (U and U/kg) = median of mealtime insulin daily 
doses during the 7 days before the day of first IMP, 
• Total insulin daily dose at baseline (U and U/kg) = median of total insulin daily doses 
during the 7 days before the day of first IMP. 
Any technical details related to the calculation of doses and the imputation for missing data are 
described in Section 2.5.3.  
Smoking/alcohol habits 
• Tobacco habits (never, current, former), including the average number of cigarettes per 
day. 
• Alcohol habits (never, occasional, at least monthly, at least weekly, at least daily) 
including the number of daily standard drink (1 or 2, >2). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 15 
2.1.2 Prior or concomitant medications 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using the version in effect at the sponsor at the time of database lock. 
• Prior medications are those the patient used within 3 months before screening and from 
screening to first IMP intake (not included). Prior medications can be discontinued before 
first administration or can be ongoing during treatment phase. 
• Concomitant medications are defined as follows: 
- 
Concomitant medications during the main 6-month treatment period are any treatments 
received by the patient concomitantly to the IMP during the main 6-month period, 
from first injection of IMP (included) to Week 26 (Visit 9) or to the last injection of 
IMP + 1 day (+ 0 day for anti-diabetic medications) (included), whichever comes 
earlier.   
- 
Concomitant medications during the 12-month treatment period are any treatments 
received by the patient concomitantly to the IMP, from first injection of IMP 
(included) to the last injection of IMP + 1 day (+ 0 day for anti-diabetic medications) 
(included). 
• A given medication can be classified both as a prior medication and as a concomitant 
medication. 
• Post-treatment medications are those the patient took in the period running from the last 
injection of IMP + 2 days (+ 1 day for anti-diabetic medications) (included) to the end of 
the study.  
Anti-diabetic medications will be identified by a list of anatomical therapeutic chemical (ATC) 
codes (see Appendix A). 
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5. 
2.1.3 Efficacy endpoints 
HbA1c and FPG are measured in a blinded fashion at a central laboratory, for scheduled (see 
study flowchart in Appendix A) and unscheduled assessments. 
In case of premature permanent IMP discontinuation, the process described in Section 2.5.3 will 
be applied to retrieve efficacy assessments performed at the end of treatment visit (Visit 8000). 
Efficacy observation period  
• The main 6-month randomized period for efficacy variables is defined as the time from 
randomization up to Week 26 (Visit 9), regardless of study treatment discontinuation. 
• The 12-month randomized period for efficacy variables is defined as the time from 
randomization date up to Week 52 (Visit 12), regardless of study treatment 
discontinuation. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 16 
2.1.3.1 Primary efficacy endpoint(s) 
The primary efficacy variable is the change in HbA1c from baseline to Week 26 which is defined 
as: HbA1c value at Week 26 - HbA1c value at baseline (%). The primary efficacy variable will be 
derived in the intent-to-treat (ITT) population, using all HbA1c values regardless of adherence to 
treatment (ITT estimand). Results for the primary efficacy variable will also be presented in 
mmol/mol. 
2.1.3.2 Secondary efficacy endpoint(s) 
All secondary efficacy endpoints are calculated on the randomized periods using the ITT 
population. 
• Change in HbA1c (%) from baseline to Week 52. 
At Week 26 and Week 52: 
• The percentage of patients with HbA1c <7% (HbA1c responders; Yes/No variable),  
• Change from baseline in FPG (in mmol/L and mg/dL), 
• Change from baseline in the mean 24-hour plasma glucose concentration, based on the 
7-point SMPG profiles (in mmol/L and mg/dL), 
• Change from baseline in postprandial plasma glucose excursions (difference between 
2-hour postprandial and pre-prandial plasma glucose values at breakfast, lunch and 
dinner), based on the 7-point SMPG profiles (in mmol/L and mg/dL), 
• Change from baseline in 7-point SMPG profiles per time-point (in mmol/L and mg/dL) 
(fasting pre-breakfast, 2 hours post-breakfast, pre-lunch, 2 hours post-lunch, pre-dinner, 
2 hours post-dinner, bedtime). 
The process of computation of SMPG variables is described in Section 2.5. 
2.1.4 Safety endpoints 
The following safety parameters will be analyzed for the main 6-month and 12-month 
on-treatment periods: 
• Hypoglycemia (according to ADA Workgroup on Hypoglycemia) (3), 
• Adverse events (AEs), serious adverse events (SAEs), 
• Laboratory data, 
• Injection site reactions, hypersensitivity reactions, 
• Vital signs: heart rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), 
• Body weight. 
In case of premature permanent IMP discontinuation, the process described in Section 2.5.3 will 
be applied to retrieve safety assessments performed at the end of treatment visit (Visit 8000). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 17 
Safety observation period  
The observation period of safety data will be divided into 3 main segments: 
• The pre-treatment period is defined as the time from informed consent up to the time of 
the first injection of IMP. 
• The 12-month on-treatment period is defined as the time from the first injection of IMP up 
to 1 day after the last injection of IMP. 
- 
The main 6-month on-treatment period is defined as the time from first injection of 
IMP up to Week 26 (Visit 9) or up to 1 day after the last injection of IMP, whichever 
comes earlier. 
• The post-treatment period is defined as the time starting 1 day after last injection of IMP 
(after the on-treatment period). 
The on-study observation period is defined as the time from first injection of IMP until the end of 
the study (defined as the date of end of participation). 
2.1.4.1 Hypoglycemia 
All hypoglycemia will be reported by patient in e-diary, transferred to the dedicated hypoglycemia 
event page in the e-CRF and reviewed by the investigator in specific items, or directly completed 
in another dedicated hypoglycemia event page in the e-CRF by the investigator. For the analyses, 
the investigator items will be used when available. 
All hypoglycemia will be categorized according to the ADA definitions (3) as described below: 
• Severe hypoglycemia: Severe hypoglycemia will be derived as an event requiring 
assistance of another person to actively administer carbohydrate, glucagon, or other 
resuscitative actions.  
• Documented symptomatic hypoglycemia: Documented symptomatic hypoglycemia will 
be derived as an event with symptoms of hypoglycemia and with a measured plasma 
glucose concentration less than or equal to 3.9 mmol/L (70 mg/dL). 
• Asymptomatic hypoglycemia: Asymptomatic hypoglycemia will be derived as an event 
without symptoms of hypoglycemia but with a measured plasma glucose concentration 
less than or equal to 3.9 mmol/L (70 mg/dL). 
• Probable symptomatic hypoglycemia: Probable symptomatic hypoglycemia will be 
derived as an event with symptoms of hypoglycemia and missing plasma glucose 
concentration. 
• Relative hypoglycemia: Relative hypoglycemia (recently termed “pseudo-
hypoglycemia”) will be derived as an event with symptoms of hypoglycemia but with a 
measured plasma glucose concentration greater than 3.9 mmol/L (70 mg/dL).  
Any technical details to categorize hypoglycemia in case of missing hypoglycemia information 
are described in Section 2.5.3.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 18 
Hypoglycemia will be evaluated regardless the time of onset during the day. 
In addition to the threshold of plasma glucose of less than or equal to 3.9 mmol/L (70 mg/dL), 
documented symptomatic hypoglycemia and asymptomatic hypoglycemia with a measured 
plasma glucose concentration less than 3.0 mmol/L (54 mg/dL) will also be analyzed. 
Hypoglycemia observation period  
• Pre-treatment hypoglycemia are events that occurred during the pre-treatment period. 
• Treatment-emergent hypoglycemia are events that occurred during the on-treatment period 
(see Section 2.1.4). 
• Post-treatment hypoglycemia are events that occurred during the post-treatment period. 
2.1.4.2 Adverse events variables 
All AEs and SAEs will be coded to a LLT, PT, HLT, HLGT and associated primary SOC using 
the version of MedDRA currently in effect at the sponsor at the time of database lock. 
Adverse event observation period  
The occurrence of AEs and SAEs is recorded from the time of signed informed consent until the 
end of the study. 
• Pretreatment AEs are AEs that developed or worsened or became serious from the signed 
informed consent date up to first administration of IMP. 
• Treatment-emergent adverse events (TEAEs) are AEs that developed or worsened or 
became serious during the on-treatment period. 
• Posttreatment AEs are AEs that developed or worsened or became serious during the 
posttreatment period. 
Injection site reactions and hypersensitivity reactions  
If the investigator or the patient recognizes any sign related to local non-allergic reaction at the 
injection site, the event should be recorded in the routine AE page in the e-CRF.  
Potential hypersensitivity reactions (allergic reactions or allergic-like reactions) will be entered on 
the AE form and the allergic reaction complementary form should be completed. An Allergic 
Reaction Assessment Committee (ARAC) will review all possible allergic reactions, 
independently from the sponsor and in a blinded way regarding the study treatment. The ARAC 
will review the reported cases, confirm whether or not the event is allergic in nature, and provide 
a diagnosis for confirmed allergic events, based on the information reported by the investigator. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 19 
For the statistical analysis, injection site and hypersensitivity reactions will be identified based on 
the AE forms (also based on ARAC diagnosis in order not to miss any event), using the following 
MedDRA codes: 
• Injection site reactions will be identified using the following MedDRA searches: under 
HLGT “Administration site reactions” and HLTs “Administration site reactions NEC”, 
“Injection site reactions”, “Infusion site reactions” and “Application and instillation site 
reactions” and excluding HLTs “Implant and catheter site reactions” and “Vaccination site 
reactions”. 
• Hypersensitivity reactions will be identified using the following MedDRA searches: 
Angioedema standardized MedDRA query (SMQ) [Narrow], Severe cutaneous adverse 
reactions SMQ [Broad], Hypersensitivity SMQ [Broad and Narrow] and excluding PTs 
related to administration, application, injection and infusion sites. HLT “Anaphylactic 
Responses” are included in those SMQs. 
Adverse events of special interest  
Adverse events of special interest include: 
• Alanine aminotransferases (ALT) increase (identified based on the ALT Increase - 
Associated Signs and Symptoms forms), 
• Pregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP/non-investigational medicinal 
product (NIMP), 
• Symptomatic overdose with IMP/NIMP (identified based on the Overdose forms). 
2.1.4.3 Deaths 
The deaths observation period are per the observation periods defined above.  
• Death on-study: deaths occurring during the on-study observation period, 
• Death on-treatment: deaths occurring during the on-treatment period,  
• Death post-study: deaths occurring after the end of the study. 
2.1.4.4 Laboratory safety variables 
Clinical laboratory data consists of blood analysis, including hematology and clinical chemistry.  
Clinical laboratory values after conversion will be analyzed into international units and 
international units will be used in all listings and tables. Results will also be presented in 
conventional US units. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 20 
The following parameters will be analyzed, grouped by biological function (see study flowchart in 
Appendix A): 
• Hematology: 
- 
Red blood cells and platelets including hemoglobin, hematocrit, red blood cells count 
and platelets, 
- 
White blood cells including white blood cell count and differential count (neutrophils, 
lymphocytes, monocytes, basophils, eosinophils). 
• Clinical chemistry: 
- 
Serum lipids including total cholesterol, high-density lipoprotein (HDL) cholesterol, 
low-density lipoprotein (LDL) cholesterol, and triglycerides (in fasting condition), 
- 
Electrolytes including sodium, potassium, 
- 
Renal function including creatinine and estimated GFR (MDRD), 
- 
Liver function including ALT, aspartate aminotransferases (AST), alkaline 
phosphatase (ALP) and total bilirubin (in case of values above the normal range, 
differentiation in conjugated and non-conjugated bilirubin). 
Technical formulas are described in Section 2.5.1. 
2.1.4.5 Vital signs variables 
Vital signs include heart rate (bpm), and systolic and diastolic blood pressure (mmHg) in sitting 
position (see study flowchart in Appendix A).  
Body weight (kg) will be presented with vital signs. 
2.1.4.6 Electrocardiogram variables 
Not applicable. 
2.1.4.7 Immunogenicity variables 
If a patient discontinues the treatment prematurely, the process described in Section 2.5.3 will be 
applied to retrieve immunogenicity assessments performed at the end of treatment visit (Visit 
8000). 
AIA assessments will be determined in a blinded fashion at a central laboratory (see study 
flowchart in Appendix A) using a validated anti-insulin antibody binding assay methodology. 
Only samples collected at least 8 hours after the last administration of mealtime insulin will be 
taken into account in the analysis. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 21 
Anti-insulin antibodies evaluation will consist of: 
• Anti-SAR341402/ NovoLog/NovoRapid antibody positive/negative status 
• Anti-SAR341402/ NovoLog/NovoRapid antibody titer  
• Cross-reactivity to human insulin positive/negative status 
The following definitions will be used to identify patients with a change in AIA response during 
the on-treatment period (see Section 2.1.4 [4]): 
• Patients with treatment-induced AIAs will be defined as patients with AIAs that developed 
de novo (seroconversion) following the IMP administration (ie, patients with at least one 
positive AIA sample at any time during the on-treatment period, in those patients without 
pre-existing AIA or with missing sample at baseline). 
• Patients with treatment-boosted AIAs will be defined as patients AIA positive at baseline 
that were boosted to a significant higher titer following the IMP administration (ie, 
patients with at least one AIA sample with at least a 4-fold increase in titers compared to 
baseline value at any time during the on-treatment period, in those patients with 
preexisting AIA). The 4-fold increase in titer corresponds to an increase of two dilution 
steps within the titration experiment. A single dilution difference (2-fold titer increase) is 
within the expected imprecision of the titration method and is therefore not considered a 
relevant change. 
Patients with treatment-emergent AIA (Yes, No, Inconclusive) will be derived as follows: 
• Patients with treatment-emergent AIAs (AIA incidence) will be defined as patients with 
treatment-induced or treatment-boosted AIAs. 
• Patients without treatment-emergent AIAs will be defined as patients without treatment 
induced or treatment-boosted AIAs. 
• Inconclusive patients will be defined as patients who cannot irrefutably be classified as 
patients without treatment-emergent AIAs. Inconclusive patients will not be included in 
the above categories and will be listed separately. 
Treatment-emergent AIAs at last on-treatment value (Yes, No, Inconclusive) will be defined using 
the same definitions based on results obtained at the last on-treatment visit (ie, taking into account 
the closest value prior to the last dose of IMP). 
The peak titer will be defined as the maximal titer observed during the on-treatment period. For 
patients with treatment-induced and treatment-boosted AIAs, the kinetics of AIA response will be 
further classified as follows: 
• Transient AIA response, defined as a response detected only at one sampling time point 
during the on-treatment period (excluding the last sampling time point); or response 
detected at two or more sampling time points during the on-treatment period, where the 
first and last AIA-positive samples (irrespective of any negative samples in between) are 
separated by a period less than 16 weeks, and the patient’s last sampling time point is 
AIA-negative. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 22 
• Persistent AIA response, defined as a response detected at two or more sampling time 
points during the on-treatment period, where the first and last AIA-positive on-treatment 
sample (irrespective of any negative samples in between) are separated by at least 
16 weeks. 
• Indeterminate AIA response, defined as a response where only the last sampling time point 
is positive or the last 2 sampling time points are positive but separated by a period less 
than 16 weeks. 
2.1.5 Pharmacokinetic variables  
Not applicable. 
2.1.6 Pharmacodynamic/genomics endpoints 
Not applicable. 
2.1.7 Quality-of-life endpoints 
Not applicable. 
2.1.8 Health economic endpoints 
Not applicable. 
2.2 
DISPOSITION OF PATIENTS 
This section describes patient disposition for both patient study status and the patient analysis 
populations. 
Screened patients are defined as all patients who have originally met inclusion criteria and have 
signed the informed consent.  
Randomized patients consist of all screened patients with a treatment arm allocated and recorded 
in the interactive response technology (IRT) database, regardless of whether the treatment was 
used or not. 
For patient study status, the total number of patients in each of the following categories will be 
presented for the main 6-month period and 12-month study period separately, using a flow-chart 
diagram or summary tables: 
• Screened patients: all patients who have originally met inclusion criteria and have signed 
the informed consent. 
• Screen failure patients and reasons for screen failure. 
• Randomized patients: all screened patients with a treatment arm allocated and recorded in 
the IRT database, regardless of whether the treatment was used or not. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 23 
• Safety population (as defined in Section 2.3.2, presented as treated). 
• Treated but not randomized patients. 
• Randomized but not treated patients. 
• The ITT population (as defined in Section 2.3.1.1), analyzed as randomized. 
• The per protocol population (Section 2.3.1.2), analyzed as randomized. 
• The randomization strata (geographical region [Europe, US, Japan], type of diabetes 
[T1DM, T2DM], screening HbA1c categories [<8%, ≥8%], prior use of 
NovoLog/NovoRapid [Yes, No]) assigned by IRT will be summarized. The discrepancy 
between the strata assigned by IRT and the information reported on e-CRF will be listed 
for all randomized patients. 
• Disposition for the main 6-month period: 
- 
Patients who completed the main 6-month treatment period (patients who have 
performed Visit 9 [Week 26] and who did not permanently discontinue treatment 
before Visit 9 [Week 26]), 
- 
Patients who permanently discontinued the IMP during the main 6-month treatment 
period, and the reasons for permanent treatment discontinuation, 
- 
Patient’s decision for treatment discontinuation during the main 6-month period, 
- 
Patients who completed the main 6-month study period (patients who have performed 
Visit 9 [Week 26]), 
- 
Patients who prematurely discontinued the study during the main 6-month period, and 
the reasons for premature study discontinuation, 
- 
Status at last study contact of patients who prematurely discontinued the study during 
the main 6-month period. 
• Disposition for the 12-month period: 
- 
Patients who completed the 12-month treatment period including 6-month extension 
(patients who have performed Visit 12 [Week 52] and who did not permanently 
discontinue treatment before Visit 12 [Week 52]), 
- 
Patients who permanently discontinued the IMP during the 12-month treatment period, 
and the reasons for permanent treatment discontinuation, 
- 
Patient’s decision for treatment discontinuation during the 12-month period, 
- 
Patients who completed the 12-month study period (patients who have performed Visit 
12 [Week 52]), 
- 
Patients who prematurely discontinued the study during the 12-month period, and the 
reasons for premature study discontinuation, 
- 
Status at last study contact. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 24 
For all categories of patients (except for the screened and nonrandomized categories) percentages 
will be calculated using the number of randomized patients as the denominator divided for 
different treatment group. 
Patients with the following deviations will be identified and described in separate listings: 
• Treated but not randomized. 
• Randomized but not treated. 
• Randomized but not treated as randomized. 
Kaplan-Meier (KM) plots/estimates of the cumulative incidence of IMP discontinuation due to 
any reason, or due to AE, will be provided for the main 6-month and for the 12-month 
on-treatment period separately. Time to treatment discontinuation will be defined as the number 
of days from the first dose of IMP until the day of treatment discontinuation. All completers will 
be considered as censored observations. The censoring time will be the number of days from the 
first dose of IMP until the last dosing date. 
A list of patients prematurely discontinued from the treatment, along with reasons for 
discontinuation, will be provided. 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any population. Their safety data will be listed separately 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
All critical or major protocol deviations (including randomization and drug-dispensing 
irregularities, see Section 2.2.1) will be summarized by treatment group among randomized 
patients (number and percentages). 
Additionally, the analysis populations for safety and efficacy will be summarized in a table by 
patient counts on the randomized population: 
• Efficacy population: ITT population, Per-Protocol population, 
• Safety population, 
• Anti-insulin antibody population. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 25 
2.2.1 Randomization and drug dispensing irregularities 
Randomization and drug-dispensing irregularities occur whenever: 
1. A randomization is not in accordance with the protocol-defined randomization method, 
such as a) an ineligible patient is randomized, b) a patient is randomized based on an 
incorrect stratum, c) a patient is randomized twice, or d) in a dynamic randomization 
scheme the treatment assignment is, in fact, not random, due to a computer program error.  
 
OR 
2. A patient is dispensed an IMP kit not allocated by the protocol-defined randomization, 
such as a) a patient at any time in the study is dispensed a different treatment kit than as 
randomized (which may or may not contain the correct-as-randomized IMP), or b) a 
nonrandomized patient is treated with IMP reserved for randomized patients. 
Randomization and drug-dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis.  
The major or critical randomization and drug-dispensing irregularities will be documented in the 
clinical study report.  If the number of irregularities is large enough to make a tabular summary 
useful, the irregularities will be categorized and summarized among randomized patients (number 
and percentages).  Nonrandomized, treated patients will be described separately.  
Randomization and drug-dispensing irregularities to be prospectively identified include but are 
not limited to:  
• Kit dispensation without IRT transaction 
• Erroneous kit dispensation 
• Randomization by error 
• Patient randomized twice 
• Stratification error 
2.3 
ANALYSIS POPULATIONS 
Patients who are dispensed study drug without calling the IRT or before calling the IRT are 
considered nonrandomized patients. They are excluded from any population for analysis, 
including safety. However, if these patients experienced any significant safety event, they should 
be documented separately in the clinical study report. 
The randomized population includes any patient who has been allocated to a randomized 
treatment regardless of whether the treatment kit was used. 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 26 
2.3.1 Efficacy populations 
The primary efficacy analysis population will be the ITT population as defined in the protocol. 
2.3.1.1 Intent–to-treat population 
The primary efficacy population will be the ITT population, which includes all randomized 
patients, irrespective of compliance with the study protocol and procedures. 
Patients will be analyzed for efficacy analyses in the treatment group to which they are 
randomized. 
2.3.1.2 Per-protocol population 
The Per-Protocol population is a subset of the ITT population, which includes all randomized and 
exposed patients, who do not permanently discontinue IMP allocated by randomization or do not 
switch from treatment group during the main 6-month period, who perform week 26 and who do 
not present major or critical protocol deviations that could impact the analysis during the main 6-
month period. The major and critical protocol deviations excluding from the per protocol 
population are defined as: 
• Missing baseline HbA1c value. 
• No Visit 9 (Week 26) HbA1c value. 
• Use of any insulin other than IMP or non-IMP for 10 days or more during the main 
6-month treatment period.  
• T1DM patients:  
- 
Use of any non-insulin glucose lowering agents during the main 6-month treatment 
period.  
• T2DM patients: 
- 
Use of any non-insulin glucose lowering agents (except continuation of pre-study oral 
antidiabetic treatments at a stable dose) during the main 6-month treatment period. 
- 
Use of sulfonylureas and glinides during the main 6-month treatment period. 
• Use of systemic glucocorticoids greater than replacement dose for more than 10 days 
during the main 6-month treatment period. 
• Initiation of weight loss drugs during the main 6-month treatment period. 
• Wrong randomization stratum of type of diabetes (T1DM, T2DM). 
• Patients who met any of the following exclusion criteria:  
- 
E02: HbA1c <7% or >10% at screening. 
- 
E08: At screening visit, body mass index (BMI) ≥35 kg/m2 in patients with T1DM and 
≥40 kg/m2 in patients with T2DM. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 27 
- 
E18: Use of investigational drugs or prohibited therapy for this study within 3 months 
or 5 half-lives, whichever is longer, prior to the screening visit. 
- 
E19: limited to the following conditions: 
o status post pancreatectomy  
o status  post pancreas and/or islet cell transplantation 
• 
Serious GCP misconduct.  
2.3.2 Safety population 
The safety population is defined as all randomized patients who receive at least one dose of IMP, 
analyzed according to the treatment actually received. 
In addition: 
• If a patient is dispensed IMP and is lost to follow-up without any documented evidence 
whether or not the patient took IMP, the patient will be considered exposed and included 
in the safety population. 
• Randomized patients for whom it is unclear whether they took the study medication will 
be included in the safety population as randomized. 
• Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately. 
• For patients receiving more than one study treatment during the trial, the patient will be 
analyzed in the treatment group in which he/she has mostly taken. 
2.3.3 Anti-insulin antibody population 
The AIA population is defined as all patients from the safety population with at least one AIA 
sample available for analysis (sample collected at least 8 hours after the last administration of 
mealtime insulin) during the on-treatment period, analyzed according to the treatment actually 
received. 
2.4 
STATISTICAL METHODS 
Continuous data will be summarized by treatment group using the number of observations 
available (N), mean, SD, minimum, median, and maximum. 
Categorical and ordinal data will be summarized using the number and percentage of patients in 
each treatment group. 
In general, descriptive statistics of quantitative efficacy and safety parameters (result and change 
from baseline) by scheduled post-baseline visits will be provided on observed cases, ie, including 
only patients having non-missing assessments at a specific visit. All statistical analyses 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 28 
(descriptive statistics, plots, and statistical models) will be performed on visits defined using the 
time windows provided in Section 2.5.4.  
Statistical analyses will be performed on the overall study population regardless the type of 
diabetes, and pooling data from the patients treated with NovoLog and NovoRapid in the 
comparator group. For descriptive purpose, subgroup analyses may be conducted by type of 
diabetes (T1DM, T2DM) and by type of comparator used (NovoLog [in US], NovoRapid [in EU 
and Japan]), as described in the sections below.  
2.4.1 Demographics and baseline characteristics 
Parameters will be summarized on the randomized population analyzed in the treatment group to 
which they were randomized. 
Parameters described in Section 2.1.1 will be summarized by treatment group and in overall 
treatment groups using descriptive statistics. 
Medical/surgical history will be summarized by primary SOC and HLT in each treatment group 
and overall. Events will be sorted by SOC internationally agreed order and decreasing frequency 
of HLT based on incidence in the overall treatment group. 
No statistical test for the between-group difference will be performed. 
Demographics and baseline characteristics will also be presented according to the type of 
comparator (NovoLog, NovoRapid) and for T1DM patients. 
2.4.2 Prior or concomitant medications 
The prior, concomitant and post-treatment medications will be presented on the randomized 
population, separately for anti-diabetic medications and non-anti-diabetic medications. 
Anti-diabetic medications will be identified by a pre-defined list of ATC codes (see Appendix A). 
Medications will be summarized by treatment group and overall (only for prior medications) 
according to the WHO-DD dictionary. Non-anti-diabetic medications will be summarized 
considering the first digit of the ATC class (anatomic category) and the first 3 digits of the ATC 
class (therapeutic category).  All ATC codes corresponding to a medication will be summarized, 
and patients will be counted once in each ATC category (anatomic or therapeutic) linked to the 
medication. Therefore patients may be counted several times for the same medication. Anti-
diabetic medications will be presented by pharmacological class (ATC3), chemical class (ATC4), 
and standardized medication name. 
The tables for prior medications will be sorted by decreasing frequency within the ATC categories 
presented based on the overall incidence across treatment groups. In case of equal frequency, 
alphabetical order will be used. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 29 
The tables for concomitant and post-treatment medications will be sorted by decreasing frequency 
within the ATC categories presented based on the incidence in the SAR341402 group. In case of 
equal frequency, alphabetical order will be used.  
Frequency statistics including number of patients and percentage will be provided. No statistical 
test for the between-group difference will be performed. 
The prohibited medications will be presented by prohibited medication category (as defined in 
protocol deviations) and standardized medication name. The following prohibited medication 
categories will be presented: 
• Use of any insulin other than IMP or non-IMP for 10 days or more during the treatment 
period.  
• T1DM patients:  
- 
Use of any non-insulin glucose lowering agents during the treatment period.  
• T2DM patients: 
- 
Use of any non-insulin glucose lowering agents (except continuation of oral 
antidiabetic treatments at a stable dose) during the treatment period 
- 
Use of sulfonylureas during the treatment period 
• Use of systemic glucocorticoids greater than replacement dose for more than 10 days 
during the treatment period. 
• Insulin pump therapy. 
• Initiation of body weight loss drugs during the treatment period. 
• Any other investigational product (ie, participation in another clinical trial). 
Concomitant and prohibited medications will be presented for the main 6-month and for the 
12-month period separately, and for T1DM patients. 
2.4.3 Extent of investigational medicinal product exposure and compliance  
The extent of IMP exposure will be assessed and summarized by actual treatment within the 
safety population (Section 2.3.2). 
2.4.3.1 Extent of investigational medicinal product exposure 
The extent of IMP exposure will be assessed by the duration of the open-label IMP exposure and 
daily insulin doses (basal, mealtime, total). 
The exposure will be presented overall then by subgroups defined by the randomization strata of 
geographical region (Europe, US, Japan), type of diabetes (T1DM, T2DM) and type of 
comparator (NovoLog, NovoRapid). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 30 
Observation period  
The observation period for exposure data will be defined as follows: 
• The main 6-month on-treatment period is defined as the time from first injection of IMP 
up to Week 26 (Visit 9) or up to the day of last injection of IMP, whichever comes earlier. 
• The 12-month on-treatment period is defined as the time from the first injection of IMP up 
to the day of last injection of IMP. 
The exposure parameters will be provided separately for the main 6-month on-treatment period 
and for the 12-month on-treatment period. 
Duration of exposure 
The duration of exposure will be the total number of days of administration of the open-label 
IMP, ignoring temporary drug discontinuation (see Section 2.5.3 for calculation in case of missing 
or incomplete data). 
The duration of exposure to the open-label IMP will be defined as: 
(Date of the last IMP administration – date of the first IMP administration) + 1 
The process described in Section 2.5.3 will be applied to define the date of the last IMP 
administration for the main 6-month on-treatment period and 12-month on-treatment period. If 
this date is missing, the IMP exposure duration should be left as missing. 
Duration of IMP exposure will be summarized descriptively as a quantitative variable (number, 
mean, SD, median, minimum, and maximum). The number (n) and proportion (%) of patients 
exposed to the open-label IMP will be presented by specific time periods for each treatment group 
in the safety population.  
The time periods of interest for the main 6-month on-treatment period are grouped as follows:  
• Up to 4 weeks, 
• >4 to 8 weeks, 
• >8 to 12 weeks, 
• >12 to 20 weeks, 
• >20 to 25 weeks, 
• >25 to 26 weeks, 
• >26 weeks. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 31 
The time periods of interest for the 12-month on-treatment period are grouped as follows:  
• Up to 4 weeks, 
• >4 to 8 weeks, 
• >8 to 12 weeks, 
• >12 to 20 weeks, 
• >20 to 26 weeks, 
• >26 to 34 weeks, 
• >34 to 40 weeks, 
• >40 to 51 weeks, 
• >51 to 52 weeks, 
• >52 weeks. 
The cumulative duration of exposure for the main 6-month on-treatment period will be described 
using the following time periods: 
• ≥ 1 day, 
• > 4 weeks, 
• > 8 weeks, 
• > 12 weeks, 
• > 20 weeks, 
• > 25 weeks, 
• > 26 weeks. 
The cumulative duration of exposure for the 12-month on-treatment period will be described 
using the following time periods: 
• ≥ 1 day, 
• > 4 weeks, 
• > 8 weeks, 
• > 12 weeks, 
• > 20 weeks, 
• > 26 weeks, 
• > 34 weeks, 
• > 40 weeks, 
• > 51 weeks, 
• > 52 weeks. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 32 
Daily insulin doses 
The process described in Section 2.5.4 will be applied to assign visits to the insulin doses 
transferred from the e-diary webportal into the clinical database, and to retrieve doses in case of 
premature treatment discontinuation.  
At baseline, the daily basal, mealtime, and total (basal plus mealtime) insulin doses (U and U/kg 
body weight) will be calculated as defined in Section 2.1.1. At Visit 3, daily insulin doses (basal, 
mealtime, and total) will be calculated as the median of daily insulin doses available in the week 
after the day of first IMP. At further visits, the daily insulin doses (basal, mealtime, and total) will 
be calculated as the median of daily insulin doses available in the week before the visit. Technical 
details related to the computation and handling of missing data are described in Section 2.5.  
The daily insulin doses (basal, mealtime, total) will be described at baseline, during the week after 
the date of the first IMP administration, then at each visit, and the changes from baseline will be 
presented. 
2.4.3.2 Compliance  
Not applicable. 
2.4.4 Analyses of efficacy endpoints 
2.4.4.1 Analysis of primary efficacy endpoint(s) 
2.4.4.1.1 Primary efficacy analysis 
First step analysis: 
The statistical test for non-inferiority assessment of SAR341402 versus NovoLog/NovoRapid on 
the primary efficacy endpoint (change in HbA1c from baseline to Week 26 as defined in the 
Section 2.1.3.1) will be one-sided, with alpha level of 0.025 and using a non-inferiority margin of 
0.3% HbA1c. 
The primary endpoint will be analyzed in the ITT population using all post-baseline data available 
during the main 6-month randomized period (ITT estimand). 
The analysis for change in HbA1c should account for missing data in a fashion consistent with 
what the measurement would have been, had it been measured. The behavior of missing data for 
those patients who are off-treatment may not be the same as that of observed data for those 
patients who are on-treatment in the same treatment arm. Therefore, it may not be appropriate to 
represent the missing data from patients who do not adhere to therapy by the data from those 
patients on the same arm who adhere to therapy. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 33 
As a consequence, a multiple imputation approach will be used where missing data from patients 
who do not adhere to IMP will be represented by the data from those patients in the same 
treatment group who also do not adhere to IMP but have the measurement for the primary 
endpoint. Imputations will be performed with the MI procedure in SAS (Statistical Analysis 
System). Details of the proposed multiple imputation analysis in two parallel parts (according the 
status of the patients), are provided below: 
Part1: Imputation for missing data in patients who prematurely discontinued IMP during the 
main 6-month randomized period: 
Missing data in patients who prematurely discontinued IMP during the main 6-month randomized 
period will be imputed using a model estimated solely from data observed in other patients who 
discontinued IMP during the main 6-month randomized period but have the measurement for the 
primary endpoint at Week 26. Due to the anticipated small number of these latter patients, a basic 
imputation model will be built, including only the randomized treatment group as predictor. 
Missing data will be imputed using the regression method. 
Part2: Imputation for missing data in patients who completed the main 6-month treatment period: 
Missing data in patients who completed the main 6-month treatment period will be imputed 
separately, using a model estimated solely from data observed in other patients who completed the 
main 6-month treatment period and have the measurement for the primary endpoint at Week 26. 
Since in general, the missing pattern will not be monotone, a two-step approach will be used: 
• 
Step 1: the Markov Chain Monte Carlo (MCMC) method will be used in conjunction with 
the IMPUTE=MONOTONE option to create an imputed data set with a monotone missing 
pattern. The imputation model will include the continuous fixed covariates of the baseline 
HbA1c value as well as the changes from baseline in HbA1c at Week 12 and Week 26. 
• 
Step 2: using the monotone data set from step 1, missing data will be imputed using the 
regression method. The imputation model will include the fixed categorical effects of the 
treatment group, the randomization strata of geographical region and type of diabetes 
(Europe T1DM, US T1DM, US T2DM, Japan T1DM) and prior use of 
NovoLog/NovoRapid (Yes, No), as well as the continuous fixed covariates of the baseline 
HbA1c value and the changes from baseline in HbA1c at Week 12 and Week 26. 
Missing values will be imputed 10,000 times. Completed datasets from the two parts detailed 
above will be combined into a single dataset. Each completed dataset will be analyzed using an 
analysis of covariance (ANCOVA) of the change in HbA1c from baseline to Week 26, including 
the fixed categorical effects of treatment group (SAR341402, NovoLog/NovoRapid), the 
randomization strata of geographical region and type of diabetes (Europe T1DM, US T1DM, US 
T2DM, Japan T1DM) and prior use of NovoLog/NovoRapid (Yes, No), as well as the continuous 
fixed covariate of baseline value. Results from the 10,000 analyses will be combined using 
Rubin's formula (MIANALYZE procedure in SAS). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 34 
The adjusted least squares (LS) mean of the change in HbA1c from baseline to Week 26 for each 
treatment group (SAR341402, NovoLog/NovoRapid) will be estimated, as well as the 
between-group LS mean difference of SAR341402 versus NovoLog/NovoRapid, with the 
corresponding standard errors and 2-sided 95% CIs. These values will be calculated using the 
observed proportions of patients in the randomization strata and the observed baseline mean 
HbA1c in the ITT population. 
Non-inferiority will be demonstrated if the upper bound of the 2-sided 95% CI of the difference 
between SAR341402 and NovoLog/NovoRapid on the ITT population is <0.3%. 
Second step analysis: 
If non-inferiority of SAR341402 over NovoLog/NovoRapid is demonstrated, using a hierarchical 
step-down testing procedure, the following additional analysis will be performed (not as primary 
objective): the inverse non-inferiority (of NovoLog/NovoRapid over SAR341402) will be tested 
looking at the lower bound of the 2-sided 95% CI of the difference between SAR341402 and 
NovoLog/NovoRapid in the ITT population. Non-inferiority of NovoLog/NovoRapid over 
SAR341402 will be demonstrated if the lower bound is >-0.3%. 
If SAR341402 is shown to be non-inferior to NovoLog/NovoRapid and NovoLog/NovoRapid 
non-inferior to SAR341402, similar efficacy (equivalence) of SAR341402 and 
NovoLog/NovoRapid will be assumed.  
2.4.4.1.2 Sensitivity analysis 
Sensitivity analyses will be conducted to assess the robustness of primary efficacy analysis with 
regard to missing data (5). 
Description of missing data 
The following analyses will be performed on the ITT population to explore the missing data 
frequency and pattern: 
• As described in Section 2.2, KM plots/estimates of the cumulative incidence of IMP 
discontinuation will be provided by treatment group for the main 6-month period, with 
hazard ratio and 95% CI estimated using Cox regression model. 
• Availability of HbA1c at each visit will be provided by treatment group according to the 
status of the patient (discontinued treatment or not). 
• The number and disposition of patients with missing data will be described according to 
the availability for the primary efficacy analysis (Consolidated Standards of Reporting 
Trials [CONSORT] diagram according to missing data pattern). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 35 
• In order to explore missing data patterns for HbA1c, number and percentage of patients in 
each of the following categories will be presented by treatment group and patient status at 
Week 26 (Patient without permanent treatment discontinuation, patient with permanent 
treatment discontinuation): 
- 
Pattern 1: patients without baseline if any, 
- 
Pattern 2: patients with baseline but without post-baseline value during the main 
6-month randomized period, 
- 
Pattern 3: patients with baseline and at least one post-baseline value during the main 
6-month randomized period but not at Week 26, 
- 
Pattern 4: patients with baseline and Week 26 value during the main 6-month 
randomized period. 
• Baseline characteristics and HbA1c values by visit will be presented by missing data 
pattern for each treatment group, using descriptive statistics and/or graphs. 
Return to baseline analysis 
To assess the robustness of primary efficacy analysis with regard to the imputation of missing 
data, a sensitivity analysis will be performed using a multiple imputation method that models a 
“return-to-baseline” for patients having missing data at Week 26. 
For each patient in the SAR341402 and NovoLog/NovoRapid group in the ITT population, the 
missing HbA1c values at Week 26 will be imputed as equal to the patient’s baseline plus an error. 
The error will be normally distributed with mean zero and standard deviation set equal to the 
estimated pooled standard deviation. No negative value will be allowed (in this case, another 
value will be redrawn). 
Missing HbA1c values will be imputed 10,000 times to generate 10,000 datasets with complete 
HbA1c values at Week 26. In each dataset, the change in HbA1c from baseline to Week 26 will 
be derived from observed and imputed HbA1c values at Week 26. Each completed dataset will be 
analyzed using an ANCOVA of change from baseline to Week 26 in HbA1c (%), including the 
fixed categorical effects of treatment group (SAR341402, NovoLog/NovoRapid), the 
randomization strata of geographical region and type of diabetes (Europe T1DM, US T1DM, US 
T2DM, Japan T1DM) and prior use of NovoLog/NovoRapid (Yes, No), as well as the continuous 
fixed covariate of baseline value. Results from the 10,000 analyses will be combined using 
Rubin's formula (MIANALYZE procedure in SAS). 
The adjusted LS mean of the change in HbA1c from baseline to Week 26 for each treatment 
group (SAR341402, NovoLog/NovoRapid) will be estimated, as well as the between-group LS 
mean difference of SAR341402 versus NovoLog/NovoRapid, with the corresponding standard 
errors and 2-sided 95% CIs. These values will be calculated using the observed proportions of 
patients in the randomization strata and the observed baseline mean HbA1c in the ITT population. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 36 
Tipping point analysis 
In order to assess the impact of missing data, a tipping-point analysis based on the pattern mixture 
model approach will be performed in the ITT population as described below. 
The considered pattern mixture model will introduce a sensitivity parameter, δ, corresponding to 
the difference in mean change from baseline in HbA1c between patients with missing data and 
patients with observed data. Estimations will be performed using the multiple imputation 
approach “return-to-baseline” as described above. δ will be added to the imputed values in the 
SAR341402 group whereas the imputed values in the NovoLog/NovoRapid group will not change 
(δ = 0 corresponding to the missing at random [MAR] assumption). For each value δ will 
correspond an estimated LS mean in HbA1c per group and an estimated treatment effect. 
To investigate how the conclusions depend on the adopted values of δ, the testing will be repeated 
over a range of plausible values for δ, the treatment effect being penalized by a positive value and 
favored by a negative value. A specific illustration on the value of the minimum penalty leading 
to a non-rejection of the null hypothesis (upper limit of the 95% CI of treatment effect greater 
than 0.3%) will be provided (6).  
2.4.4.1.3 Supportive analysis 
In the case the per-protocol population will represent less than 95% of the ITT population, a 
supportive analysis will be conducted on the per-protocol population to evaluate the robustness of 
the conclusion of the primary efficacy analysis when excluding the patients that may increase the 
chance of reaching non inferiority conclusion. 
Data in the per-protocol population will be analyzed using an ANCOVA of the change in HbA1c 
from baseline to Week 26, including the fixed categorical effects of treatment group (SAR341402, 
NovoLog/NovoRapid), the randomization strata of geographical region and type of diabetes 
(Europe T1DM, US T1DM, US T2DM, Japan T1DM) and prior use of NovoLog/NovoRapid 
(Yes, No), as well as the continuous fixed covariate of baseline value. 
The adjusted LS mean of the change in HbA1c from baseline to Week 26 for each treatment 
group (SAR341402, NovoLog/NovoRapid) will be estimated, as well as the between-group LS 
mean difference of SAR341402 versus NovoLog/NovoRapid, with the corresponding standard 
errors and 2-sided 95% CIs. These values will be calculated using the observed proportions of 
patients in the randomization strata and the observed baseline mean HbA1c in the PP population. 
2.4.4.1.4 Subgroup analyses 
The primary efficacy endpoint will be further analyzed to examine whether the treatment effect 
varies in subgroups defined by the following baseline covariates: 
• Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than One Race, Unknown or Not 
Reported), 
• Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown /Not Reported),  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 37 
• Age group (<65,  ≥65 to <75, ≥75 years of age), 
• Sex (male, female), 
• Baseline BMI (<30, ≥30 kg/m²), 
• Baseline estimated GFR categories (<60, ≥60 mL/min/1.73m²), 
• Randomization stratum of type of diabetes (T1DM, T2DM), 
• Randomization stratum of screening HbA1c (<8.0%, ≥8.0%), 
• Randomization stratum of  prior use of NovoLog/NovoRapid (Yes, No), 
• Type of comparator (NovoLog, NovoRapid), 
• Regions (North America, Western Europe, Eastern Europe, ROW), 
• Duration of diabetes (<10, ≥10 years). 
The treatment effect across the subgroups defined above will be estimated for the primary efficacy 
variable (change in HbA1c from baseline to Week 26) in the ITT population and separately for the 
T1DM patients, using all post baseline HbA1c data available during the main 6-month 
randomized period. The same multiple imputation approach as described for primary analysis will 
be applied, using the 10,000 completed datasets generated for the primary analysis. Each 
completed dataset will be analyzed using an ANCOVA of change from baseline to Week 26 in 
HbA1c, including the fixed categorical effects of treatment group (SAR341402, 
NovoLog/NovoRapid), the randomization stratum of prior use of NovoLog/NovoRapid (Yes, No), 
the corresponding subgroup factor and subgroup factor-by-treatment interaction, and the 
continuous fixed covariate of baseline value. The randomization strata of geographical region and 
type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM) will not be included in the 
model. Results from the 10,000 analyses will be combined using Rubin's formula (MIANALYZE 
procedure in SAS). 
When the subgroup considered is the randomization stratum of screening HbA1c (<8.0, ≥8.0%), 
the baseline HbA1c value will be removed from the model. 
When the subgroup considered is the randomization stratum of prior use of NovoLog/NovoRapid 
(Yes, No), the randomization stratum of prior use of NovoLog/NovoRapid (Yes, No) will be 
included only once in the model (as subgroup factor). 
The adjusted LS mean of the change in HbA1c from baseline to Week 26 for each treatment 
group (SAR341402, NovoLog/NovoRapid) within each subgroup will be estimated, as well as the 
between-group LS mean difference of SAR341402 versus NovoLog/NovoRapid, with the 
corresponding standard errors and 2-sided 95% CIs. The significance level of the 
treatment-by-subgroup factor interaction will be provided for descriptive purpose. Forest plots 
will be provided. 
Further subgroup analyses may be performed if deemed necessary for interpretation of results.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 38 
2.4.4.1.5 Additional analyses 
The James-Stein (J-S) shrinkage estimator will be used to evaluate the treatment effect in each 
subgroup defined by type of comparator (NovoLog, NovoRapid), with a different approach (7). 
This estimate will be derived from the overall and subgroup treatment effect estimates in order to 
use all study information (including information collected in the other subgroup). 
Subgroup treatment effect estimates will correspond to regular sample estimates in each subgroup 
obtained using a similar ANCOVA model of the primary efficacy analysis in the ITT population 
(see Section 2.4.4.1.1) applied to the data in each specific subgroup. For the NovoLog subgroup 
(US-approved comparator), the fixed categorical effect of the randomization strata of 
geographical region and type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM) 
will be replaced by the randomization strata of type of diabetes (T1DM, T2DM), and for the 
NovoRapid subgroup (EU-approved comparator), the fixed categorical effect of the 
randomization strata of geographical region and type of diabetes (Europe T1DM, US T1DM, US 
T2DM, Japan T1DM) will be replaced by the randomization strata of geographical region 
(Europe, Japan). The overall treatment effect estimate will be obtained as a combination of the 
two subgroup treatment effect estimates weighted with the inverses of the variances observed in 
the two models. 
Results (including treatment effect estimates and their 95% confidence intervals) will be presented 
by type of comparator and illustrated using forest plots. 
Details on the estimator derivation are provided in Section 2.5.2. 
2.4.4.2 Analyses of secondary efficacy endpoints 
Secondary efficacy endpoints defined in Section 2.1.3.2 will be analyzed in the ITT population 
and separately for the T1DM patients, using all post-baseline data available during the main 6-
month randomized period (for analyses at Week 26) or the 12-month randomized period (for 
analyses at Week 52). 
2.4.4.2.1 Continuous endpoints 
All continuous secondary efficacy endpoints (except for 7-point SMPG profiles per time-point) 
will be analyzed using a similar multiple imputation approach in two parts, as for the primary 
efficacy endpoint, followed by a similar ANCOVA model (as described in Section 2.4.4.1.1). 
• At Week 26: 
- 
Missing data in patients who prematurely discontinued IMP during the main 6-month 
randomized period will be imputed using a model including only the treatment group 
as predictor (Part 1), 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 39 
- 
Missing data in patients who completed the main 6-month treatment period will be 
imputed in step 1 using a model including the continuous fixed covariates of the 
baseline value and the change from baseline at Week 12 and Week 26, in step 2 using 
a model including the fixed categorical effects of the treatment group, the 
randomization strata of geographical region and type of diabetes (Europe T1DM, US 
T1DM, US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%) (except when 
analyzing the change in HbA1c) and prior use of NovoLog/NovoRapid (Yes, No), as 
well as the continuous fixed covariates of the baseline value and the changes from 
baseline at Week 12 and Week 26 (Part 2). 
• At Week 52 : 
- 
Missing data in patients who prematurely discontinued IMP during the 12-month 
randomized period will be imputed using a model including only the treatment group 
as predictor (Part 1), 
- 
Missing data in patients who completed the 12-month treatment period will be imputed 
in step 1 using a model including the continuous fixed covariates of the baseline value 
as well as the changes from baseline at Week 12, Week 26, Week 40 (except for 
SMPG endpoints) and Week 52, in step 2 using a model including the fixed categorical 
effects of the treatment group, the randomization strata of geographical region and 
type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM), screening 
HbA1c (<8%, ≥8%) (except when analyzing the change in HbA1c) and prior use of 
NovoLog/NovoRapid (Yes, No), as well as the continuous fixed covariates of the 
baseline value and the changes from baseline at Week 12, Week 26, Week 40 (except 
for SMPG endpoints) and Week 52 (Part 2). 
For 7-point SMPG profiles per time-point, only descriptive statistics and graphs will be provided. 
2.4.4.2.2 Categorical endpoints 
The categorical secondary endpoint HbA1c responders (HbA1c <7%) will be analyzed using a 
logistic regression model with fixed-effect term for treatment, randomization strata of 
geographical region and type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM), 
screening HbA1c (<8%, ≥8%), and prior use of NovoLog/NovoRapid (Yes, No). If the logistic 
model does not converge (e.g., due to sparse data), randomization strata may be removed from the 
model. Patients without assessment at Week 26 (or Week 52 for the analysis at Week 52) will be 
considered as failure. Odds-ratios and 95% CI will be presented. 
2.4.4.3 Multiplicity issues 
In order to handle the multiple comparisons of the non-inferiority of SAR341402 over 
NovoLog/NovoRapid and then the inverse non-inferiority of NovoLog/NovoRapid over 
SAR341402, corresponding respectively to the primary efficacy analysis and a secondary step 
analysis of the primary efficacy variable, the type-I error will be controlled by the use of the 
sequential inferential approach. Only if non-inferiority is demonstrated, inverse non-inferiority on 
the mean change from baseline to Week 26 in HbA1c will be assessed. The tests for the primary 
endpoint (Week 26) will be performed one-sided at level α = 0.025. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 40 
The secondary efficacy variables at Week 26 and Week 52 will be analyzed for exploratory 
purpose only. 
2.4.4.4 Additional efficacy analysis(es) 
No additional efficacy analyses are planned.  
2.4.5 Analyses of safety data 
The summary of safety results will be presented by treatment group on treated population. 
General common rules 
All safety analyses will be performed on the safety population as defined in Section 2.3.2, unless 
otherwise specified, using the following common rules: 
• Safety data in patients who do not belong to the safety population (eg, exposed but not 
randomized) will be listed separately. 
• The baseline value is defined as the last available value prior to the first injection of IMP. 
When the time of assessment is not available, the value is considered as baseline if 
assessment date is the date of 1st IMP intake. 
• The potentially clinically significant abnormality (PCSA) values are defined as abnormal 
values considered medically important by the sponsor according to predefined 
criteria/thresholds based on literature review and defined by the sponsor for clinical 
laboratory tests, and vital signs (PCSA criteria are provided in the ADaM metadata and in 
Appendix C). 
• PCSA criteria will determine which patients had at least 1 PCSA during the on-treatment 
period, taking into account all evaluations performed during the on-treatment period, 
including nonscheduled or repeated evaluations. The number of all such patients will be 
the numerator for the on-treatment PCSA percentage. 
• The treatment-emergent PCSA denominator by group for a given parameter will be based 
on the number of patients assessed for that given parameter in the on-treatment period by 
treatment group on the safety population. 
• For quantitative safety parameters based on central laboratory/reading measurements, 
descriptive statistics will be used to summarize results and change from baseline values by 
visit and treatment group. Summaries will include the last on-treatment value. The last on 
treatment value is defined as the value collected at the same day/time of the last dose of 
IMP. If this value is missing, this on-treatment value is the closest one prior to the last 
dose intake. 
• The analysis of the safety variables will be essentially descriptive and no systematic 
testing is planned. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 41 
2.4.5.1 Analyses of Hypoglycemia 
All analyses of hypoglycemia will be performed on the safety population and for the T1DM 
patients (except for analyses monthly, by time of the day and by subgroup), separately on events 
occurring during the main 6-month on-treatment period and during the 12-month on-treatment 
period (as defined in Section 2.1.4).  
Incidence of patients with at least one hypoglycemia 
• Incidence of patients with at least one hypoglycemia will be presented by treatment group 
for any hypoglycemia and for each hypoglycemia category (as described in Section 
2.1.4.1). 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
incidence of patients with at least one hypoglycemia will be compared for SAR341402 
versus NovoLog/NovoRapid using a logistic regression method. The model will include 
fixed-effect terms for treatment group, the randomization strata of geographical region and 
type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM), screening HbA1c 
(<8%, ≥8%), and prior use of NovoLog/NovoRapid (Yes, No). If the logistic model does 
not converge (e.g., due to sparse data), randomization strata may be adapted or removed 
from the model. Odds-ratios and 95% CIs will be displayed using forest plots. 
• Incidence of patients with at least one severe hypoglycemia will be summarized by 
symptom. 
• The number of severe hypoglycemia and the number of documented symptomatic 
hypoglycemia <3.0 mmol/L (54 mg/dL) per patient will be summarized by treatment 
group. 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
incidence of patients with at least one hypoglycemia will be summarized by time of the 
day. Histograms will be provided. 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
incidence of patients with at least one hypoglycemia will be presented by subgroup and 
compared between SAR341402 and NovoLog/NovoRapid using a similar logistic 
regression model as described above, with added fixed-effect terms for the subgroup and 
the subgroup-by-treatment interaction. When the subgroup considered will be equal (or 
close) to one of the randomization strata, this randomization stratum will be removed from 
the model. Odds-ratios and 95% CIs will be presented across subgroups using forest plots. 
The significance level of the subgroup-by-treatment interaction will be also provided for 
descriptive purpose. The following subgroups will be displayed: 
- 
Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than One Race, Unknown  or Not 
Reported), 
- 
Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown /Not Reported),  
- 
Age group (<65,  ≥65 to <75, ≥75 years of age), 
- 
Sex (male, female), 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 42 
- 
Baseline BMI (<30, ≥30 kg/m²), 
- 
Baseline estimated GFR categories (<60, ≥60 mL/min/1.73m²), 
- 
Randomization stratum of type of diabetes (T1DM, T2DM), 
- 
Randomization stratum of screening HbA1c (<8%, ≥8%), 
- 
Randomization stratum of prior use of NovoLog/NovoRapid (Yes, No), 
- 
Type of comparator (NovoLog, NovoRapid), 
- 
Regions (North America, Western Europe, Eastern Europe, ROW), 
- 
Duration of diabetes (<10, ≥10 years). 
The analyses of hypoglycemia by type of comparator (NovoLog, NovoRapid) will also be 
performed on the T1DM patients. 
Further subgroup analyses may be performed if deemed necessary for interpretation of 
results. 
Number and rate of hypoglycemia per patient-year 
• Number and rate of hypoglycemia per patient-year (computed as 365.25 x [total number of 
episodes of hypoglycemia] / [total number of days exposed]) will be summarized by 
treatment group for any hypoglycemia and for each hypoglycemia category (as described 
in Section 2.1.4.1). Non classified hypoglycemia will be displayed. 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
incidence of patients with at least one hypoglycemia will be summarized over time using 
Nelson-Aalen estimates. Figures will be provided. 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
number and rate of hypoglycemia per patient-year will be presented by time of the day. 
Histograms will be provided. 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, 
number and rate of hypoglycemia per patient-year will be compared for SAR341402 
versus NovoLog/NovoRapid using an overdispersed Poisson regression model with a 
log-link function, and the logarithm of the treatment-emergent period as offset (using 
PROC GENMOD). The dispersion parameter will be estimated by Pearson’s chi-square 
statistic divided by its degrees of freedom (option SCALE=PEARSON). The model will 
include fixed-effect terms for treatment group and randomization strata of geographical 
region and type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM), 
screening HbA1c (<8%, ≥8%), and prior use of NovoLog/NovoRapid (Yes, No). If a 
model does not converge (eg, due to sparse data), the randomization strata may be adapted 
or removed from the model. Rate ratios and 95% CIs will be displayed using forest plots. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 43 
• For any hypoglycemia, severe and documented symptomatic hypoglycemia category, the 
number and rate of hypoglycemia per patient-year will be presented by subgroup type of 
comparator (NovoLog, NovoRapid) and compared between SAR341402 and 
NovoLog/NovoRapid using a similar overdispersed Poisson regression model as described 
above. If a model does not converge (eg, due to sparse data), the randomization strata may 
be adapted or removed from the model. Rate ratios and 95% CIs will be displayed using 
forest plots. 
2.4.5.2 Analyses of adverse events 
Generalities 
The primary focus of adverse event reporting will be on treatment-emergent adverse events.  
Pretreatment and posttreatment adverse events will be described separately. Analyses will be 
presented separately for the main 6-month and the 12-month on-treatment periods. 
If an adverse event date/time of onset (occurrence, worsening, or becoming serious) is incomplete, 
an imputation algorithm will be used to classify the adverse event as pretreatment, treatment-
emergent, or posttreatment.  The algorithm for imputing date/time of onset will be conservative 
and will classify an adverse event as treatment emergent unless there is definitive information to 
determine it is pretreatment or posttreatment.  Details on classification of adverse events with 
missing or partial onset dates are provided in Section 2.5.3. 
Adverse event incidence tables will present by SOC, HLGT, HLT, and PT, sorted in alphabetical 
order for each treatment group, the number (n) and percentage (%) of patients experiencing an 
adverse event.  Multiple occurrences of the same event in the same patient will be counted only 
once in the tables within a treatment phase.  The denominator for computation of percentages is 
the safety population within each treatment group. 
Sorting within tables ensures the same presentation for the set of all adverse events within the 
observation period (pretreatment, treatment-emergent, and posttreatment).  For that purpose, the 
table of all treatment-emergent adverse events presented by SOC and PT sorted by the 
internationally agreed SOC order and decreasing frequency of PTs within SOCs will define the 
presentation order for all other tables unless otherwise specified. Sorting will be based on results 
for the SAR341402 treatment arm. 
Analyses of all TEAE(s) will be generated for the safety population and for the T1DM patients 
(except for analyses by subgroup). 
Analysis of all TEAE(s) 
• Overview of TEAEs, summarizing number (%) of patients with any 
- 
TEAE, 
- 
serious TEAE, 
- 
TEAE leading to death, 
- 
TEAE leading to permanent treatment discontinuation. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 44 
• All TEAEs by primary SOC, showing number (%) of patients with at least one TEAE, 
sorted by internationally agreed order of primary SOC. 
• All TEAEs by primary SOC, HLGT, HLT, and PT, showing number (%) of patients with 
at least one TEAE sorted by SOC internationally agreed order. The other levels (HLGT, 
HLT, PT) will be presented in an alphabetic order. 
• Number (%) of patients experiencing TEAE(s) presented by PT, sorted by decreasing 
incidence of PT. 
• All TEAEs by primary SOC and PT, showing number (%) of patients with at least one 
TEAE, sorted by SOC internationally agreed order and decreasing incidence of PTs within 
SOC. This sorting order will be applied to all other tables, unless otherwise specified.  
• Number (%) of patients experiencing common TEAE(s) (HLT incidence ≥2% in any 
treatment group) presented by primary SOC, HLT, and PT, sorted by SOC internationally 
agreed order. The other levels (HLT, PT) will be presented in an alphabetic order. 
Analysis performed overall and by subgroup. The following subgroups will be displayed: 
- 
Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than One Race, Unknown  or Not 
Reported), 
- 
Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown /Not Reported),  
- 
Age group (<65,  ≥65 to <75, ≥75 years of age), 
- 
Sex (male, female), 
- 
Baseline BMI (<30, ≥30 kg/m²), 
- 
Baseline estimated GFR categories (<60, ≥60 mL/min/1.73m²), 
- 
Randomization stratum of type of diabetes (T1DM, T2DM), 
- 
Randomization stratum of screening HbA1c (<8%, ≥8%), 
- 
Randomization stratum of prior use of NovoLog/NovoRapid (Yes, No), 
- 
Type of comparator (NovoLog, NovoRapid), 
- 
Regions (North America, Western Europe, Eastern Europe, ROW), 
- 
Duration of diabetes (<10, ≥10 years). 
• All TEAEs regardless of relationship and related to IMP by primary SOC, HLGT, HLT, 
and PT, showing number (%) of patients with at least one TEAE, sorted by SOC 
internationally agreed order. The other levels (HLGT, HLT, PT) will be presented in an 
alphabetic order. 
• All TEAEs by maximal severity, presented by primary SOC and PT, showing number (%) 
of patients with at least one TEAE by severity (ie, mild, moderate, or severe), sorted by the 
sorting order defined above. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 45 
• Number (%) of patients experiencing TEAE(s) presented by Primary and Secondary SOC, 
HLGT, HLT, and PT, sorted by SOC internationally agreed order. The other levels 
(HLGT, HLT, PT) will be presented in an alphabetic order. 
Analysis of all treatment-emergent SAE(s) 
• All treatment-emergent SAEs by primary SOC, HLGT, HLT, and PT, showing number 
(%) of patients with at least one serious TEAE, sorted by SOC internationally agreed 
order. The other levels (HLGT, HLT, PT) will be presented in an alphabetic order. 
• All treatment-emergent SAEs regardless of relationship and related to IMP by primary 
SOC, HLGT, HLT, and PT, showing number (%) of patients with at least one 
treatment-emergent SAE, sorted by SOC internationally agreed order. The other levels 
(HLGT, HLT, PT) will be presented in an alphabetic order.  
Analysis of all TEAE(s) leading to treatment discontinuation 
• All treatment-emergent adverse events leading to treatment discontinuation, by primary 
SOC, HLGT, HLT, and PT, showing the number (%) of patients sorted by the 
internationally agreed SOC order.  The other levels (HLGT, HLT, PT) will be presented in 
alphabetical order. 
Analysis of TEAE(s) related to injection site reactions and hypersensitivity reactions 
• All TEAEs related to injection site reactions, hypersensitivity reactions, or events 
confirmed as allergic reactions by ARAC, by PT, showing number (%) of patients sorted 
by decreasing incidence of PT in the SAR341402 group. 
• All TEAEs related to injection site reactions, hypersensitivity reactions, or events 
confirmed as allergic reactions by ARAC, regardless of relationship and related to IMP, by 
PT, showing number (%) of patients sorted by decreasing incidence of PT in the 
SAR341402 group. 
• A summary and/or listing of all events adjudicated by ARAC will be provided with the 
result of the adjudication. 
Analysis of adverse events of special interest 
• A listing of patients with symptomatic overdose with IMP/NIMP will be provided. 
Analysis of pretreatment and posttreatment adverse events  
• A listing of all pre-treatment and post-treatment AEs will be provided. 
2.4.5.3 Deaths 
The following deaths summaries will be generated on the safety population, during the main 
6-month on-treatment period and for the 12-month on-treatment period separately: 
• Number (%) of patients who died by study period (on-study, on-treatment, post-study) and 
reasons for death; 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 46 
• All TEAEs leading to death (death as an outcome on the adverse event e-CRF page as 
reported by the investigator), by primary SOC, HLGT, HLT, and PT, showing number (%) 
of patients sorted by SOC internationally agreed order. The other levels (HLGT, HLT, PT) 
will be presented in an alphabetic order; 
• A listing of all deaths. 
2.4.5.4 Analyses of laboratory variables  
The summary statistics (including number, mean, median, standard deviation, minimum, and 
maximum) of all laboratory variables (central laboratory values and changes from baseline) will 
be calculated for each visit or study assessment (baseline, each post-baseline time-point, last 
on-treatment value during the main 6-month and 12-month on-treatment periods) by treatment 
group. This section will be organized by biological function as specified in Section 2.1.4.4.  
The incidence of PCSAs (list provided in Appendix C) at any time during the main 6-month 
on-treatment period and during the 12-month on-treatment period will be summarized by 
biological function and treatment group whatever the baseline level and according to the 
following baseline status categories:  
• 
Normal/missing, 
• 
Abnormal according to PCSA criterion or criteria. 
For parameters for which no PCSA criteria are defined, similar table(s) using the normal range 
will be provided. 
Drug-induced liver injury 
The liver function tests, namely AST, ALT, ALP, and total bilirubin, are used to assess possible 
drug-induced liver toxicity. The proportion of patients with PCSA values at any post-baseline visit 
by baseline status will be displayed by treatment group for each parameter. 
A graph of distribution of peak values of ALT versus peak values of total bilirubin will also be 
presented. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The 
graph will be divided into 4 quadrants with a vertical line corresponding to 3 x upper limit of 
normal (ULN) for ALT and a horizontal line corresponding to 2 x ULN for total bilirubin. 
Listing of possible Hy’s law cases will be identified and provided by treatment group (eg, patients 
with any elevated ALT>3 x ULN, and associated with an increase in bilirubin >2 x ULN) with 
ALT, AST, ALP, total bilirubin, and the following complementary parameters (if available): 
conjugated bilirubin and prothrombin time / international normalized ratio (INR), CPK, serum 
creatinine, complete blood count. 
The incidence of liver-related TEAEs will be summarized by treatment group. The selection of 
PTs will be based on the “Hepatic disorder” SMQ. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 47 
2.4.5.5 Analyses of vital sign variables 
The summary statistics (including number, mean, median, standard deviation, minimum, and 
maximum) of all vital signs variables (raw values and changes from baseline) described in Section 
2.1.4.5 including body weight, will be calculated for each visit or study assessment (baseline, each 
post-baseline time-point, last on-treatment during the main 6-month and 12-month on-treatment 
periods) by treatment group.  
The incidence of PCSAs at any time during the main 6-month on-treatment period and during the 
12-month on-treatment period will be separately summarized by treatment group whatever the 
baseline level. 
2.4.5.6 Analyses of electrocardiogram variables 
Not applicable. 
2.4.5.7 Analyses of anti-insulin antibody data 
The analyses of immunogenicity data will be descriptive (no formal statistical testing) and based 
on the AIA population. Separate analyses will be performed for the T1DM and T2DM patients. 
Analyses will be presented separately for the main 6-month and the 12-month on-treatment 
periods. 
For T1DM patients, all analyses of immunogenicity will be produced except for analyses by 
subgroups defined by baseline and screening factors. Analyses by type of comparator (NovoLog, 
NovoRapid) will be produced. 
For T2DM patients, the following analyses will be produced: 
• Summary of AIA response, 
• Summary of AIAs by visit, 
• Summary of AIA response by prior NovoLog/NovoRapid (Yes, No), 
• Summary of change in HbA1c (%) from baseline to Week 26 by treatment-emergent AIA, 
• Summary of change in insulin dose (mealtime, basal, total daily) from baseline to Week 26 
by treatment-emergent AIA, 
• Scatterplot analyses to assess the relationship between immunogenicity endpoints and 
efficacy/safety assessments, 
• Boxplots of maximal AIA titer. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 48 
Anti-insulin antibody response 
The number and percentage of patients will be provided by treatment group for each of the 
following categories: 
• Patients with treatment-induced AIAs, 
• Patients with treatment-boosted AIAs, 
• Patients with treatment-emergent AIA (AIA incidence), 
• Patients without treatment-emergent AIA, 
• Patients with pre-existing AIAs or treatment-induced AIAs (AIA prevalence). 
For exploratory purposes, the difference between SAR341402 and NovoLog/NovoRapid in the 
percentage of patients with treatment-emergent AIAs (AIA incidence) will be provided with 
associated 2-sided 90% CI. Patients with inconclusive results will not be part of the analysis. 
Results will be obtained by fitting a binomial regression model with an identity-link function. The 
model will include fixed categorical effects for treatment, the randomization strata of 
geographical region and type of diabetes (Europe T1DM, US T1DM, US T2DM, Japan T1DM), 
screening HbA1c (<8%, ≥8%), and prior use of NovoLog/NovoRapid (Yes, No). The risks within 
each treatment group and risk difference will be provided with their 90% CIs using the adjusted 
LS mean estimates of the treatment effect. 
For patients with treatment-induced and treatment-boosted AIAs, the kinetics of AIA response 
(transient, persistent, or indeterminate AIA response as defined in Section 2.1.4.7) will be further 
summarized using number and percentage of patients, and the peak titer will be described using 
median, Q1 and Q3. 
Incidence of patients with treatment emergent AIA will be compared, for SAR341402 versus 
NovoLog/NovoRapid using a logistic regression method. The model will include fixed-effect 
terms for treatment group, the randomization strata of geographical region and type of diabetes 
(Europe T1DM, US T1DM, US T2DM, Japan T1DM), screening HbA1c (<8%, ≥8%), and prior 
use of NovoLog/NovoRapid (Yes, No). If the logistic model does not converge (e.g., due to sparse 
data), randomization strata may be removed from the model. Odds-ratios and 95% CIs will be 
displayed using forest plots. 
The number and percentage of patients with treatment-induced, treatment-boosted and 
treatment-emergent AIAs will also be presented by visit in each treatment group using tables 
and/or graphs. 
Boxplots of the peak AIA titer will be presented by treatment group and according to the 
treatment-emergent AIA status (Yes, No). These graphs will be used to identify AIA ‘outliers’, 
defined as peak AIA titers higher than the boxplot upper whiskers (ie, higher than 1.5 times the 
interquartile range above the third quartile). 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 49 
Anti-insulin antibody data by visit 
The number and percentage of patients with anti-SAR341402/NovoLog/NovoRapid antibody 
positive and antibody negative samples will be summarized by treatment group at each visit and at 
the last on-treatment value. The number and percentage of patients with anti-
SAR341402/NovoLog/NovoRapid antibody positive sample will be displayed graphically by 
visit.  
On the group of patients with anti-SAR341402/NovoLog/NovoRapid antibody positive sample at 
a given visit, anti-SAR341402/NovoLog/NovoRapid antibody titers will be summarized (using 
descriptive statistics by number (N), median, Q1, Q3, variation coefficient, minimum, maximum, 
geometric mean, SD, and 95% CI), and the number and percentage of patients with cross-
reactivity to human insulin will be provided.  
Boxplots of AIA titers will be presented at each visit. 
The above by-visit summaries will be performed on the overall AIA population and separately for 
patients with treatment-induced, treatment-boosted and treatment-emergent AIAs. 
Subgroup analyses 
Exploratory analyses will be performed by subgroups defined by baseline and screening factors.  
The following subgroups will be displayed: 
• Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than One Race, Unknown  or Not 
Reported), 
• Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown /Not Reported),  
• Age group (<65,  ≥65 to <75, ≥75 years of age), 
• Sex (male, female), 
• Baseline BMI (<30, ≥30 kg/m²), 
• Baseline estimated GFR categories (<60, ≥60 mL/min/1.73m²), 
• Randomization stratum of type of diabetes (T1DM, T2DM), 
• Randomization stratum of screening HbA1c (<8%, ≥8%), 
• Randomization stratum of prior use of NovoLog/NovoRapid (Yes, No), 
• Type of comparator (NovoLog, NovoRapid), 
• Regions (North America, Western Europe, Eastern Europe, ROW), 
• Duration of diabetes (<10, ≥10 years), 
• Anti-SAR341402/NovoLog/NovoRapid antibody status at baseline (Positive, Negative). 
Further subgroup analyses may be performed if deemed necessary for interpretation of results. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 50 
Relationship between immunogenicity endpoints and efficacy/safety assessments 
Subgroup analyses and scatterplots will be conducted to assess the relationship between 
immunogenicity endpoints and efficacy/safety assessments.  
The following efficacy/safety assessments will be summarized by treatment-emergent AIA (Yes, 
No) and treatment-emergent AIA at last on-treatment value (Yes, No): 
• Primary efficacy endpoint (change in HbA1c from baseline to Week 26) (for the main 
6-month analyses) and change in HbA1c from baseline to Week 52 (for the 12-month 
analyses): same statistical model as described in Section 2.4.4.1.4 for subgroup analyses 
will be performed. 
• Hypoglycemia (any, severe, documented symptomatic): the proportion of patients with at 
least one event will be compared between treatment groups using the same statistical 
model as described in Section 2.4.5.1 for hypoglycemia subgroup analyses. The number of 
severe hypoglycemia and the number of documented symptomatic hypoglycemia 
<3.0 mmol/L (54 mg/dL) per patient will also be displayed for each treatment group. 
• Common TEAEs: descriptive statistics by primary SOC, HLT, and PT, showing number 
(%) of patients sorted by SOC internationally agreed order. The other levels (HLT, PT) 
will be presented in an alphabetic order. 
• Serious TEAEs: descriptive statistics by primary SOC, HLGT, HLT, and PT, showing 
number (%) of patients sorted by SOC internationally agreed order. The other levels 
(HLGT, HLT and PT) will be presented in an alphabetic order. 
• Injection site and hypersensitivity reactions: descriptive statistics by PT, showing number 
(%) of patients sorted by decreasing incidence of PT in the SAR341402 group. 
• Change in daily insulin doses (basal, mealtime, total) as defined in Section 2.4.3.1. 
In order to assess the impact of pre-existing antibodies that may cross-react with SAR341402, the 
above parameters will also be summarized by AIA status at baseline (Positive, Negative). 
The relationship between the AIA titer and the efficacy and safety assessments will be explored 
using scatter-plots of the peak AIA titer versus the parameters below for patients from the AIA 
population with titer available: 
• Primary efficacy endpoint (change in HbA1c from baseline to Week 26) (for the main 
6-month analyses) and change in HbA1c from baseline to Week 52 (for the 12-month 
analyses) 
• Change in total insulin dose (U/kg) from baseline to Week 26 (for the main 6-month 
analyses) and to Week 52 (for the 12-month analyses) 
• Rate per year of treatment-emergent hypoglycemia during the on-treatment period (severe 
hypoglycemia, documented symptomatic < 3.0 mol/L [54 mg/dL]) 
• Presence/absence of treatment-emergent hypersensitivity reactions during the on-treatment 
period 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 51 
• Presence/absence of treatment-emergent injections site reactions during the on-treatment 
period 
The scatterplots will also be presented separately for patients with treatment-emergent AIAs. 
Listings of baseline characteristics, insulin doses, HbA1c, hypoglycemia, hypersensitivity 
reactions, and injection site reactions will be provided for patients with treatment-emergent AIAs 
and high AIA titers (AIA ‘outliers’ as defined above). 
Additionally, descriptive statistics by categories of HbA1c change from baseline to Week 26 (for 
the main 6-month analyses) or Week 52 (for the 12-month analyses) (<-1%, ≥-1 to ≤1%, >1%) 
will be performed on the number (%) of patients with or without treatment-emergent AIA and 
associated peak titer, and on insulin doses (basal, mealtime, total). Listings of anti-insulin 
antibody, insulin doses, and HbA1c data will be provided for patients with treatment-emergent 
AIAs and HbA1c change from baseline > 1% at Week 26 (for the 6-month analyses) or Week 52 
(for the 12-month analyses). 
2.5 
DATA HANDLING CONVENTIONS 
This section describes general rules for data handling conventions, especially for patients with 
missing data. 
2.5.1 General conventions 
The following formulas will be used for computation of parameters. 
Reference day 
The reference day for the calculation of extent of exposure, time to onset and relative days is the 
day of the first administration of open-label IMP, denoted as Day 1. 
Disease characteristics formulas 
Duration of diabetes (years) = (Date of informed consent – date of diagnosis of diabetes 
+1)/365.25. 
Age at onset of diabetes (years) = (Date [DD-MM-YYYY] of diagnosis of diabetes – date 
[DD-MM-YYYY] of birth +1) /365.25. In case of unavailable date of birth, only the year of the 
date of diabetes diagnosis and the year of the date of birth (retrieve using the age recorded at 
screening) will be considered in the age at onset calculation. 
Duration of previous mealtime insulin treatment (years) = Duration of mealtime insulin treatment 
in patient life (years) = (Date of informed consent – Date of first intake of mealtime Anti-
hyperglycemic therapy in patient life +1)/365.25. 
Duration of basal insulin treatment (years) = (Date of informed consent – Date of first intake of 
Basal Anti-hyperglycemic therapy +1)/365.25 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 52 
HbA1c conversion 
IFCC in mmol/mol = (10.93× NGSP in %) - 23.5 
Renal function formulas  
Creatinine clearance (CLcr) value will be derived using the equation of Cockroft and Gault, using 
weight assessed at the same visit: 
• 
For Male:  
CLcr (mL/min) = 
mol/L)]
( 
creatinine
 
serum
 x 
[0.814
kg)]
 x weight(
)
age(years)
 - 
[(140
µ
 
• 
For Female: result above multiplied by 0.85. 
GFR will be derived using MDRD formula: 
GFR (mL/min/1.73m2) = 
⎥
⎦
⎤
⎢
⎣
⎡
female)
 
(if
 
0.742
 x 
black)
 
(if
 
1.212
 x 
Age
 x 
 
(mg/dL)
 
Creatinine
 
Serum
175x 
-0.203
-1.154
 
2.5.2 Data handling conventions for efficacy variables 
James-Stein shrinkage derivation for subgroup by type of comparator (7) 
Overall treatment effect estimator: 
2
2
2
1
2
2
2
2
1
1
0
ˆ
/
1
ˆ
/
1
ˆ
/
ˆ
ˆ
/
ˆ
ˆ
σ
σ
σ
δ
σ
δ
δ
+
+
=
 where 
iδˆ
 is the sample difference estimator between both treatment arm obtained in subgroup i.  
2ˆi
σ  is the variance estimator for subgroup i. 
James-Stein shrinkage estimator for subgroup i:  
0ˆ
)ˆ
1(
ˆ
ˆ
δ
δ
δ
c
c
i
i
−
+
=
(
 where   
)
/(
)
(
2
)
/(
)
(
2
2
2
1
2
2
1
2
2
2
1
2
2
1
σ
σ
δ
δ
σ
σ
δ
δ
+
−
+
+
−
=
c
 assuming a common c  for all subgroups (
2
1
c
c =
), 
 and by replacing 
iδ  with 
iδˆ
 and 
2
i
σ  with 
2ˆi
σ  in the calculation of c.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 53 
For any specific c : 
)
var( 1
δ
(
=
2
2
2
2
1
4
2
2
1
2
2
2
2
2
2
2
1
)
/
1
/
1(
/
/
)
1(
/
2
/
1
σ
σ
σ
σ
σ
σ
σ
+
+
−
+
+
c
c
c
 
and by replacing 
2
i
σ  with 
2ˆi
σ  in the calculation of the variance.  
2.5.3 Missing data 
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified.  When relevant, the number of patients with missing data 
is presented. 
Derived variables are considered missing if the original variables required to calculate them are 
missing unless otherwise specified. For example, if either a baseline assessment or an endpoint 
assessment is missing for a particular patient, then the change from baseline at endpoint is 
missing. Depending upon the assessment, analyses may not include all patients in the analysis 
population, because certain patients in the intended population may have missing data. 
Handling of computation of treatment duration if investigational medicinal product end of 
treatment date is missing 
For the calculation of the treatment duration, if the date of last IMP administration is missing, the 
exposure duration should be left as missing.  
For the main 6-month on-treatment period, the date of the last IMP administration will be defined 
as: date of last administration reported on the end-of-treatment e-CRF page or date of Week 26 
visit, whichever comes earlier. If the date of Week 26 visit is missing, the date of the last IMP 
administration will be defined as date of last administration reported on the end-of-treatment 
e-CRF page or date of randomization visit + 185 days, whichever comes earlier. 
For the 12-month on-treatment period, the date of the last IMP administration will be defined as 
the date of last administration reported on the end-of-treatment e-CRF page. 
The last dose intake should be clearly identified in the case report form and should not be 
approximated by the last returned package date. 
Handling of medication missing/partial dates 
No imputation of medication start/end dates or times will be performed.  If a medication date or 
time is missing or partially missing and it cannot be determined whether it was taken prior or 
concomitantly, it will be considered a prior, concomitant, and posttreatment medication. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 54 
Handling of adverse events/hypoglycemia with missing or partial date/time of onset 
Missing or partial adverse event / hypoglycemia onset dates and times will be imputed so that if 
the partial event onset date/time information does not indicate that the event started prior to 
treatment or after the on-treatment period, the event will be classified as treatment-emergent.  No 
imputation of event end dates/times will be performed.  These data imputations are for 
categorization purpose only and will not be used in listings. No imputation is planned for 
date/time of event resolution. 
Handling of adverse events/hypoglycemia when date and time of first IMP administration is 
missing 
When the date and time of the first IMP administration is missing, all adverse events / 
hypoglycemia that occurred on or after the day of randomization should be considered as 
treatment-emergent.  The exposure duration should be kept as missing. 
Handling of hypoglycemia classification when some classification items are missing 
Rule for handling missing data in classification items for hypoglycemia will be provided in 
ADaM metadata. 
Handling of missing assessment of relationship of adverse events to investigational medicinal 
product  
If the assessment of the relationship to IMP is missing, then the relationship to IMP has to be 
assumed and the adverse event considered as such in the frequency tables of possibly related 
adverse events, but no imputation should be done at the data level. 
Handling of potentially clinically significant abnormalities  
If a patient has a missing baseline he will be grouped in the category “normal/missing at 
baseline.” 
For PCSAs with 2 conditions, one based on a change from baseline value or a normal range and 
the other on a threshold value, with the first condition being missing, the PCSA will be based only 
on the second condition. 
For a PCSA defined on a threshold and/or a normal range, this PCSA will be derived using this 
threshold if the normal range is missing; eg, for eosinophils the PCSA is > 0.5 GIGA/L or >ULN 
if ULN ≥0.5 GIGA/L.  When ULN is missing, the value 0.5 should be used. 
Measurements flagged as invalid by the laboratory will not be summarized or taken into account 
in the computation of PCSA values.   
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 55 
Handling of missing data in the calculation of HbA1c responders 
For HbA1c responders (defined by HbA1c<7%), patients without any available assessment at 
endpoint (Week 26 for the main 6-month period, and Week 52 for the 12-month period) will be 
treated as failures (non-responders) in the analysis. 
Handling of missing data in the calculation of 7-point SMPG variables 
For a given 7-point SMPG profile, at least 5 available measurements will be required to take the 
profile into account in the statistical analyses (including descriptive analyses at each time-point). 
For each profile with at least 5 available measurements, the mean 24-hour plasma glucose 
concentration and the postprandial plasma glucose excursions will be calculated.  
At a given visit, the mean 24-hour plasma glucose concentration analyzed will be the average of 
the mean 24-hour plasma glucose concentrations (as previously calculated) available in the week 
before the visit. No minimum number of available mean 24-hour plasma glucose concentrations 
will be required. The same will apply to the postprandial plasma glucose excursions and to the 
values at each time-point. 
Handling of missing data in the calculation of insulin doses 
The daily mealtime insulin dose will be calculated as the sum of the mealtime insulin doses 
collected on the same day. At least 3 available mealtime insulin doses and no more than 1 snack 
will be required to calculate the daily mealtime insulin dose. 
The daily total insulin dose will be calculated as the sum of the daily basal and daily mealtime 
insulin doses. If one of the daily insulin doses is missing (basal or mealtime), the daily total 
insulin dose will not be calculated. 
At baseline, daily insulin doses (basal, mealtime, and total) will be calculated as the median of the 
daily insulin doses (as previously calculated) available in the 7 days before the day of first IMP. 
At Visit 3, daily insulin doses (basal, mealtime, and total) will be calculated as the median of the 
daily insulin doses (as previously calculated) available in the 7 days after the day of first IMP.  At 
further visits, the daily insulin doses (basal, mealtime, and total) will be calculated as the median 
of the daily insulin doses (as previously calculated) available in the 7 days before the visit. No 
minimum number of available doses will be required. For insulin doses in U/kg, if the body 
weight measurement is missing at a given visit, the last available measurement from previous visit 
will be used. 
2.5.4 Windows for time points 
The following process will be applied for visit re-allocation. Re-allocated visits will be used in all 
statistical analyses (descriptive statistics, plots, and statistical models).  
No re-allocation will be performed for nominal visits already provided in the clinical database 
(Visit 1 to Visit 13), and for unscheduled assessments.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 56 
SMPG profiles and insulin doses 
In the clinical database, SMPG profiles and insulin doses transferred from the e-diary will not be 
assigned to a protocol visit. For the analysis, they will be assigned to the next on-site visit actually 
performed by the patient after the date of data collection (Visit 3 to Visit 12, or Visit 8000). 
End of treatment visit 
If a patient discontinues the treatment prematurely, end of treatment (Visit 8000) assessments will 
be re-allocated to the next scheduled on-site visit for the patient. The next scheduled on-site visit 
for each patient will be determined as the next on-site visit that should be performed as per 
protocol, following the last visit actually performed by the patient before Visit 8000. 
For a given parameter, the value will not be re-allocated in the following cases: 
• If the parameter is not planned to be collected at the re-allocation visit. 
• If a value is already available for the parameter at the re-allocation visit. 
This process will be used to retrieve all assessments (including efficacy, safety, and 
immunogenicity data) performed at the end of treatment visit (Visit 8000), and will apply to 
insulin doses assigned to Visit 8000 following the process described above. 
2.5.5 Unscheduled visits 
The determination of baselines for efficacy and safety parameter variables is based on all 
measurements from both scheduled and unscheduled visits (measurements from the central 
laboratory only), as mentioned in Section 2.5.4. The determination of the last on-treatment value 
for safety and immunogenicity parameters is also based on all assessments from both scheduled 
and unscheduled visits (measurements from the central laboratory only). 
Measurements from the unscheduled visits (measurements from the central laboratory only) are 
also considered for PCSA summary of safety parameters. 
Unscheduled visit measurements are not included in the by-visit summaries. 
2.5.6 Pooling of centers for statistical analyses 
No pooling of centers is planned for statistical analyses. Center and country will not be included 
in the statistical analysis. However, the randomization stratum of geographical region (Europe, 
US, Japan) will be included in the models. 
2.5.7 Statistical technical issues 
Not Applicable. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 57 
3 
INTERIM ANALYSIS 
No interim analysis is planned.  
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 58 
4 
DATABASE LOCK 
It is planned to lock the database approximately 4 weeks after the last patient last visit (LPLV) of 
the 6-month comparative efficacy and safety treatment period. 
It is further planned to lock the database approximately 4 weeks after the LPLV of the 6-month 
safety extension phase. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 59 
5 
SOFTWARE DOCUMENTATION 
All summaries and statistical analyses will be generated using SAS Enterprise Guide version 5.1 
or higher. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 60 
6 
REFERENCES 
 
1. 
US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 
Guidance for Industry. Diabetes mellitus: Developing drugs and therapeutic biologics for 
treatment and prevention. Draft guidance. February 2008:1-34. 
2. 
EMA. Guideline on clinical investigation of medicinal products in the treatment or 
prevention of diabetes mellitus. 14 May 2012.CPMP/EWP/1080/00 Rev. 1:1-28. 
3. 
American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting 
Hypoglycemia in Diabetes: a report from the American Diabetes Association Workgroup 
on Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. 
4. 
Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. American 
Association of Pharmaceutical Scientists.. Assessment and reporting of the clinical 
immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical 
recommendations. AAPS J. 2014 Jul;16(4):658-73. 
5. 
Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The 
prevention and treatment of missing data in clinical trials. N Engl J Med. 2012 Oct 4; 
367(14):1355-60. 
6. 
Kock GG. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med. 2008 Feb 10;27(3):333-42. 
7. 
Quan H, Mao X, Chen J, Shih WJ, Ouyang SP, Zhang J, et al. Multi-regional clinical trial 
design and consistency assessment of treatment effects. Stat Med. 2014 Jun 
15;33(13):2191-205. 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 61 
7 
LIST OF APPENDICES 
 
Appendix A: 
Anti-diabetic drug ATC codes 
Appendix B: 
Study flowchart 
Appendix C: 
Potentially clinically significant abnormalities criteria 
 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 62 
Appendix A 
Anti-diabetic drug ATC codes 
The list of ATC codes for anti-diabetic drugs is based on the WHO-DD version of September 
2017. It will be updated using the version currently in effect at Sanofi at the time of database lock. 
 
ATCNUM ATCLEVEL 
ATCTYPE 
A10 
2 
DRUGS USED IN DIABETES 
A10A 
3 
INSULINS AND ANALOGUES 
A10AB 
4 
INSULINS AND ANALOGUES FOR INJECTION, FAST-ACTING 
A10AC 
4 
INSULINS AND ANALOGUES FOR INJECTION, INTERMEDIATE-ACTING 
A10AD 
4 
INSULINS AND ANALOGUES FOR INJECTION, INTERMEDIATE- OR 
LONG-ACTING COMBINED WITH FAST-ACTING 
A10AE 
4 
INSULINS AND ANALOGUES FOR INJECTION, LONG-ACTING 
A10AF 
4 
INSULINS AND ANALOGUES FOR INHALATION 
A10B 
3 
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 
A10BA 
4 
BIGUANIDES 
A10BB 
4 
SULFONYLUREAS 
A10BC 
4 
SULFONAMIDES (HETEROCYCLIC) 
A10BD 
4 
COMBINATIONS OF ORAL BLOOD GLUCOSE LOWERING DRUGS 
A10BF 
4 
ALPHA GLUCOSIDASE INHIBITORS 
A10BG 
4 
THIAZOLIDINEDIONES 
A10BH 
4 
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS 
A10BJ 
4 
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES 
A10BK 
4 
SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS 
A10BX 
4 
OTHER BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 
A10X 
3 
OTHER DRUGS USED IN DIABETES 
A10XA 
4 
ALDOSE REDUCTASE INHIBITORS 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 63 
Appendix B 
Study flowchart 
Period 
Screening
Treatment period (26 weeks) 
Comparative 
Safety Extension 
period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 Wk-1 
 a 
Wk 0 
(Baseline) 
Wk2 
 a
Wk4 Wk8 
 a Wk12 Wk20 
Wk26 b 
(Endpoint) 
Wk34 
 a 
Wk40 
Wk52 b 
(End of 
treatment) 
+1 day c 
 a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 
(±3) 
238 
(±5) 
280 
(±5) 
364 
(±5) 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion criteria 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
Demography, medical history, 
diabetes history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination  
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Vital signs d 
X 
 
X 
 
X 
  
X 
X 
X 
 
X 
X 
 
Body weight, height e 
X 
 
X 
 
 
 
 
 
X 
 
 
X 
 
12-lead ECG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Dispensation of study glucometer 
and e-diary 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Training (glucometer, SMPG 
profiles, hypoglycemia reporting 
e-diary) 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
(electronic 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 64 
Period 
Screening
Treatment period (26 weeks) 
Comparative 
Safety Extension 
period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 Wk-1 
 a 
Wk 0 
(Baseline) 
Wk2 
 a
Wk4 Wk8 
 a Wk12 Wk20 
Wk26 b 
(Endpoint) 
Wk34 
 a 
Wk40 
Wk52 b 
(End of 
treatment) 
+1 day c 
 a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 
(±3) 
238 
(±5) 
280 
(±5) 
364 
(±5) 
 
Training or refresher instructions 
on glucose meter use and 
routine review of diet and lifestyle 
counseling along with 
instructions on dosage self-
adjustment  including 
carbohydrate intake f  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispensation of study 
medicationg 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
• IMP (SAR341402 or 
NovoLog/NovoRapid) 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
• NIMP (Lantus) 
 
 
X 
 
X 
 
X 
X 
X 
 
X 
 
 
Counting / collecting used, 
unused and in use pens 
 
 
 
 
X 
 
X 
X 
X 
 
X 
X 
 
Compliance check 
(Review of diary, returned IMP) 
 
 
 
 
X 
 
X 
X 
X 
 
X 
X 
 
IRT call 
X 
 
X 
 
X 
 
X 
X 
X 
 
X 
X 
X 
Visit date confirmation in e-diary 
web portal 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
(electronic 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 65 
Period 
Screening
Treatment period (26 weeks) 
Comparative 
Safety Extension 
period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 Wk-1 
 a 
Wk 0 
(Baseline) 
Wk2 
 a
Wk4 Wk8 
 a Wk12 Wk20 
Wk26 b 
(Endpoint) 
Wk34 
 a 
Wk40 
Wk52 b 
(End of 
treatment) 
+1 day c 
 a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 
(±3) 
238 
(±5) 
280 
(±5) 
364 
(±5) 
 
Randomization h 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Patient to come fasting to study 
site 
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Insulin dose collected i 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
7-point SMPG j 
 
 
X 
 
 
 
X 
 
X 
 
 
X 
 
SMPG to support insulin dose 
titration k 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Central laboratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
HbA1c  
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Fasting plasma glucose 
 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
C-peptide (fasting) 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Anti-insulin antibody l 
 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
 
Safety laboratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology m, Clinical chemistry 
n 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Lipids (fasting) o 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
Hepatitis serology 
X 
 
 
 
 
 
 
 
 
 
 
 
 
(electronic 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 66 
Period 
Screening
Treatment period (26 weeks) 
Comparative 
Safety Extension 
period  
(26 weeks) 
Post 
treatment/Follow-
up 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Week:  
Wk-2 Wk-1 
 a 
Wk 0 
(Baseline) 
Wk2 
 a
Wk4 Wk8 
 a Wk12 Wk20 
Wk26 b 
(Endpoint) 
Wk34 
 a 
Wk40 
Wk52 b 
(End of 
treatment) 
+1 day c 
 a 
Day (window [days]) 
-14 
-7 
(±3) 
1 
(±3) 
14 
(±3) 
28 
(±3) 
56 
(±3) 
84 
(±3) 
140 
(±3) 
182 
(±3) 
238 
(±5) 
280 
(±5) 
364 
(±5) 
 
Pregnancy test (WOCBP only) p 
X 
 
X 
 
 
 
X 
 
X 
 
X 
X 
 
Serum FSH and estradiol 
(menopausal women only) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
AE / SAE 
To be assessed and reported (if any) throughout the study (report SAE to the sponsor within 24 
hours) 
X 
Injection site reactions 
To be assessed and reported (if any)  throughout the study 
X 
Hypersensitivity reactions 
To be assessed and reported (if any)  throughout the study 
X 
Hypoglycemia recording 
To be assessed and reported (if any)  throughout the study 
SMPG to be performed and documented in e-diary / e-CRF in case of symptoms suggesting 
hypoglycemia 
X 
ALP: alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, eGFR: estimated glomerular filtration rate, FSH: follicle stimulating hormone, IMP: investigational medicinal product, IRT: 
interactive response technology, NIMP: noninvestigational medicinal product, SMPG: self-measured plasma glucose, Wk: week 
a Mandatory telephone visit or optional clinical visit.  
b Or early termination visit. When early termination, refer to the e-CRF completion guidelines. 
c Or 2 to 3 days in the event this visit falls on a weekend or holiday. 
d Heart rate, blood pressure (BP). At screening visit only: determination of reference arm for BP. 
e Height only at Visit 1. 
f 
Site will provide training at screening visit and baseline visit on the correct handling including regular calibration of the glucose meter provided by the Sponsor; regular refresher instructions will be provided at each 
on-site visit throughout the study. 
g Patients are trained on the use of IMP and NIMP pens and needles by the study staff and provided with instruction leaflets during the randomization visit. 
h Randomization should be performed only after all baseline evaluations have been done. 
(electronic 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 67 
i 
Mealtime and basal insulin doses are to be documented in the 7 days prior to Baseline (Visit 3) and during the first 7 days after start of IMP, and on 2 days in the weeks prior to Visit 5 (Week 4), Visit 7 (Week 12), 
Visit 9 (Week 26), Visit 11 (Week 40) and Visit 12 (Week 52). 
j 
7-point SMPGs (fasting prebreakfast, 2 hours postbreakfast, pre- and 2 hours after lunch, pre- and 2 hours after dinner, and at bedtime) are requested on at least 2 days in the week before Visit 3 (Baseline), Visit 
7 (Week 12), Visit 9 (Week 26 [Endpoint]), and Visit 12 (Week 52; End of treatment), measured in a single, 24-hour period; they must be recorded into the e-diary before the visit. 
k SMPG for titration oversight and supporting insulin dosing and carbohydrate intake documentation are recommended daily during the first weeks of study treatment until reaching target ranges for SMPG, and 
thereafter on at least 3 days each week or more frequently as requested by the investigator (as specified in titration manual):  
Î To assist titration of the basal insulin (Lantus):  fasting (prebreakfast) SMPG. 
Î To assist titration of SAR341402 or NovoLog/NovoRapid: either postprandial or next-meal preprandial (in the case of dinner, bedtime) SMPG will be used, depending on the preference of the 
investigator and patient and consistent with standard of care. 
These SMPGs, supporting optimization of the basal and mealtime insulin dose are recommended to be recorded in the e-diary at least weekly; they will be uploaded in the Web Portal for review by the site 
or the Sponsor (titration oversight working group). See titration oversight manual. The results will be discussed between investigator and patient during on-site and scheduled or unscheduled telephone 
visits at the discretion of the investigator. 7-point SMPG can also be used for titration oversight. 
For SMPG ≤3.0 mmol/L (≤70 mg/dL) the hypoglycemia form has to be completed. 
l 
Eight-hour delay must be respected between the last mealtime insulin dose and antibody sampling. 
m Hematology: erythrocytes, hemoglobin, hematocrit, leukocytes, differential blood count (neutrophils, lymphocytes, monocytes, eosinophils, basophils) and platelets. 
n Clinical chemistry: sodium, potassium, creatinine, eGFR (MDRD), ALT, AST, ALP and total bilirubin (in case of values above the normal range, differentiation in conjugated and non-conjugated bilirubin). 
o Serum lipids: total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides (in fasting conditions). 
p For women of childbearing potential (WOCBP): Serum pregnancy test for screening; urine pregnancy test for subsequent monitoring. 
 
(electronic 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 68 
Appendix C 
Potentially clinically significant abnormalities criteria  
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
Clinical Chemistry 
ALT 
By distribution analysis : 
>3 ULN 
>5 ULN 
>10 ULN 
>20 ULN 
Enzymes activities must be expressed 
in ULN, not in IU/L.  
Concept paper on DILI – FDA draft 
Guidance Oct 2007. 
Internal DILI WG Oct 2008. 
Categories are cumulative. 
First row is mandatory. Rows following 
one mentioning zero can be deleted. 
AST 
By distribution analysis : 
>3 ULN 
>5 ULN 
>10 ULN 
>20 ULN 
Enzymes activities must be expressed 
in ULN, not in IU/L.  
Concept paper on DILI – FDA draft 
Guidance Oct 2007. 
Internal DILI WG Oct 2008. 
Categories are cumulative. 
First row is mandatory. Rows following 
one mentioning zero can be deleted. 
Alkaline Phosphatase 
>1.5 ULN 
Enzymes activities must be expressed 
in ULN, not in IU/L. 
Concept paper on DILI – FDA draft 
Guidance Oct 2007. 
Internal DILI WG Oct 2008. 
Total Bilirubin 
>1.5 ULN 
>2 ULN 
Must be expressed in ULN, not in 
µmol/L or mg/L. Categories are 
cumulative. 
Concept paper on DILI – FDA draft 
Guidance Oct 2007. 
Internal DILI WG Oct 2008. 
Conjugated Bilirubin 
>35% Total Bilirubin and TBILI>1.5 ULN 
Conjugated bilirubin dosed on a case-
by-case basis. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 69 
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
ALT and Total Bilirubin 
ALT>3 ULN and TBILI>2 ULN 
Concept paper on DILI – FDA draft 
Guidance Oct 2007. 
Internal DILI WG Oct 2008. 
To be counted within a same treatment 
phase, whatever the interval between 
measurements. 
CPK 
>3 ULN 
>10 ULN 
FDA Feb 2005. 
Am J Cardiol April 2006. 
Categories are cumulative. 
First row is mandatory. Rows following 
one mentioning zero can be deleted. 
CLcr (mL/min) 
(Estimated creatinine clearance based on 
the Cokcroft-Gault equation)  
<15 (end stage renal disease) 
≥15 - <30 (severe decrease in GFR) 
≥30 - < 60 (moderate decrease in GFR) 
≥60 - <90 (mild decrease in GFR) 
≥ 90 (normal GFR) 
FDA draft Guidance 2010 
Pharmacokinetics in patients with 
impaired renal function-study design, 
data analysis, and impact on dosing 
and labeling 
eGFR (mL/min/1.73m2) 
(Estimate of GFR based on an MDRD 
equation)  
 
<15 (end stage renal disease) 
≥15 - <30 (severe decrease in GFR) 
≥30 - < 60 (moderate decrease in GFR) 
≥60 - <90 (mild decrease in GFR) 
≥ 90 (normal GFR) 
FDA draft Guidance 2010 
Pharmacokinetics in patients with 
impaired renal function-study design, 
data analysis, and impact on dosing 
and labeling 
Creatinine 
≥150 µmol/L (Adults) 
≥30% change from baseline 
≥100% change from baseline 
Benichou C., 1994. 
 
Uric Acid 
Hyperuricemia  
Hypouricemia  
 
>408 µmol/L 
<120 µmol/L  
Harrison- Principles of internal Medicine 
17th Ed., 2008. 
Blood Urea Nitrogen 
≥17 mmol/L 
 
Chloride 
<80 mmol/L 
>115 mmol/L 
 
Sodium 
≤129 mmol/L 
≥160 mmol/L 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 70 
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
Potassium 
<3 mmol/L 
≥5.5 mmol/L 
FDA Feb 2005. 
Total Cholesterol 
≥7.74 mmol/L  
Threshold for therapeutic intervention. 
Triglycerides 
≥4.6 mmol/L 
Threshold for therapeutic intervention. 
Lipasemia 
≥3 ULN 
 
Amylasemia 
≥3 ULN 
 
Glucose 
Hypoglycaemia 
Hyperglycaemia 
 
≤3.9 mmol/L and <LLN 
≥11.1 mmol/L (unfasted); ≥7 mmol/L 
(fasted) 
 
ADA May 2005. 
ADA Jan 2008. 
HbA1c 
>8% 
 
Albumin 
≤25 g/L 
 
CRP 
>2 ULN or >10 mg/L (if ULN not provided) 
 FDA Sept 2005. 
Hematology 
WBC 
<3.0 Giga/L (Non-Black); <2.0 Giga/L 
(Black) 
≥16.0 Giga/L 
Increase in WBC: not relevant. 
To be interpreted only if no differential 
count available. 
Lymphocytes 
>4.0 Giga/L 
 
Neutrophils 
<1.5 Giga/L (Non-Black);<1.0 Giga/L (Black) International Consensus meeting on 
drug-induced blood cytopenias, 1991. 
FDA criteria. 
Monocytes 
>0.7 Giga/L 
 
Basophils 
>0.1 Giga/L 
 
Eosinophils 
>0.5 Giga/L or >ULN (if ULN≥0.5 Giga/L) 
Harrison- Principles of internal Medicine 
17th Ed., 2008. 
Hemoglobin 
≤115 g/L (Male); ≤95 g/L (Female) 
≥185 g/L (Male); ≥165 g/L (Female) 
 
Decrease from Baseline ≥20 g/L 
Criteria based upon decrease from 
baseline are more relevant than based 
on absolute value. Other categories for 
decrease from baseline can be used 
(≥30 g/L, ≥40 g/L, ≥50 g/L). 
Hematocrit 
≤0.37 v/v (Male) ; ≤0.32 v/v (Female) 
≥0.55 v/v (Male) ; ≥0.5 v/v (Female) 
 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 71 
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
RBC 
≥6 Tera/L 
Unless specifically required for 
particular drug development, the 
analysis is redundant with that of Hb. 
Otherwise, consider FDA criteria. 
Platelets 
<100 Giga/L 
≥700 Giga/L 
International Consensus meeting on 
drug-induced blood cytopenias, 1991. 
Urinalysis 
pH 
≤4.6 
≥8 
 
Vital signs 
HR 
≤50 bpm and decrease from baseline ≥20 
bpm 
≥120 bpm and increase from baseline≥20 
bpm 
To be applied for all positions (including 
missing) except STANDING. 
SBP 
≤95 mmHg and decrease from baseline 
≥20mmHg 
≥160 mmHg and increase from baseline 
≥20 mmHg 
To be applied for all positions (including 
missing) except STANDING. 
DBP 
≤45 mmHg and decrease from baseline ≥10 
mmHg 
≥110 mmHg and increase from baseline 
≥10 mmHg 
To be applied for all positions (including 
missing) except STANDING. 
Orthostatic Hypotension 
Orthostatic SDB 
Orthostatic DBP 
 
 
≤-20 mmHg 
≤-10 mmHg 
 
Weight 
≥5% increase from baseline  
≥5% decrease from baseline 
FDA Feb 2007. 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 72 
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
ECG 
Ref.: ICH E14 guidance (2005) and E14 
Q&A (2012), and Cardiac Safety 
Research Consortium White Paper on 
PR and QRS (Nada et al. Am Heart J. 
2013; 165(4) : 489-500) 
HR 
<50 bpm 
<50 bpm and decrease from baseline ≥20 
bpm 
<40 bpm 
<40 bpm and decrease from baseline ≥20 
bpm 
<30 bpm 
<30 bpm and decrease from baseline ≥20 
bpm 
 
>90 bpm 
>90 bpm and increase from baseline 
≥20bpm 
>100 bpm  
>100 bpm and increase from baseline 
≥20bpm 
>120 bpm  
>120 bpm and increase from baseline ≥20 
bpm 
Categories are cumulative 
 
 
 
 
 
 
Categories are cumulative 
 
PR 
>200 ms 
>200 ms and increase from baseline ≥25% 
> 220 ms 
>220 ms and increase from baseline ≥25% 
> 240 ms 
> 240 ms and increase from baseline ≥25% 
Categories are cumulative 
 
QRS 
>110 ms 
>110 msec and increase from baseline 
≥25% 
>120 ms 
>120 ms and increase from baseline ≥25% 
Categories are cumulative 
(electronic 
 
 
 
1.0)


Statistical Analysis Plan  
28-Feb-2018 
SAR314102-EFC15081 - insulin aspart 
Version number: 1 
 
Property of the Sanofi Group - strictly confidential 
Page 73 
CRITERIA for POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES 
for phase 2/3 studies (oncology excepted) 
 
Parameter 
PCSA 
Comments 
QT 
>500 ms 
 
QTc 
 
Absolute values (ms) 
 
 
>450 ms 
>480 ms 
>500 ms 
 
Increase from baseline 
Increase from baseline ]30-60] ms 
Increase from baseline >60 ms 
To be applied to any kind of QT 
correction formula.  
Absolute values categories are 
cumulative 
 
QTc >480 ms and ∆QTc>60 ms are the 
2 PCSA categories to be identified in 
individual subjects/patients listings. 
 
 
 
(electronic 
 
 
 
1.0)


 
 
 
 
 
 
 
 
 
ELECTRONIC SIGNATURES 
 
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFC15081 16.1.9 Statistical Analysis Plan
Clinical Approval
01-Mar-2018 10:00 GMT+0100
Clinical Approval
01-Mar-2018 18:23 GMT+0100